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Summary 
The Myeloid differentiation primary response protein (MyD88) plays a central 
role in innate immune signalling by acting as an adaptor protein downstream of most 
of the Toll-like receptor (TLR) family and all the IL-1 receptor family members. 
Activation of MyD88 dependent signalling is critical for the immune response during 
infections, however dysregulation of these pathways can contribute to the 
development of immune mediated diseases.  
The first aim of my thesis was to understand the role IL-33 signalling type 2 innate 
lymphoid cells and to identify potential targets to modulate their response. Stimulation of 
ILC2 cells with IL-33 induced phosphorylation of p38 and ERK1/2 and secretion of 
IL-13, IL-5, IL-6, IL-9 and GM-CSF. Inhibition of p38 using the specific inhibitor 
VX745 showed that p38 is crucial for cytokine production in ILC2s. MK2 and MK3, 
two kinases downstream of p38, were also found to regulate production of IL-6 and 
IL-13. In addition to cytokine production, stimulation of ILC2 cells with IL-33 
induced an increase in ILC2 size and granularity. Moreover, IL-33 stimulated ILC2 
cells had a higher uptake of the tryptophan metabolite kynurenine in comparison to 
unstimulated cells, which was dependent on the amino acid transporter Slc7a5.  
The second aim in my thesis was to understand the role of the A20 binding 
inhibitor of NF-κB (ABIN1) in the development of lupus like autoimmunity in mice. 
Mice carrying a mutation of Asp485 to Asn in the ubiquitin binding domain of ABIN1 
develop spontaneous autoimmunity with hallmarks of SLE including splenomegaly, 
presence of autoreactive antibodies against nuclear antigens and glomerulonephritis. 
Characterisation of innate immune populations in ABIN1[D485N]  mice showed that 
these mice have a massive increase of Ly6C-ve patrolling monocytes. Crossing 
ABIN1[D485N] mice to TLR7, MyD88 knock out mice or to mice with catalytically 
inactive IRAK1 or IRAK4 kinases prevented the increase in the monocytes, 
suggesting that a TLR7-MyD88-IRAK4-IRAK1 pathway not only drives lupus in 
ABIN1[D485N] mice but also increases the number of patrolling monocytes. 
Targeting this pathway using an IRAK4 specific inhibitor blocked the expansion of 
the Ly6C-ve patrolling monocytes and the disease development in ABIN1[D485N] 
mice.  Therefore, inhibition of the IRAK4 kinase could have beneficial effect in SLE 
patients with mutation in the tnip1 genes or dysregulation of the TLR pathways. 
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I. Introduction 
 Innate immune system 
The immune system evolved to protect the organisms from infectious 
microorganisms and other pathogens and also plays a role in tissue homeostasis and 
tumour surveillance. There are two branches of the immune system: innate and 
adaptive immunity. While the innate immune system is conserved and present in all 
multicellular organisms, the adaptive immunity is characterised in higher vertebrates 
(Pancer and Cooper, 2006). The innate immune system is divided into a cellular and 
humoral components. Innate immune cells include granulocytes such as neutrophils, 
eosinophils and mast cells, macrophages and dendritic cells and the recently identified 
group of innate lymphoid cells (Eberl et al., 2015). The humoral component is 
represented by the complement system, which is made of plasma proteins involved in 
the opsonisation of pathogens and their removal by phagocytosis (Sarma and Ward, 
2011). Innate immunity provides the first line of host defence and innate immune cells 
rely on a variety of germline-encoded receptors to recognise conserved molecular 
structures expressed by the pathogens (Turvey and Broide, 2010). This concept was 
first introduced in 1989 by Charles Janeway who described these receptors as Pattern 
Recognition Receptors (PRRs) and correspondingly their ligands  as Pathogen-
Associated Molecular Patterns (PAMPs) (Janeway, 1989). The PRRs include Toll-like 
receptors (TLR), Nucleotide Oligomerization Domain (NOD)-like receptors (NLR), 
Retinoic acid‐Inducible Gene I (RIG-I)-like receptors and C-type lectins (Takeuchi 
and Akira, 2010). In addition to the PAMPs, innate immune cells can sense the so 
called danger signals or Danger Associated Molecular Patterns (DAMPs), also 
referred as alarmins, which are released upon tissue damage or necrosis. DAMPs 
include endogenous molecules such as the high mobility group box1 protein (HMGB-
1), IL-33, IL-1α, uric acid, ROS, DNA and ATP (Bianchi, 2007). Finally, innate 
immune such as NK cells can recognise “altered self” or missing structures. For 
example virus infected cells or cancer cells which lose the expression of MHC I are 
then recognised and killed by NK cells (Jaeger and Vivier, 2012). 
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 Receptors utilising MyD88 adaptor protein 
The MyD88 protein plays a central role in the inflammatory pathways and acts 
as an adaptor protein downstream of members of the TLR family (with the exception 
of TLR3) and the IL-1 receptor family. MyD88 signalling is involved in both innate 
and adaptive immune responses to a variety of pathogens (Deguine and Barton, 2014). 
The MyD88 protein is made up of a C-terminal TIR domain (Toll/IL-1R homology 
domain), which mediates the interaction with TLRs and IL-1R members, an 
intermediate domain and N-terminal death domain (DD) (Bonnert et al., 1997). The 
last associates with the DD of the IL-1 associated kinases (IRAKs) (Neumann et al., 
2007, George et al., 2011). The importance of MyD88 has been highlighted by studies 
using MyD88 deficient animals. These mice are susceptible to a large number of 
pathogens and have been extensively used as a model of TLR deficiency (Takeuchi et 
al., 2000, Feng et al., 2003). 
 
 Toll-like receptors 
The discovery of the TLR4 in the mid-1990s was a key event in the innate 
immunity field (Lemaitre et al., 1996). The Toll protein was initially described in 
Drosophila where it was required for the establishment of dorsal-ventral polarity 
during development (Anderson et al., 1985).  Subsequently it was found that it also 
mediated survival in response to infection with the fungal pathogen Aspergillus 
(Lemaitre et al., 1996).  In 1997, Medzhitov et al discovered TLR4 as the first 
mammalian homologous of the Drosophila Toll protein and demonstrated that TLR4 
is involved in the activation of NF-κB singling and production of inflammatory 
cytokines such as IL-1, IL-6 and IL-8 (Medzhitov et al., 1997). The importance of 
TLR4 in immunity was confirmed by the observation that C3H/HeJ mice, which are 
resistant to the bacterial endotoxin LPS, had a mutation in the TLR4 gene (Poltorak et 
al., 1998).  In agreement with this, TLR4 knockout mice were also found to be resistant 
to LPS induced endotoxic shock (Hoshino et al., 1999).  13 TLRs have been described 
in mice and 10 TLRs in humans, with TLR11/12 and 13 not found in humans (Kawai 
and Akira, 2010). TLR1, TLR2, TLR4, TLR5 and TLR6 are expressed on the cell 
surface, whereas TLR3, TLR7, TLR8, TLR9, TLR11, TLR12 and TLR13 have 
intracellular localisation and are expressed in the endosomes, lysosomes and 
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endoplasmic reticulum (ER) (Kawai and Akira, 2010, Raetz et al., 2013).  The TLRs 
and their ligands are illustrated in Figure 1.1. 
 
Figure 1.1 Toll-like Receptors. 
TLR1/2/4 and 5 are expressed on the cell surface and recognise bacterial and fungal pathogens. 
TLR2 forms a heterodimeric complex with either TLR1 or TLR6 and recruits MyD88 adaptor 
protein via a 2nd adaptor Mal. TLR4 recognises LPS and could signals both using TRIF and 
MyD88 adaptor proteins. The ligand for TLR5 is flagellin. TLR3 binds dsRNA, TLR7/8 
recognise ssRNA and TLR9 recognises unmethylated CpG DNAmotifs. TLR11/12 have been 
shown to bind profilin protein in parasites and TLR13 binds to 23S ribosomal RNA. All 
intracellular TLR recruit MyD88 adaptor protein apart from TLR3, which binds to TRIF. 
Activation of the TLRs triggers production of proinflammatory cytokines and NF-κB 
activation.  
 
TLR2 forms heterodimeric complexes with either TLR1 or TLR6 and 
recognises lipoproteins, peptidoglycans, zymosan, mannans and others (West et al., 
2006). In addition, TLR2 can act as a homodimer and recognise ligands such as the 
lipoteichoic acids or lipoarabinomannan (Triantafilou et al., 2004, Bhattacharya et al., 
2010). TLR3 is recognising double-stranded RNA (dsRNA) and triggers responses 
mediating anti-viral immunity. Studies with TLR3 deficient mice show variable roles 
of TLR3 in mediating resistance to viral infections. This may reflect a role for other 
PRRs (eg RIG-1 and MDA5) which can also recognise viral RNA.  TLR3-/- mice were 
more resistant to intraperitoneal administration of West Nile virus due to enhanced 
viral load in the periphery, but had lower viral load in the brain. However, upon 
intracerebroventricular administration of the virus, wild type (WT) and TLR3-/- 
deficient animals had similar responses (Wang et al., 2004). In humans TLR3 
deficiency has been associated with impaired immunity to herpes simplex virus 1 and 
viral dissemination (Zhang et al., 2007).  
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TLR4 is one of the most extensively studied TLRs. TLR4 binds to bacterial 
lipopolysaccharide (LPS, a component of gram negative bacterial cell walls) in 
complex with the protein MD2 (Park et al., 2009). LPS/TLR4 interaction elicits 
production of proinflammatory cytokines such as TNF-α, IL-1 and IL-6 (Perera et al., 
2001, Kawai and Akira, 2010). TLR4 can bind other ligands such as viral proteins 
(Kurt-Jones et al., 2000) or antimicrobial peptides such as beta-defensin 2 (Biragyn et 
al., 2002). TLR5 binds to a specific site of the protein flagellin, which is a component 
from the bacterial flagellum (Smith et al., 2003). This binding leads to the activation 
of NF-κB and the production of TNF-α (Hayashi et al., 2001). TLR7 and TLR8 
recognise single stranded RNA (ssRNA) and similar to TLR3 have intracellular 
localisation and mediate responses to RNA viruses and bacterial nucleic acids (Heil et 
al., 2004). Ligation of these receptors in plasmacytoid dendritic cells leads to 
activation of pathways regulating IFN production (Diebold et al., 2004). Deficiency 
of TLR7 and TLR8 in humans are associated with susceptibility to hepatitis C virus 
infections (Wang et al., 2011). TLR9 binds to unmethylated CpG DNA motifs in the 
endosomal compartment. TLR9 recognises viral and bacterial DNA and, similar to 
TLR7/8, induces IFN production in plasmacytoid dendritic cells. (Lund et al., 2003, 
Stetson and Medzhitov, 2006). TLR7, 8 and 9 are also expressed on macrophages 
where their activation is able to induce the production of pro-inflammatory cytokines 
such as TNF, IL-6 and IL-12 (Pauls et al., 2013).  Although the endosomal location of 
TLR7/8/9 prevents them to interact with host DNA and RNA, uptake of 
Immunoglobulin complexes conjugated to nucleic acids could trigger activation of 
these receptors in the absence of pathogens leading to the so called sterile 
inflammation (Leadbetter et al., 2002, Wang et al., 2007). The TLR11/12 and 13 are 
less well characterised. TLR11 and TLR12 recognise the profilin protein in parasites 
(Raetz et al., 2013), whereas ligand for TLR13 is the 23S ribosomal RNA, which is 
found in bacteria, but not in eukaryotic cells (Li and Chen, 2012).  
The TLRs are made of an extracellular N-terminal ligand binding domain, a 
transmembrane domain and a conserved cytoplasmic C-terminal Toll/IL-1R 
homology (TIR) domain, which is required to trigger downstream signalling (Botos et 
al., 2011). The extracellular domain contains leucine-rich repeat motifs and forms a 
horseshoe structure. Ligand binding to the extracellular domains induces dimerisation 
of the TLRs. The dimerisation of the TIR domains is required for the recruitment of 
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adaptor proteins. All TLRs recruit the MyD88 adaptor protein, apart from TLR3, 
which interacts with the TIR-domain-containing adaptor protein inducing interferon-
β. Although MyD88 can bind directly to the TIR domains of the TLRs, in some cases 
of TLR4 and the TLR1/2 and TLR2/6 this interactions is facilitated by the TIR-domain 
containing adaptor protein (TIRAP or Mal) (Kenny et al., 2009). However, it should 
be noted that Mal was required only during stimulation of TLR2/6 and TLR2/1 at low 
ligand concentration (Kenny et al., 2009). Interestingly, Mal was found to negatively 
regulate TLR3-dependent production of IFN-β (Siednienko et al., 2010). In the context 
of other TLRs such as TLR9 the requirement for Mal seems to be cell specific (Gravina 
et al., 2016).  
TLR4 utilises both TRIF and MyD88 pathways in response to LPS (Shen et 
al., 2008, Fitzgerald et al., 2003). TLR4 could have both surface expression and 
endosomal expression. Whereas TLR4 utilises MyD88 adaptor protein on the cell 
surface, endosomal TLR4 also recruits the TRIF-related adaptor molecule TRAM and 
TRIF (Kagan et al., 2008). Downstream of TLR4, TRIF was found to play a role in 
regulating expression of costimulatory molecules in LPS stimulated dendritic cells 
(Shen et al., 2008). TRIF adaptor protein interacts with TRAF3 and TRAF6. Upon 
ligand binding of TLR3, TRIF activates TRAF3 leading to activation of the TANK-
binding kinase (TBK1) and the IKK-ε, which in turns regulate IRF3 and IRF7 and the 
induction of type I IFN (Hacker et al., 2006, Perry et al., 2004).   
 
 IL-1 receptor family 
The IL-1 receptor family includes 11 members, which depending on the 
function can be classified into four groups: ligand binding receptors, IL-1R accessory 
proteins, inhibitory proteins and orphan receptors (Figure 1.2). These proteins form 4 
major receptor signalling complexes the IL-1R, IL-33R, IL-36R and IL-18R (Garlanda 
et al., 2013).  The IL-1 receptors share an intracellular signalling domain (TIR domain) 
with the TLRs and similarly require MyD88 as an adaptor protein (Garlanda et al., 
2013).   The IL-1R complex binds to IL-1α, IL-β and IL-38. IL-1α is present in 
epithelial cells and is released during necrosis and therefore is classified as an 
“alarmin” or danger signal (Suwara et al., 2013). IL-1α precursors are active and 
induce the production of the proinflammatory cytokines such as TNF-α and IL-6 in 
6 
 
human peripheral blood mononuclear cells (Kim et al., 2013). IL-1β is produced by 
hematopoietic cells, however unlike IL-1α, the IL-1β precursor is not active and 
requires activation. This is mediated by a multiprotein complex referred to as the 
inflammasome. Activation of inflammasomes leads to conversion of pro-caspase-1 
into an active caspase-1, which cleaves pro-IL-1β into its mature form. Activation of 
IL-1β can also occur in the absence of caspase-1 and is mediated by the neutrophil 
proteinase-3 (Guma et al., 2009). IL-1β is a proinflammatory cytokine which is 
implicated in different immune mediated diseases including, arthritis, type 2 diabetes 
and others (Dinarello, 2011).  The action of IL-1β can be blocked by another member 
of the IL-1 family, IL-1Ra, which competes with IL-1β for binding to the IL-1 
receptor.  Unlike IL-1, binding of IL-1Ra is unable to induce signalling downstream 
of the receptor (Dinarello, 2011).  Mutations in the inflammasome that lead to 
increased IL-1β production or mutation in IL-1Ra are associated with the development 
of a number of auto-inflammatory diseases (Manthiram et al., 2017). 
IL-18 is constitutively expressed in nearly all cells and, similar to IL-1β, 
activation of IL-18 requires cleavage by caspase-1. IL-18 is a proinflammatory 
cytokine and stimulation with IL-18 augments production of IFN-γ in NK cells and 
Th1 cells (Shigehara et al., 2001, Stegmann et al., 2015, Dinarello et al., 2013). IL-36 
is another member of the IL-1 cytokine family and is found in different cells including 
immune and non-immune cells. IL-36 is also abundantly expressed in the skin and is 
involved in the promotion of IL-17 and IL-23 responses and thereby promotes the 
pathology of psoriasis (Lowes et al., 2013, Foster et al., 2014, Bridgewood et al., 
2018). IL-38 is the least studied members of the IL-1 family. IL-38 binds to the IL-
1R1 or IL-1Rp2 and competes with IL-1 and IL-36. It has been demonstrated that IL-
38 has a protective effect in LPS-induced sepsis model in mice, as well as in 
experimental mouse model of arthritis (Xu et al., 2018) (Boutet and Najm, 2017). 
Overexpression of IL-38 in human THP-1 monocyte cell line led to a reduced 
production of inflammatory cytokines (Boutet and Najm, 2017). Addition of IL-38 to 
the culture medium also led to a partial reduction of  IL-17 and IL-22 production in 
Candida-stimulated T cells in vitro (van de Veerdonk et al., 2012). IL-33 and the IL-
33 receptor complex will be extensively discussed further in this chapter.  
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Figure 1.2 IL-1 Receptor family  
IL-1R2 binds to IL-1β, however due to lack of the TIR domain this binding does not initiate 
signalling.  IL-1R1 associates with the IL-1RAcP to form the IL-1R complex, which 
recognises IL-1α, IL-1β and IL-38. Similarly, ST2 also associates with the IL-1RAcP to form 
the IL-33R. The IL-36 receptor is made of IL-1Rrp2 which associates with IL-1RAcP and 
recognises the different isoforms of IL-36. The ligand binding receptor for IL-18 is made of 
IL-18Rα and IL-18Rβ. The soluble IL-18BP can bind IL-18 and acts as an inhibitory protein. 
The two orphan receptors TIGIRR-1 and TIGIRR-2 are not thought to use co-receptors. 
Homology studies suggest that these receptors can bind IL-18, however no activation has been 
demonstrated upon IL-18 stimulation. The SIGIRR has a single Ig extracellular domain and 
acts as a negative regulator of the IL-1R signalling.   
 
 IL-33/ST2 signalling pathway 
 ST2 receptor discovery 
IL-33 is recognised by the ST2 receptor (encoded by the IL1RL1). ST2 
(originally named T1, DER4 and Fit-1) was discovered in 1989, preceding the 
discovery of its ligand (Tominaga, 1989, Werenskiold et al., 1989). Despite the 
similarity between the IL-1 family receptors, ST2 binds IL-33 but not to any of the 
other IL-1 family cytokines (Kumar et al., 1995). At present there is no evidence for 
the existence of other ligands that are recognised by ST2. The IL1RL1 gene is located 
on chromosome 2 in humans and chromosome 1 in mice together with other IL-1 
receptor family members (Molofsky et al., 2015). There are  two distinct promotors 
within the IL1RL1 gene leading to expression of two forms of ST2: a soluble (sST2) 
and membrane bound form, with the membrane form more abundantly expressed 
(Bergers et al., 1994).   
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 Soluble ST2 
sST2 acts as a decoy receptor and sequesters free IL-33 resulting in no 
signalling. The presence of sST2 might have evolved as an extracellular mechanism 
to limit the activity of IL-33. sST2 is produced spontaneously by a variety of cells. 
sST2 is found in human serum from healthy people, but its levels are further induced 
during inflammatory and heart diseases (Dieplinger and Mueller, 2015). Higher levels 
of sST2 are associated with poor outcomes in patients with heart failure and mortality 
in patients with acute respiratory distress syndrome. Increased sST2 is detectable in 
patients with asthma, chronic obstructive pulmonary disease (COPD), systemic lupus 
erythematosus, rheumatoid arthritis, ulcerative colitis (Oshikawa et al., 2001, Li et al., 
2015, Shi et al., 2018, Italiani et al., 2018, Diaz-Jimenez et al., 2017).  
 
 Expression of membrane bound ST2 on immune cells 
T helper cells were one of the first subsets of immune cells that were 
discovered to express the ST2 receptor. ST2 was found to be preferentially expressed 
on Th2 differentiated cells, but not on Th1 (Lohning et al., 1998). The expression of 
ST2 on T cells is regulated by the transcription factor GATA3, which binds one of the 
two GATA consensus sites on the IL1RL1 gene (Nawijn et al., 2001, Hayakawa et al., 
2005). IL-33 is able to induce IL-5 production in T cells and in vivo administration of 
IL-33 led to an exacerbation in OVA asthma mouse model that was independent of 
IL-4 or STAT6 (Kurowska-Stolarska et al., 2008). A recent study indicates that IL-33 
induces amphiregulin producing memory type Th2 cells which have a pathogenic role 
in airway lung fibrosis. Amphiregulin is a growth factor part of the EGF family which 
promotes regeneration of the epithelium. Dysregulation of amphiregulin production 
however has been associated with fibrosis (Zaiss et al., 2015). Moreover the T cell 
derived amphiregulin was also required for the activation and reprogramming of 
eosinophils, which in turn produce osteopontin and induce fibrosis (Morimoto et al., 
2018).  
 Expression of ST2 is found also on regulatory T cells. Colonic Foxp3+ve Treg 
cells, but not splenic Foxp3+ve Treg cells were found to express ST2. IL-33 induces 
phosphorylation of GATA3 in inducible Treg (iTreg) cells. Once phosphorylated,  
GATA3 can bind to the FOXP3 promotor and IL1RL1 enhancer sites leading to their 
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induction (Schiering et al., 2014). ST2+ve Treg cells were also expanded in colonic 
tumours and in APC Min/+ve mice, which are used as a model of human familial 
adenomatous polyposis.  This suggests that ST2 plays a negative role and promotes 
tumour development (He et al., 2017, Zhou et al., 2018a). ST2+ve Tregs are also present 
in adipose tissue. In these circumstances, in vivo administration of IL-33 led to an 
expansion of ST2+ve Tregs and reduced the obese phenotype in NZO mice, an inbred 
stain that develops severe obesity (Vasanthakumar et al., 2015).  
Another major cell type involved in mediating IL-33 responses are the type 2 
innate lymphoid cells (ILC2), which will be discussed later in this chapter. Because of 
their ability to produce cytokines in response to IL-33, ILC2 are involved in mediating 
a number of immune mediated diseases including helminth infections, respiratory viral 
infections, asthma, atopic dermatitis, allergic rhinitis, arthritis (Poposki et al., 2017, 
Mashiko et al., 2017, Newland et al., 2017, Klein Wolterink et al., 2012). 
Human and murine mast cells express constitutively high levels of ST2 and 
produce a variety of cytokines including IL-5, IL-13, IL-6, TNF, GM-CSF, CXCL8 
and CCL1 in response to IL-33 stimulation (Moritz et al., 1998, Schmitz et al., 2005a, 
Allakhverdi et al., 2007). The exacerbating effect of IL-33 in a mouse model of 
collagen induced arthritis was partially dependent on mast cell responses (Xu et al., 
2008).  Mast cells are also involved in the pathology of psoriasis induced by cutaneous 
injection of IL-33 (Hueber et al., 2011). In contrast, mast cell deficient KitW-sh/W-sh 
mice exhibited exacerbated phenotype in experimental model of papain-induced lung 
inflammation; in this study the authors showed evidence that mast cell derived IL-2 
promotes regulatory T cells which supress the IL-33 driven lung inflammation (Morita 
et al., 2015).  
Eosinophils and basophils also express ST2. Transcriptomic analysis of IL-33 
stimulated eosinophils revealed that IL-33 induced changes in more than 500 genes 
(Bouffi et al., 2013, Kroeger et al., 2009). Bone marrow can be induced to differentiate 
into eosinophils by culture in IL-5 containing media.  Replacement of IL-5 by IL-33 
for the final 6 days of culture resulted in eosinophils with a higher expression of the 
activation markers CD11b and CD69, increased granzyme B levels and a higher 
capacity for killing tumour cells (Lucarini et al., 2017).   
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NK and invariant NKT cells upregulate expression of ST2 when stimulated 
with IL-12. (Smithgall et al., 2008). Addition of IL-33 could also amplify the 
production of IFN-γ in IL-12 stimulated NK cells or after antigen stimulation of iNKT 
cells (Smithgall et al., 2008). iNKT cells express particular TCR rearrangement 
(Vα14Jα281 in mice and Vα24JαQ in humans) and recognise peptides loaded onto the 
MHC-I like CD1 molecule (Brutkiewicz and Sriram, 2002). iNKT cells had increased 
proliferation in response to in vivo stimulation with IL-7 and IL-33 compared to IL-7 
alone (Bourgeois et al., 2009). Deficiency of ST2 in NK cells led to an impaired 
response to viral infection in mice (Nabekura et al., 2015).  IL-33 was found to inhibit 
tumour growth in vivo by promoting expansion of NK cells and inducing higher IFN-
γ production in CD8 T cells (Gao et al., 2015). 
Dendritic cells also express ST2 and produce cytokines following stimulation 
with IL-33(Li et al., 2017, Göpfert et al., 2018). IL-33 induces activation of MAPK 
and NF-κB signalling pathways in bone marrow derived dendritic cells (Göpfert et al., 
2018). The role of IL-33 mediated dendritic cell responses was highlighted by a study 
showing that conditional deletion of MyD88 in dendritic cells using a CD11c-Vav Cre 
leads to a reduction in the pathological inflammation during an experimental model of 
atopic dermatitis induced by the vitamin D3 analog MC903 (Li et al., 2017).  
It has also been suggested in the literature that IL-33 is associated with an  
“alternative” or M2a -like activation of macrophages in vivo (Seo et al., 2017, 
Furukawa et al., 2017). “Alternative” activation of macrophages was originally 
described in response to the Th2 cytokine IL-4 and similar polarisation can also be 
driven via IL-13 (Stein et al., 1992, Doherty et al., 1993), suggesting that IL-33 might 
not directly affect macrophage function.  
CD11b+ve peritoneal B1 B cells have been found to upregulate ST2 expression 
and expand in vivo in response to IL-33 intraperitoneal injection. IL-33 stimulation 
induced the production of IL-5, IL-13 and IgM in CD19+veCD11b+veCD5+ve and 
CD19+veCD11b+veCD5-ve , but not in CD19+veCD11b-ve B cells, suggesting that only 
specific B cell subsets are IL-33 responsive (Komai-Koma et al., 2011). 
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 IL-33/ST2 complex formation 
Like the other members of the IL-1 receptor family, ST2 has an extracellular 
ligand binding domain made of 3 Immunoglobulin (Ig) like domains (D1, D2 and D3), 
a transmembrane domain and an intracellular portion containing the Toll-IL-1-
intracellular domain (TIR domain) (Boraschi et al., 2018). The crystal structure of IL-
33/ST2 complex has been solved, showing 1:1 stoichiometry. Similar to other IL-1 
members, IL-33 has two binding regions, one which interacts with the D1 and D2 
domains and the other interacts with the D3 domain of ST2 (Lingel et al., 2009).  
Upon IL-33 binding to ST2, the IL-1 accessory protein (IL-1RAcP, also 
known as IL-1R3) is recruited, leading to formation of trimeric complex (Figure 1.3).  
IL-1RAcP is not able to bind IL-33 on its own, but has an essential role for downstream 
signalling. IL-1RAcP deficient mice did not respond to IL-33 stimulation in vivo and 
had reduced type two cytokine production and IgE levels in comparison to IL-33 
stimulated WT mice (Chackerian et al., 2007).   
The IL-33/ST2 signalling complex has been also shown to interact and cross 
activate the receptor tyrosine kinase c-Kit (CD117), known as a proto-oncogene since 
mutations in the Kit gene are linked to human cancers (Figure 1.3). c-Kit is activated 
by the stem cell factor SCF and the downstream signalling promotes cell survival, 
proliferation and migration (Foster and Zaidi, 2018). IL-33 stimulation of bone 
marrow derived mast cells (BMMC) leads to phosphorylation of Y721 in c-Kit 
independent of SCF (Drube et al., 2010). Stimulation of c-kit deficient BMMC with 
IL-33 failed to induce phosphorylation of ERK1/2 and led to a lower production of 
IL-6. Furthermore, SCF was found to enhance signalling and cytokine production in 
IL-33 stimulated BMMC. A co-immunoprecipitation experiment suggested that c-Kit 
binds to IL-1RAcP constitutively in mast cells, whereas association of c-Kit with ST2 
receptor requires ligation of IL-33 and recruitment of the IL-1RAcP (Drube et al., 
2010).  
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Figure 1.3 Activation of IL-33/ST2 receptor complex.   
The extracellular domain of ST2 interacts with IL-33, followed by recruitment of the  
IL-1RAcP. The formation of trimeric complex facilitates dimersiation of the TIR domains of 
ST2 and IL-1RAcP and initiates signalling. In mast cells, the IL-1RAcP can also interact with 
the phosphorylated tyrosine receptor kinase c-Kit to further amplify the IL-33 signalling.  
 
There are multiple mechanism of IL-33/ST2 complex formation (Figure 1.4). 
First, as described above the soluble ST2 can sequester free IL-33 preventing its 
binding to the receptor bound form and initiating signalling. Second, the IL-1 family 
member SIGIRR (TIR8 or IL-1R8) inhibits IL-33/ST2 signalling in Th2 cells. SIGIRR 
is highly expressed on polarised Th2 cells and forms a complex with IL-33 and ST2. 
SIGIRR deficiency leads to higher production of type two cytokines in TCR and IL-
33 stimulated Th2 cells and enhanced response during OVA challenge (Bulek et al., 
2009). The last known mechanism of regulating the formation of IL-33/ST2 complex 
involves the phosphorylation of ST2 on S446 by the glycogen synthase kinase 3β 
(GSK3β), which may be dependent on the focal adhesion kinase (FAK). This 
phosphorylation of ST2 leads to internalisation and degradation of the receptor and is 
limiting the IL-33 dependent cytokine production in Mouse lung epithelial (MLE-12) 
cells (Zhao et al., 2015).  The GSK3β phosphorylation is required for the 
ubiquitination of the ST2 receptor by the E3 ligase FBXL19 and the consequent 
proteasomal degradation of  ST2 (Zhao et al., 2012). 
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Figure 1.4 Inhibition of IL-33/ST2 receptor complex.   
The soluble ST2 limits IL-33 signalling by acting as a decoy receptor and sequestering the 
free IL-33. The IL-1 family member SIGIRR prevents the formation of the IL-33/ST2/IL-
RAcP trimeric complex and inhibit the inflammatory signaling. Phosphorylation of the TIR 
domain of ST2 by the GSK3β kinase leads to the internalization of the receptor, ubiquitination 
by the E3 ligase FBXL19 and proteasomal degradation.  
 
 IL-33/ST2 signalling pathway 
 Formation of the MyDDosome  
The dimerisation of the TIR domains of ST2 and IL-1RAcP initiates the 
recruitment of MyD88, the interleukin-1 receptor associated kinases (Biragyn et al., 
2002) and the E3 ligase TRAF6, which leads to MAPK signalling and NF-κB 
activation and production of inflammatory cytokines involved in type two immunity 
(Figure 1.5) (Schmitz et al., 2005).  
MyD88 acts as an adaptor protein for most of the Toll-like receptors as well 
as the IL-1, IL-18 and IL-33 receptors (Cohen, 2014). While signalling downstream 
of the IL-33 receptor has not been studied in as much detail as IL-1 or TLR signalling, 
it is likely that it follows a canonical MyD88 dependent pathway.  Where experimental 
evidence exists, this would support this view as discussed further below.  The C-
terminal domain of MyD88 binds to the TIR domain of the corresponding receptor, 
while the N-terminal death domain interacts with the IRAK kinases (Deguine and 
Barton, 2014). In vivo studies using MyD88 deficient mice highlighted its importance 
during IL-33 dependent type two inflammatory conditions such as lung inflammation, 
atopic dermatitis and gut inflammation (Yang et al., 2013, Denis et al., 2013, Li et al., 
2017). Bone marrow derived basophils from MyD88-/- mice failed to secrete IL-4 and 
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IL-13 in response to IL-33 stimulation (Kroeger et al., 2009).  MyD88 also plays a 
role in promoting eosinophil survival upon IL-33 stimulation and IL-5 withdraw 
(Willebrand and Voehringer, 2016, Li et al., 2018). 
 
Figure 1.5 Model of IL-33 signalling pathway.  
Ligation of IL-33 with the ST2 receptors leads to recruitment of the MyD88 adaptor protein. 
MyD88 interacts with the IL-1 receptor-associated kinase 4 (IRAK4). IRAK4 forms a 
complex with IRAK1 and IRAK2 and the E3 ligase TRAF6 (TNF receptor-associated factor 
6).  This then promotes the formation of K63 linked ubiquitin chains, most probably via 
TRAF6 and Pellino1/2.  The linear ubiquitin assembly complex LUBAC generates the M1 
linear ubiquitin chains which branch of the K63 chains leading to the formation of K63/M1 
chains. TAB2/3 (TAK-1 binding protein 2 and 3) and NEMO bind to the K63 and M1 linear 
ubiquitin chains respectively so that the TAK1 (TGFβ activated protein kinase1) and IKK 
complexes co-localise, allowing TAK1 to activate IKKβ.  TAK1 can activate the p38 and JNK 
MAPK pathways while IKKβ activates the canonical NF-κB pathway.  IKK also activates 
TPL2, via the phosphorylation of p105.  Tpl2 acts as the MAP3K for the ERK1/2 pathway in 
Myd88 dependent signaling. p38 and ERK1/2 activate further downstream kinases including 
MK2/3 (p38), MSK1/2 (ERK1/2 or p38) and RSK1/2/3 (ERK1/2). 
 
The IRAK kinases are rapidly recruited to ST2 following stimulation of ST2-
transfected 293 cells via MyD88 (Schmitz et al., 2005). There are four members of the 
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IRAK family: IRAK1, IRAK2, IRAK-M (also known as IRAK3) and IRAK4. While 
IRAK1 and IRAK4 are catalytically active, IRAK2 and IRAK-M are considered as 
pseudokinases since they lack kinase activity.  IRAK4 phosphorylates IRAK1 and 2, 
these two then dissociate from the complex and activate the E3 ligase TRAF6. 
Interestingly, there seems to be a differential regulation of TLR and IL-33 signalling 
pathways by IRAK kinases (Rhyasen and Starczynowski, 2014).  Mast cells lacking 
IRAK2 responded normally to LPS and PGN, but had impaired response to IL-33 
stimulation and secreted lower levels of IL-6 (Sandig et al., 2013). In contrast, in 
BMMC cells deficient for IRAK1 the response to LPS or peptidoglycan (PGN) 
stimulation was dramatically inhibited, while IRAK1-/- deficient mast cells responded 
normally to IL-33 stimulation. Despite this, BMMCs from mice expressing a kinase 
dead IRAK1 knockin mutation showed reduced levels of IL-33 induced cytokine 
production (unpublished data).  BMMCs from mice with a mutation that disrupts the 
interaction between IRAK2 and TRAF6 also showed reduced IL-33 induced cytokine 
production, while a combination of both IRAK1 and IRAK2 mutations had an even 
greater effect (unpublished data).  This would suggest that both IRAK1 and IRAK2 
are involved downstream of IL-33, but further work would be need to resolve these 
results with the earlier studies in IRAK knockouts. The importance of IRAK2 in 
mediating IL-33 responses was further highlighted using a small molecule which 
mimics the α-helical domain of IRAK2. This compound was found to compromise 
IRAK2-IRAK4 interaction, attenuated the downstream activation of NF-κB 
transcriptional activity and IL-5 and IL-13 cytokine production in IL-33 stimulated T 
cells. In vivo administration of this compound in mice led to an amelioration of the 
pro-inflammatory effects of OVA-induced asthma model (Li et al., 2018).  
IRAK-M is a negative regulator of the TLR and IL-1R signalling (Kobayashi 
et al., 2002).  A recent study suggest that IRAK-M controls IL-33 signalling through 
the prolyl-cis-trans isomerase PIN1. Upon IL-33/ST2 complex formation, the 
activated PIN1 recognises the phosphorylated form of IRAK-M and catalyses IRAK-
M cis-trans isomerisation of a pS110-P motif, and this is required for the nuclear 
translocation of IRAK-M.  Production of Th2 cytokines was dramatically reduced in 
PIN1 and IRAK-M knock out mice following intranasal treatment with IL-33 
(Nechama et al., 2018). 
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The E3 ligase TRAF6 is also required for the IL-33 signalling pathway. 
TRAF6 deficiency in mouse embryonic fibroblasts (MEFs) was associated with loss 
of p38, JNK and NF-κB activation in response to IL-33. Production of IL-6, MCP-1 
and MCP-3  in response to IL-33 was also decreased in TRAF6-/- MEFs (Funakoshi-
Tago et al., 2008). Downstream of IL-1, TRAF6 and Pellino1/2 generate the K63 
ubiquitin chains required for the TAK1 activation (Strickson et al., 2017). The E3 
ligase LUBAC on the other hand generates M1 chains, which bind to the K63 chains 
to form linear ubiquitin chains facilitating the colocalisation of the TAK1 and the 
NEMO/IKK complexes (Emmerich et al., 2013).  While the role of ubiquitination has 
not been extensively examined in IL-33 signalling, it is likely that it would follow a 
similar pattern to IL-1 signalling. 
 
 MAPK activation 
14 MAPKs have been identified in mammalian cells that have been divided in 
to 4 main groups, the classical MAPKs ERK1 and 2, p38 MAPKs, JNKs and a group 
of less well understood atypical MAPKs.  Activation of MAPKs requires 
phosphorylation of the MAPK TXY activation motif via a dual specificity MAPK 
Kinase (MAP2K), which is in turn activated by a MAPK Kinase Kinase (MAP3K) 
(Figure 1.6).   
In the context of classical MyD88 dependent signalling, the TAK1 complex is 
required for the activation of the p38 and JNK MAPK pathways and indirectly for the 
activation of ERK1/2 via the IKK complex and TPL2 (Figure 1.5 and 1.6) (Arthur and 
Ley, 2013).  p38 and ERK1/2  are the most studied MAPKs downstream of MyD88 
and play key roles in MyD88 dependent cytokine production.  The role of JNK is less 
clear, however it negatively regulates IFN production in BMDMs (McGuire et al., 
2017).  
ERK1/2 are also activated in response to IL-33 stimulation in ST2-transfected 
293 cells (Schmitz et al., 2005a).  ERK1/2 phosphorylation was detected in mouse 
MEFs upon IL-33 stimulation, surprisingly this was not dependent on TRAF6 in 
contrast to the phosphorylation of p38 and JNK, which was completely abolished in 
the TRAF6 -/- MEFs (Funakoshi-Tago et al., 2008). Drube et al found that blocking  
c-Kit signalling attenuates ERK1/2 activation in HMC-1.1 cells and SCF stimulation 
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of BMMC cells  amplifies ERK1/2 activation, highlighting the existence of differential 
regulation of ERK1/2 activation and a possible cross talk between the IL-33 and c-Kit 
signalling pathways (Drube et al., 2010).  This highlights a potential difference 
between IL-33 and IL-1 or TLR signaling where ERK1/2 activation is dependent on 
TRAF6. 
The role of JNKs is less studied in comparison to those of p38 and ERK1/2. 
JNK were found to regulate the production of IL-8 in IL-33 stimulated human 
umbilical vein endothelial cells (HUVECs) (Umebashi et al., 2018). A recent study 
demonstrates that IL-33 expression is increased in patients with renal cell carcinoma. 
Moreover, IL-33 was found to promote proliferation of renal carcinoma cells in vitro 
in a JNK-dependent manner, based on the use of SP600125.  Further work would be 
required to confirm this due to the poor selectivity of SP600125 (Bain et al., 2003). 
Surprisingly, in this study IL-33 stimulation of the RCC did not induce activation of 
p38 and ERK1/2 (Wu et al., 2018). The IL-33 dependent proliferation of colon cancer 
cells and upregulation of cancer associated genes such as Oct3/4 and Notch3 were also 
dependent on JNK activation. (Fang et al., 2017).  
p38 is possibly the most studied MAPK in MyD88 dependent signalling.  p38 
has 4 isoforms, , ,  and .  Of these p38 is the most studied and is responsible for 
most of the effects of p38 inhibitors in immune cells; p38  and  are not targeted by 
most p38 inhibitors while p38 does not seem to play a major role (Bain et al., 2007, 
Beardmore et al., 2005).  Originally TAK1 was thought to be the MAP3K for the p38 
pathway in TLR signalling.  A recent study has however challenged this (Pattison et 
al., 2016).  The authors showed that Tpl2 may phosphorylate MKK3 and MKK6 in 
addition to MKK1 and 2.  Thus in some circumstances, such as TNF signalling, p38α 
activation may be dependent on Tpl2 (Pattison et al., 2016).  In TLR4 signalling, 
MKK4 (normally considered as an MAP2K for JNK and a direct TAK1 target) is able 
to feed into the activation of p38, resulting in TLR4 stimulated p38 activation being 
independent of Tpl2.  An important role for p38α in the IL-33 signalling pathway has 
been suggested by number of studies. p38α is phosphorylated upon IL-33 stimulation 
in different immune cells such as BMMC, ILC2 cells, Th2 cells (McCarthy et al., 
2018, Tung et al., 2014, Furusawa et al., 2013, Endo et al., 2015, Gopfert and Andreas, 
2018). In mast cells, p38 is critical for the IL-33 induced secretion of IL-13, IL-6, TNF 
and GM-CSF (McCarthy et al., 2018).  The pharmacological inhibition of p38 using 
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the inhibitor SB203580 led to a significant reduction of IL-5 in human and murine 
Th2 cells, but did not affect the secretion of IL-4 and IL-13. The authors suggested a 
mechanism in which inhibition of p38 leads to reduction of the histone acetylation and 
methylation, inducing a chromatin remodelling at the IL5 locus (Endo et al., 2015). In 
ILC2 cells stimulation with IL-33 induced activation and p38 dependent 
phosphorylation of GATA3. The authors found that phosphorylated GATA3 binds to 
the IL5 and IL13 promotor and could induce their transcription (Furusawa et al., 
2013a).  
  
Figure 1.6 MAPK signalling cascade. 
The MAP3K RAF and TPL2 phosphorylate and activate the MKK1/2, which then activate 
ERK1/2.  TPL2 can also phosphorylate and activate MKK3/6 upon TLR and TNFR activation. 
MKK3/6 are activated by TAK1, MEKK1/4 or TAO1/2. MKK3/6 phosphorylate p38 MAPKs. 
TAK1 can also activate MKK4/7, which in turns phosphorylate and induce activation of the 
JNK1/2/3. MKK4, but not MKK7 also phosphorylate p38. The MAPKs have several 
substrates.. p38 and ERK1/2 can activate MSK1/2 and the MNKs. RSK1/2 are activated by 
ERK1/2, while MK2/3 phosphorylation is mediated by p38α 
 
 MAPKAPK 2/3 role in IL-33 signalling 
ERK1/2 can phosphorylate and activate the downstream MAPKAP kinases 
RSKs (Ribosomal s6 kinase), MNK1/2 (Mitogen-Activated Protein Kinase Interacting 
Protein Kinase) and MSK1/2 (Mitogen- and stress-activated kinases). Similarly, p38 
can activate MNKs, MSKs and the two MAPKAPKs (Mitogen-activated protein 
kinase-activated protein kinases) MK2 and MK3 (Figure 1.6) (Arthur and Ley, 2013).  
The two isoforms MK2/3 are phosphorylated by p38α (Rouse et al., 1994). 
MK2/3 form a complex with p38α and stabilise p38α expression (Kotlyarov et al., 
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2002) (Ronkina et al., 2007). MK2 deficient macrophages have a reduction in TNF 
production in response to LPS in vitro and are resistant to LPS-induced endotoxic 
shock (Kotlyarov et al., 1999). Although MK2 and 3 share functional similarities, loss 
of MK3 alone did not affect p38α expression or cytokine production in LPS-stimulated 
macrophages, however MK2/3 DKO mice displayed a further reduction in the ability 
to secrete TNF upon stimulation in comparison to MK2 KO cells. (Ronkina et al., 
2007). In macrophages MK2 regulates TNF-α production at post-transcriptional level 
through a mechanism dependent on the AU-rich element-binding protein 
tristetraprolin (TTP) (Hitti et al., 2006). TTP binds mRNA AU-rich elements (ARE) 
in the 3’UTRs region and promotes their degradation by recruiting enzymes mediating 
mRNA deadenylation and or competing with the ARE-stabilising factor human 
antigen R (HuR) for binding to the 3’UTR (Marchese et al., 2010, Tiedje et al., 2012). 
MK2 phosphorylates S52 and S178 in tristetraprolin (TTP) (Chrestensen et al., 2004), 
which leads to the association of TTP with 14-3-3 protein and impairs the ability of 
TTP to recruit deadenylases (Clement et al., 2011). The importance of these 
phosphorylation events has been demonstrated using mice with mutation in the TTP 
encoding gene ZFP36 in which S52 and S178 codons are replaced with alanine 
codons. Although the expression of TTP was lower in macrophages isolated from 
these mice, TTP levels were sufficient to mediate the degradation of cytokine mRNA 
such as TNF, CXCL1 and IL10 following stimulation with LPS. Moreover, ZFP36aa/aa 
displayed a protective phenotype upon i.p administration of LPS with significantly 
lower cytokine levels in the serum and hepatic damage in comparison to ZFP36+/+ 
mice (Ross et al., 2015).  
Work done in our lab demonstrated that MK2/3 regulate the production of 
multiple cytokines in IL-33 stimulated mast cells, including TNF-α, IL-6, IL-13 and 
GM-CSF (McCarthy et al., 2018). Whereas the production of TNF-α in response to 
LPS is regulated by the MK2/3 dependent phosphorylation of TTP, in mast cells TTP 
seems to be dispensable and MK2/3 might regulate the IL-33 cytokine production by 
phosphorylating the TTP related proteins Brf1 and/or Brf2 (McCarthy et al., 2018). 
In addition to TTP, MK2 and/or 3 have a number of other substrates.  MK2 
can phosphorylate RSK in TLR stimulated dendritic cells, allowing RSK activation to 
bypass dependence on ERK1/2 (Zaru et al., 2007, Zaru et al., 2015).  MK2 has also 
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recently been found to phosphorylate RIPK1 and protect cells from apoptosis (Menon 
et al., 2017). 
 
 NF-κB 
The NF-κB family of transcription factors (Nuclear factor- κB) play an 
essential role in innate and adaptive immune function in addition to being involved in 
many other cellular processes. NF-κB regulates expression of inflammatory mediators 
such as genes encoding cytokines and chemokines, genes involved in promoting cell 
survival and inflammasome regulation. Therefore the activation of NF-κB is critical 
for mediating host defense, however dysregulation of NF-κB contributes to the 
development of inflammatory diseases and as a result must be tightly regulated (Liu 
et al., 2017). NF-κB transcription factors include five structurally related members: 
NF-κB1 (p105/p50), NF-κB2 (p100/p52), RelA (p65), RelB and c-Rel. NF-κB1 and 
NF-κB2 are post-translationally cleaved to p50 and p52, respectively (Liu et al., 2017). 
The NF-κB1 transcription factors act as homo- and heterodimers and can act both as 
transcriptional activators or repressors (Ryseck et al., 1992, Ruben et al., 1992). A 
number of different pathways has been shown to regulate NF-κB, however the 
canonical pathway is most relevant to MyD88 dependent signalling.  In the canonical 
NF-κB  pathway, NF-κB transcription factors are sequestered in the cytoplasm in 
resting cells by IκB proteins and this prevents their translocation to the nucleus 
(Yamamoto and Gaynor, 2004). The IκB family includes IκBα, IκBβ, IκBγ, IκBε, 
Bcl3 and IκBζ. All IκB family members are characterised by an Ankyrin repeats at the 
C-terminal region, which are required for the interaction with the NF-κB proteins. A 
key step of the canonical activation of NF-κB is the phosphorylation IκBα/β proteins 
by the IκB kinases (IKK). The activation of IKKβ relies on formation of the IKK 
complex containing NEMO, IKKα and IKKβ. IKKβ phosphorylates the IκB proteins 
at S32 and Ser36 in IκBα and S23 and S19 in  IκBβ (Zandi et al., 1997). Once 
phosphorylated, the IκBα/β proteins are ubiquitinated by the E3 ligase β-TrCP SCF 
(Skip1/Cullin1 F box E3 ligase) (Cohen et al., 2004, Orian et al., 2000). This 
ubiquitination results in the addition of K48 linked polyubiquitin chains targeting the 
IκB protein for degradation by the proteasome (Sakurai et al., 1999, Zandi et al., 1997).  
The degradation of IκB proteins frees NF-κB and allows its translocate to the nucleus.  
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Similarly to other IL-1 members, IL-33 signalling leads to the activation of the 
NF-κB (Schmitz et al., 2005a). Upregulation of ICAM-1 and VCAM-1 in endothelial 
and mast cells in response to IL-33 is also dependent on the NF-κB activation (Choi 
et al., 2012, Numata et al., 2016). It has been also proposed that IL-33 can act as a 
transcription factor and modulate NF-κB. It has been demonstrated that IL-33 can bind 
the promotor of p65 in endothelial cells and induce its expression (Choi et al., 2012).  
However, it has been also demonstrated that IL-33 can bind p65 via protein-protein 
interaction and limit the ability of p65 to associate with its target genes (Ali et al., 
2011).  
 
 Interleukin-33  
Interleukin-33 is a pleiotropic cytokine that plays a key role in regulating both 
innate and adaptive immunity. IL-33 was discovered in 2005 by Schmitz et al as a 
novel member of the IL-1 superfamily and most closely related to IL-18. IL-33 was 
shown to bind to the orphan IL-1 Receptor ST2 (the suppressor of tumorigenic 2) and 
trigger activation of both MAP kinases and NF-κB to promote type two immunity 
(Schmitz et al., 2005). IL-33 was later shown to be identical to a protein called nuclear 
factor from high endothelial venules (NF-HEV), which was found two years earlier in 
endothelial cells (Moussion et al., 2008).  
 
 Interleukin-33 expression 
 Endothelial cells 
IL-33 is abundantly expressed in the nuclei of vascular endothelial cells in 
healthy human tissues. Due to the constitutive expression along the vascular system 
IL-33 is found in all human tissues (Moussion et al., 2008). During inflammation the 
expression of IL-33 in human endothelial cells can be further induced or 
downregulated depending on the circumstance. For example human endothelial cells 
were found to be the major source of IL-33 during inflammatory conditions such as 
rheumatoid arthritis and Crohn’s disease (Moussion et al., 2008a), but its expression 
was downregulated in angiogenic wound healing (Kuchler et al., 2008). 
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In contrast to humans, where IL-33 is constitutively expressed in vascular 
endothelial cells, in mice the steady-state expression of IL-33 is observed only in few 
tissues including the vascular bed of adipose tissue and in liver sinusoidal endothelial 
cells (LSEC).  However, IL-33 expression could be further induced in liver endothelial 
cells in response to viral or poly(I:C) hepatic injury, in colonic endothelial cells during 
inflammatory conditions like DSS-induced colitis and in the cardiac endothelial cells 
in response to myocardial pressure overload (Pichery et al., 2012, Arshad et al., 2015, 
Arshad et al., 2013, Chen et al., 2015).   
 
 Epithelial cells 
Epithelial cells are the other major source of IL-33, particularly the epithelial 
cells in the respiratory system, gastrointestinal tract and skin. Increased IL-33 
expression has been reported in sinonasal epithelial (SNEC) cells in patients with 
chronic rhinosinusitis with nasal polyps (Paris et al., 2014) (Lam et al., 2015). While 
in healthy controls IL-33 staining was observed only in the nuclei of the SNE cells, in 
patients with rhinosinusitis IL-33 was found also in the cytoplasm (Paris et al., 2014). 
Studies with IL-33-LacZ gene trap reporter mice, in which βgeo insertion in 
the IL-33 gene was used to asses il-33 promotor activity, showed that IL-33 is 
expressed in alveolar epithelial cells (Pichery et al., 2012). To study IL-33 expression 
in vivo, Hardman et al developed another IL-33 reporter mouse strain, in which the 
GFP-derived Citrine gene was inserted after the il33 start codon.  The expression of 
IL-33 in lungs was confirmed using this reporter strain. In fact, the citrine positive 
cells were found positive for the type-2 pneumocyte markers CD138 and the surfactant 
protein C (SPC) (Hardman et al., 2013). Expression of IL-33 was further induced in 
the type2 pneumocytes during challenge with ovalbumin and the fungal pathogens 
Alternaria alternata and Cryptococcus neoformans (Heyen et al., 2016, S. et al., 
2013).  
As mentioned above expression of IL-33 has been also reported in epithelial 
cells of the gastrointestinal tract and a number of studies have shown that IL-33 
expression is increased in patients with inflammatory bowel disease (IBD) and in 
mouse models of IBD (Seidelin et al., 2010, Pastorelli et al., 2010, Gundersen et al., 
2016). Skin keratinocytes are another source of IL-33(Anna et al., 2012, Balato et al., 
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2014). Mouse keratinocytes express IL-33 constitutively, whereas in humans the 
expression of IL-33 is inducible (Sundnes et al., 2015, Pichery et al., 2012). Increased 
IL-33 expression in human keratinocytes has been found in patients with vitiligo, in 
the skin lesions of patients with atopic dermatitis and psoriasis (P. et al., 2015, Savinko 
et al., 2012, Balato et al., 2014). 
 
 IL-33 expression in other cell types 
Using IL-33-LacZ gene trap reporter mice it was found that IL-33 is expressed 
in the nuclei of the fibroblastic reticular cells in mouse spleens and lymph nodes 
(Pichery et al., 2012). Mahapatro et al. showed that the pericryptal fibroblasts in the 
small intestine upregulate IL-33 in response to intraperitoneal injection of LPS 
(Mahapatro et al., 2016). Myofibroblast from colonic lesions of patients with 
ulcerative colitis, but not from Crohn’s disease were also found to be positive for IL-
33 (Sponheim et al., 2010). Induced expression of IL-33 was also found in mice 
cardiac fibroblasts and cardiomyocytes in response to injury (Sanada et al., 2007).  
Immunohistochemistry analysis of tissues from healthy and asthmatic patients 
showed that along the epithelial and endothelial cells, the airway smooth muscle cells 
are also expressing IL-33. Stimulation of primary airway smooth muscle cells with 
TNF-α and IFN-γ led to an upregulation of IL-33 at mRNA and protein levels 
(Préfontaine et al., 2009).  
A few reports suggest that IL-33 is also found in the nucleus of immune cells 
and more specifically in the monocytic cell line THP-1, in primary human monocytes 
and in M2 macrophages in the salivary glands from patients with Sjörgen’s syndrome 
(Furukawa et al., 2017) (Nile et al., 2010). A small number of citrine positive immune 
cells (macrophages, DCs and neutrophils) were detected in the lungs of the IL-33 
citrine reporter mice and the absolute numbers of IL-33 expressing cells was further 
increased in ovalbumin treated mice (Hardman et al., 2013). Interestingly, increased 
IL-33 expression was found in peritoneal macrophages from IL-10 deficient mice 
(Chen et al., 2017). 
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 Interleukin-33 activity and release from the nucleus 
 IL-33 structure 
IL-33 has a nuclear localisation sequence (NLS), a chromatin-binding motif, a 
central domain and a C-terminal IL-1-like cytokine domain (Figure 1.7). The presence 
of both chromatin binding motif and the cytokine domain suggests that IL-33 may 
have a dual function and could acts as a cytokine and regulator of gene transcription. 
IL-33 can bind the p65 subunit of NF-κB and inhibit NF-κB dependent gene 
expression following stimulation with IL-1β (Ali et al., 2011). The nuclear localisation 
of IL-33 is required for maintaining immune homeostasis since mice lacking the NLS 
succumbed to systemic inflammation due to inappropriate IL-33 release (Bessa et al., 
2014).  Lack of the NLS domain leads to release of IL-33 in the extracellular space, 
recruitment of eosinophils, inflammatory monocytes and consequently to lung 
inflammation, enlargement of the mesenteric lymph nodes (Bessa et al., 2014).   
 
 
Figure 1.7 IL-33 structure.   
IL-33 protein has three domains: nuclear localisation domain, a central domain and IL-1-like 
cytokine domain. The nuclear localisation domain is highly conserved among species and 
contains a chromatin binding motif. The central domain is linking the two other domains and 
contains cleavage sites for inflammatory proteases. The ST2 binding sites are located on the 
IL-1like domain, which also has cleavage sites for caspase-3 and caspase-7.  
 
 Caspase cleavage and inactivation of IL-33 
IL-33 does not have a secretory sequence like other cytokines (Kakkar et al., 
2012). Initially it was proposed that similar to the other members of the IL-1 family 
IL-1β and IL-18, IL-33 maturation requires cleavage in the IL-1 like domain by 
caspase-1 (Schmitz et al., 2005, Cayrol and Girard, 2009). However, it was later shown 
that the proteolytic cleavage of IL-33 is mediated by caspase-3 and 7, and not by 
caspase-1 (Luthi et al., 2009). Both murine and human IL-33 have a conserved 
cleavage motif  “DGVD”  located at Asp178 in humans and Asp175 in mice.  Mutation 
in this motif results in completely impaired cleavage by caspase-3 and caspase-7. 
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Interestingly, in both studies of Luthi et al and Caryol et al it was found that caspase 
processing renders inactive IL-33 and mice stimulated with cleaved IL-33 had 
significantly decreased granulocyte infiltration in the peritoneum, blood and spleen 
and lower IL-5 and IL-4 production in comparison to mice treated with uncleaved IL-
33 (Cayrol and Girard, 2009).  
 
 Secretion of active IL-33 form 
IL-33 does not have a secretory sequence. In fact, IL-33 release is triggered 
during cell necrosis (such as induced by hydrogen peroxide or sodium azide 
treatment), endothelial cells undergoing mechanical injury, exposure to membrane 
damaging detergents or by freezing-thawing (Cayrol and Girard, 2009, Luthi et al., 
2009). Therefore, IL-33 has been classed as an alarmin, which act as a danger signals 
following cellular damage resulting from tissue injury or inflammation (Cayrol and 
Girard, 2014).  Increased levels of extracellular ATP  have also been shown to induce 
IL-33 release from the airway epithelial cells challenged with the fungal pathogen 
Alternaria alternata  through a mechanism relying on accumulation of Ca2+ in 
epithelial cells (Kouzaki et al., 2011).  
Whereas cleavage of IL-33 by caspase-3 and caspase-7 leads to inactivation of 
the cytokine, a growing number of studies are showing that IL-33 can be cleaved by 
inflammatory proteases into active form (Figure 1.8). For example the neutrophil 
proteases elastase and cathepsin G can generate cleaved mature forms of IL-33, that 
have a higher biological activity than the full length IL-33 (FLIL-33) (Cayrol and 
Girard, 2014). The mast cell derived serine proteases chymase, tryptase and granzyme 
B can also cleave IL-33 resulting in mature forms with more than 30-fold higher 
activity than the FLIL-33 (Lefrancais et al., 2014). The cleavage sites for the 
inflammatory proteases were all located in the central domain of IL-33 (Cayrol and 
Girard, 2014, Lefrancais et al., 2014) .  
More recent studies suggest that in the absence of immune cell derived 
inflammatory proteases, allergen derived proteases are also capable of cleaving and 
producing mature IL-33 (Snelgrove et al., 2014, Scott et al., 2018, Cayrol et al., 2018). 
Cayrol et al screened a variety of clinically relevant allergens causing asthma, rhinitis, 
and dermatitis and showed that the allergen derived proteases are able to cleave  FLIL-
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33 into highly active shorter mature forms. Although FLIL-33 is still active, the authors 
suggested that the protease mediated processing of FLIL-33 is critical for increasing its 
biological activity, with the release and cleavage tightly coupled. Using a specific 
antibody against the central domain, which masks the protease cleavage sites but does 
not impair the activity of the IL-1 like cytokine domain, they demonstrated that airway 
eosinophilia, mucus and cytokine production are dependent on IL-33 protease 
processing (Cayrol et al., 2018).  The cell endogenous Ca2+-dependent proteases 
calpains can also cleave FLIL-33 in vitro. However, inhibition treatment with the 
calpeptin inhibitor did not prevent the IL-33 processing in vivo in Alternaria treated 
animals, most likely because the allergen derived proteases are sufficient to mediate 
the cleavage of IL-33 (Scott et al., 2018).  
 
Figure 1.8 IL-33 release regulation.  
A. In healthy tissues at steady state IL-33 is located in the nucleus. B.  During apoptosis the 
full length IL-33 is cleaved by caspase-3 and caspase-7 and converted to inactive form. C IL-
33 is released during necrosis caused by allergen challenge, mechanical injury or infection. 
The full length protein is then cleaved by immune cells or allergen derived proteases, which 
generate the mature short forms of IL-33. These are then recognized by the ST2 expressed on 
immune cells such as ILC2, mast cells, Th2 and Treg cells.  
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 Type 2 innate lymphoid cells (ILC2s) 
 Innate lymphoid cells 
Innate lymphoid cells are a recently identified group of lymphocytes within 
the innate immune system. ILCs lack antigen specific receptors, however in terms of 
the cytokines they produce they mimic various Th cell subsets. ILCs are found in both 
lymphoid and non-lymphoid tissues, particularly at the barrier sites including skin, 
respiratory and gastrointestinal systems (Spits et al., 2013).  Based on their effector 
function, cell surface markers and the transcription factors required for their 
development, ILCs are subdivided into several distinct groups, summarised in Figure 
1.9 (Spits et al., 2013). Group 1 includes NK cells and ILC1 cells, which are involved 
in protective immunity to viral infections and antimicrobial responses (Seillet et al., 
2016). The second group includes type 2 innate lymphoid cells (ILC2s). ILC2 cells 
secrete type two cytokines in response to stimulation with the epithelial derived 
cytokines IL-25, IL-33 and TSLP and regulate immune responses during helminth 
infection, asthma and atopic diseases (Moro et al., 2010, Neill et al., 2010, Klein 
Wolterink et al., 2012). The third group includes lymphoid tissue inducer cells and 
ILC3s. LTi cells regulate the development of secondary lymphoid tissues (lymph 
nodes, spleen, tonsils, Peyer’s patches and fat associated lymphoid clusters) (Mebius 
et al., 1997, Meier et al., 2007). ILC3 cells are involved in the maintenance of intestinal 
homeostasis, protection against extracellular bacteria and inflammatory bowel 
diseases (IBD) (Takatori et al., 2009). In 2017 a new group of ILCs with regulatory 
functions was discovered. ILCreg are found in human and mouse gut and limit the 
activity of ILC1s and ILC3s by secreting the anti-inflammatory cytokine IL-10. In 
contrast to regulatory T cells, the FoxP3 transcription factor was not required for their 
development, but they did require the cytokines TGF-β and IL-2 (Wang et al., 2017).  
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Figure 1.9 Innate lymphoid cells. 
ILCs can be divided into 4 main groups, type 1, type 2 (yellow), type 3 (red) and ILCreg 
(green).  The transcription factor required for their development along with the stimuli 
required for their activation and the main cytokines / inflammatory mediators they produce 
are indicated.  The conventional NK cells are cytotoxic cells responding to IL-12, IL-15 and 
IL-18 stimulation and secreting perforin, granzymes and IFN. Similarly, ILC1s are also 
activated by IL-12 and IL-18 and produce IFN and TNF. ILC2s differentiation is dependent 
on GATA3. ILC2s respond to IL-25, IL-33 and TSLP and modulate type two immunity by 
secreting IL-5, IL-6, IL-9 and IL-13. Group 3 ILC is represented by LTi and ILC3s which 
require transcription factor ROR-γt and stimulation with IL-23, IL-1β for their effector 
functions. ILC3s express also the T-bet transcription factor and depending on the conditions 
they can adopt an ILC1s phenotype. ILCreg have regulatory functions. They respond to TGF-
β stimulation and secrete IL-10 to limit over excessive inflammation in the gut.  
 
 Group 2 innate lymphoid cells discovery and characterisation 
The first evidence for the existence of ILC2 cells was found in 2006 when 
Fallon et al. showed that during helminth infection with Nippostrongylus brasilienis a 
population of non-T and non-B cells secrete IL-4, IL-5 and IL-13 and promote 
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helminth expulsion (Fallon et al., 2006). However, it was not until 2010 that several 
labs reported the characterisation of ILC2s as a distinct population of cells, which were 
initially referred to as either neuocytes, innate helper 2 cells or natural helper cells 
(Moro et al., 2010, Neill et al., 2010, Price et al., 2010). ILC2s are found in lymphoid 
tissues such as spleen and mesenteric lymph nodes, as well as in some non-lymphoid 
organs including fat associated lymphoid clusters, lungs, skin and liver. In mice ILC2s 
are characterised by the lack of expression of markers of other immune cells (CD3, 
CD4, CD8, CD19, CD11b, CD11c, F4/80, FcεR,) and the expression of the IL-7R, IL-
33 receptor (ST2), IL-25 receptor (IL-17RB), KLRG1, ICOS and c-kit. Human ILC2 
are lineage negative and express IL-7R and the prostaglandin receptor CRTH2, CD161 
and CCR6 (Trabanelli et al., 2018).  
Similar to other ILCs, ILC2s originate from Common Lymphoid Progenitors 
(CLPs) in the bone marrow and their development requires multiple transcription 
factors. The transition of CLPs to the specific common helper innate lineage 
progenitor (CHILP) requires the transcription factor inhibitor Id2. Id2 regulates the 
activity of a group of E proteins and supresses the differentiation of T and B cells 
allowing divergence of the CLPs to the innate linage. Id2 is critical for the 
development of all innate lymphoid cells. (Yokota et al., 1999, Moro et al., 2009, 
Cherrier et al., 2012). Downstream of the CHILP, the development and maintenance 
of ILC2s depends on multiple transcription factors including ROR-α, Bcl11b, Gfi1 
and GATA3 (Halim et al., 2012b, Walker et al., 2015, Spooner et al., 2013). Staggerer 
RORαsg/sg mice with a spontaneous deletion in the Rora gene resulting in truncated 
protein, have severely reduced ILC2s numbers (Halim et al., 2012). Given the 
importance of RORα in ILC2 development, an ILC2 deficient mouse model was made 
by specifically deleting RORα in IL-7R expressing cells (Rorafl/sgIl7rCre mice), which 
resulted in a deletion in the lymphoid lineage. These mice have normal numbers of T 
cells and NK cells in the mesenteric lymph nodes, but no ILC2 cells. Rorafl/sgIl7rCre 
mice had delayed worm expulsion during N. brasiliensis infection, reduced ILC2 
expansion and T helper cellular responses. The authors suggested that ILC2 cells are 
required for the activation of Th2 cells through their MHC II expression  (Oliphant et 
al., 2014).  
Hoyler et al. demonstrated that the transcription factor GATA3 is expressed at 
high levels in ILC2 cells isolated from different tissues as well as in ILC bone marrow 
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progenitors, suggesting that GATA3 plays a role in the development and maintenance 
of ILC2 cells (Hoyler et al., 2012).  Conditional deletion of GATA3 in Id2 positive 
cells resulted in complete loss of ILC2 populations (Hoyler et al., 2012). Blc11b is 
another transcription factor implicated in ILC2s development. Bcl11b is also a 
transcriptional regulator expressed in T cells, which plays a crucial role in defining T 
cell fate (Albu et al., 2011). Using Bcl11b reporter mice crossed to Id2 reporter mice 
it was shown that Bcl11b is expressed in mature ILC2s and ILC progenitors (Walker 
et al., 2015). In mature ILC2s Bcl11b was found to act upstream of GATA3 and 
RORα. Bcl11b deficient ILC2s have reduced expression of GATA3 and ROR-α and 
instead upregulate the ILC3s transcription factor ROR-γt and IL-23 receptor (Califano 
et al., 2015).  
 
 
Figure 1.10 Innate lymphoid cells development.  
ILCs develop from a common lymphoid progenitor (CLP) in the bone marrow. The 
transcription factor TCF-1 defines an early ILC progenitor EILP, which give rise to all innate 
lymphoid cells. Development of NK cells from the EILP is dependent on NFIL3. The EILP 
give rise to a specific common helper innate lineage progenitor (CHILP), from which helper 
like ILC develop. The transcription factor PLZF characterises committed Id2+veGATA3+ve ILC 
progenitor from which ILC1, ILC2 and ILC3 can develop. Development of LTi is independent 
of PLZF and results from upregulation of ROR-γt in the CHILP. Following of that the fate of 
the ILCs is determined by expression of T-bet for ILC1, GATA3 and RORα for ILC2 and 
ROR-γt for ILC3.  
 
 Activation and inhibition of ILC2 function 
All innate lymphoid cells lack antigen specific receptors and are instead 
activated by cytokine stimulation. ILC2s responses are triggered by the cytokines  
IL-33, IL-25 or TSLP. In addition, lipid mediators such as prostaglandins and 
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leukotrienes or neuronal derived neuropeptides can also induce ILC2s activation 
(Figure 1.11) (Klose and Artis, 2016). 
 
Figure 1.11 ILC2s activation.  
ILC2s get activated by multiple signals including the epithelial derived cytokines IL-33, 
TSLP, and IL-25, lipid mediators such as Prostaglandin D2 or leukotriene D4 or neuron 
derived neuropeptides such as neuromedin U. Once activated ILC2s secrete effector molecules 
and mediate the function of other cells. By secreting Met-Enkephalin ILC2s stimulate the 
beiging of the white adipose tissue. Production of IL-13 leads to the activation of alternatively 
activated macrophages, IL-13 is also required for the goblet cell metaplasia and mucus 
production, smooth airway muscle cell contractions. Both IL-13 and IL-5 are promoting 
eosinophil survival and recruitment. ILC2s stimulate mast cell hyperplasia by secreting IL-9. 
IL-9 leads to increased expression of inflammatory proteases and cytokine production in mast 
cells. ILC2s can mediate adaptive immune cell function by secreting IL-6 and IL-4, which are 
promoting antibody production in B cells and differentiation of Th2 cells. The amphiregulin 
production by ILC2s promotes wound healing.  
 
 
 Activation of ILC2s by IL-33  
IL-33 is a cytokine from the IL-1 family, which is released from cells 
undergoing necrosis or damage caused by inflammatory stimuli, allergens or 
mechanical injury (Cayrol and Girard, 2009). Murine ILC2s isolated from various 
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tissues including mesenteric fat, lungs, bone marrow and small intestine express the 
IL-33 receptor chain ST2 (Moro et al., 2015). ST2 is also expressed in ILC2 precursors 
(ILC2P) in the bone marrow (Hoyler et al., 2012).  In fact stimulation with IL-33 and 
IL-7 is used as system to generate ILC2 from CLPs (Wong et al., 2012). Il33−/− and 
St2−/− mice have significant increase of ILC2s precursors in the bone marrow, but 
decreased mature ILC2s in the periphery (Stier et al., 2017).  This suggests that loss 
of IL-33 signalling is required for the ILC2s egress from the bone marrow. 
Mechanistically, this was explained by the fact that stimulation with IL-33 leads to 
downregulation of the chemokine receptor CXCR4 which regulates the retention of 
developing leukocytes in the bone marrow (Stier et al., 2017, Brestoff et al., 2014). 
Human ILC2s isolated from skin or white adipose tissues also express ST2 (Salimi et 
al., 2013). Similar to mice, IL-33 was shown to have chemoattractant properties and 
induce migration of human ILC2s (Salimi et al., 2013).  
IL-33 is considered as one of the most prominent activators of ILC2s function 
(Barlow et al., 2013).  IL-33 induces production of type two cytokines both in human 
and murine ILC2s during in vitro stimulation (Salimi et al., 2013, Bartemes et al., 
2014, Furusawa et al., 2013b).  Upon in vivo administration of IL-33 in mice, ILC2s 
are a major subset producing IL-5 and IL-13 in the lungs of mice with house dust mite‐
induced or ovalbumin‐induced allergic asthma (Klein Wolterink et al., 2012). ILC2 
are also the predominant source of IL-13 during early stage of N. brasiliensis infection 
and loss of IL-33 led to a substantial reduction in the ILC2-derived IL-13 during N. 
brasiliensis without affecting Th2 responses (Neill et al., 2010, Hung et al., 2013). 
Because of their ability to mount a strong response to IL-33 stimulation, ILC2s play 
an important role in the pathology of asthma (Bartemes et al., 2012, Halim et al., 
2012).  
 
 Activation of ILC2s by IL-25  
IL-25 (IL-17E) is a cytokine which is part of the IL-17 family. Despite IL-25 
sharing structural homology and some functional overlap with other members of the 
family, IL-25 has a distinct biological activities and induces type two like response. In 
vivo administration of IL-25 leads to splenomegaly, eosinophilia, increased production 
of IL-5 and IL-13 and increased IgE production (Fort et al., 2001). These in vivo 
effects of IL-25 were found to be mediated by a cell population that did not express T 
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and B cells markers or FcεR, but were positive for c-Kit (Fallon et al., 2006). 
Consequent studies suggested that IL-25 induces multipotent progenitor cells 
(MMPtype 2) which have the potential to differentiate into myeloid subsets and also 
type two innate lymphoid cells (Saenz et al., 2010, Huang et al., 2015, Saenz et al., 
2013). Some groups suggest that IL-25 elicit specific type of inflammatory ILC2s, 
which upregulate KLRG1 expression and could adopt ILC3s phenotype due to 
expression of the RORγt transcription factor during lung inflammation (Huang et al., 
2014).  
In the gut IL-25 derived from tuft cells plays an important role in the 
maintenance of ILC2s. IL-25 knock out mice have reduced frequencies of ILC2s in 
the small intestine at steady state and following helminth infection. Tuft cell derived 
IL-25 was also found to stimulate IL-13 production by ILC2s, which was then required 
for tuft cell maintenance and IL-25 secretion, suggesting a homeostatic circle between 
the tuft cells and ILC2s (von Moltke et al., 2015).   
 
 Activation of ILC2s by TSLP  
Thymic stromal lymphopoietin (TSLP) is secreted by epithelial, stromal and 
mast cells and its expression is highly induced in skin of patients with atopic dermatitis 
(Soumelis and Liu, 2004). Human and murine ILC2 cells express the TSLP receptor 
and its co-receptor CD127 (Mjösberg et al., 2012). When stimulated with TSLP, 
ILC2s from human blood and nasal polyps had a significant increase in the production 
of IL-13. Stimulation with both IL-33 and TSLP further amplified the ILC2s responses 
and led to an induction of other cytokines including IL-5, IL-9, GM-CSF and IL-4 
(Mjösberg et al., 2012). In an experimental model of atopic dermatitis (AD) ILC2s 
were massively expanded in wild type mice, however genetic deletion of TSLP 
receptor resulted in impaired ILC2s expansion and reduced AD-like inflammation 
(Kim et al., 2013). Analysis of in vitro stimulated ILC2s isolated from human blood, 
showed that TSLP also promotes ILC2s survival (Camelo et al., 2017).   
 
 
 Activation of ILC2s by Lipid mediators 
ILC2s function can be regulated not only by cytokine stimulation but also by 
lipid mediators like prostaglandins and leukotrienes (Konya and Mjösberg, 2016).  
These lipid mediators signal via specific G Protein Coupled Receptors (GPCRs).  As 
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different GPCRs couple to various downstream signalling pathways via heterotrimeric 
G proteins with different G alpha subunit, different lipid mediators can have very 
different effects on the ILC2s.  Inflammatory signals can induce the release of 
arachidonic acid from membrane lipids. Arachidonic acid is then converted to 
prostaglandins or leukotrienes. The COX enzymes catalyse the conversion of 
arachidonic acid to prostaglandin H2 (PGH2), which is then converted further to either 
PGI2, PGF2α, PGD2 and PGE2 (Harris et al., 2002). PGD2 has strong association with 
asthma and allergic airway inflammation. During allergic response PGD2 is released 
by mast cells or epithelial cells and promotes type two immunity (Arima and Fukuda, 
2011). Human ILC2s are characterised by the expression of the prostaglandin PGD2 
receptor CRTH2 (Trabanelli et al., 2018, Mjosberg et al., 2011).  PGD2 has a 
chemoattractant effect on human ILC2s and can influence their migration to the 
inflamed tissues. PGD2 stimulation also induces cytokine production in ILC2s (Xue et 
al., 2014). In contrast to human ILC2, PGD2 did not activate murine ILC2s to produce 
cytokines, neither did it amplify the IL-33 dependent response.  However, ILC2s 
accumulated in mouse lungs following in vivo intranasal administration of PGD2.  
Ptgdr2-/- (also called Gpr44−/−) mice which lack the prostaglandin PGD2 receptor 
CRTH2 displayed less severe pathological changes following infection with N. 
brasiliensis. The authors suggested that this effect was mediated by lack of CRTH2 
specifically in ILC2s, since Ptgdr2-/- mice which received adoptive transfer of WT 
ILC2 cells had significantly increased pathology in comparison to Ptgdr2-/- mice that 
were not reconstituted (Tait Wojno et al., 2015). 
Prostaglandin E2 (PGE2) has opposite role than PGD2 and inhibits IL-33-
dependent cytokine production in ILC2s. In vivo co-administration of IL-33 and PGE2 
resulted in lower ILC2s infiltration in the bronchoalveolar lavage fluid (BALF) in 
comparison to treatment with IL-33 alone (Zhou et al., 2018). Furthermore, PGE2 was 
found to inhibit the IL-33-dependent increase of GATA3 and ST2 expression in ILC2s 
(Zhou et al., 2018). The same effect of PGE2 on GATA3 expression was found also in 
human ILC2s (Maric et al., 2018).  
Like the prostaglandins the leukotrienes are also synthesised from the 
arachidonic acid. The enzyme 5-lipoxygenase converts arachidonic acid to LTA4. The 
last is converted to LTC4. LTD4 and LTE4 are then synthesised from LTC4.. LTC4, 
LTD4 and LTE4 are referred as cysteinyl leukotrienes or cysLTs. The cysLTs are 
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synthesised by variety of immune cells including mast cells, eosinophils and basophils 
(Peters-Golden et al., 2006). cysLTs signalling results in Ca2+ influx in cells, decreased 
levels of cyclic AMP, activation of the PI3K-Akt pathway, as well as RAS-Raf-ERK 
pathway (Burke et al., 2016). Stimulation of ILC2s with LTD4 induced production of 
IL-4, IL-5 and IL-13, this was accompanied by increased Ca2+ influx. In vivo 
administration of LTD4 led to an increase in IL-5 positive ILC2s.  Interestingly, 
increased levels of cysLTs were found in the BALF of mice stimulated with the fungal 
pathogen Alternaria. Furthermore, co-adminstration of Alternaria and cysLTs 
induced higher ILC2s expansion in comparison to treatment with Alternaria alone 
(Doherty et al., 2013). Double deletion of LTC4 synthase and the LTB4 receptor 1 in 
mice resulted in severely reduced ILC2s accumulation during chitin or N. brasiliensis 
induced lung inflammation (von Moltke et al., 2017).  Taken together, these studies 
provide evidence that lipid mediators have an important role in ILC2 activation or 
inhibition and could be targeted to modulate ILC2 function.  
 
 Activation of ILC2 by neuropeptides and neurotransmitters  
Recent studies identified a novel type of regulation of ILC2 cells by neuronal 
cells. Murine and human ILC2s express the G-protein-coupled receptor neuromedin 
U1 (Nmur), which recognises the neuropeptide neuromedin U (Endo et al., Eder et al., 
Cardoso et al., 2017, Klose et al., 2017, Wallrapp et al., 2017). NUM is preferentially 
found in the gut and the genitourinary system, but is also found in the spinal cord and 
brain (Raddatz et al., 2000). NUM alone was able to induce IL-5 and IL-13 production 
in ILC2 isolated from either gut or lungs. NMU induced calcium influx and ERK1/2 
activation in ILC2s.  Inhibition of ERK1/2 or calcineurin in NMU stimulated ILC2s 
led to a decrease in IL-5 production (Cardoso et al., 2017). The authors showed that 
neurons secrete NMU in response to stimulation with IL-33 or N. brasiliensis and this 
process was dependent on MyD88 (Cardoso et al., 2017). Furthermore conditional 
deletion of MyD88 in neurons resulted in impaired cytokine production by ILC2s 
during N. brasiliensis infection (Cardoso et al., 2017). The link between ILC2s and 
neurons was suggested by another group showing that in the small intestine ILC2s co-
localise with NMU positive neurons. Similarly, they showed that NMU induces 
cytokine production by ILC2s and in vivo administration of NMU triggers ILC2-
dependent lung inflammation (Klose et al., 2017). Interestingly, ILC2s could also 
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sense neuronal signals which limit their response. Expression of β2-adrenergic 
receptor (β2AR) was found on ILC2s isolated from mouse gut. Treatment with β2AR 
agonist resulted in impaired cytokine production in ILC2 and impaired worm 
clearance in vivo (Moriyama et al., 2018).  
 
 E-cadherin-KLRG1 interaction 
KLRG1 (killer-cell lectin like receptor) is a C-type lectin expressed on NK 
cells, T cells and ILC2s (Hoyler et al., 2012, Jonjic, 2010, Corral et al., 2000). KLRG1 
is an inhibitory receptor with an intracellular immunoreceptor tyrosine based 
inhibitory motif (ITIM). KLRG1 binding tomembers of the cadherin family leads to 
inhibition of NK and T cell function (Jonjic, 2010). Upregulated KLRG1 expression 
is commonly associated with activation in ILC2s (Wallrapp et al., 2017). However, 
treatment of PMA or IL-33 stimulated human ILC2 cells with E-Cadherin led to a 
reduced levels of GATA3, IL13, and IL5 mRNA levels relative to PMA or IL-33 
stimulation alone.  The authors suggested that the interaction of E-cadherin and 
KLRG1 could have an important role in the pathology of atopic dermatitis, a condition 
in which the expression of E-cadherin in keratinocytes is reduced and ILC2 numbers 
and type two cytokines are increased (Salimi et al., 2013, Trautmann et al., 2001).  
 
 ICOS-ICOSL interaction in ILC2s 
ILC2s express inducible T-cell co-stimulator (ICOS) (Paclik et al., 2015). In 
T cells the ICOS signalling plays an important role in survival and regulates cytokine 
production (Coyle et al., 2000).  ILC2 numbers are significantly reduced in ICOS and 
ICOS ligand deficient mice (Paclik et al., 2015). The response of ICOSL and ICOS 
deficient mice was also impaired during IL-33 induced airway inflammation (Paclik 
et al., 2015, Maazi et al., 2015). ICOS ligand expression was also detected on mouse 
and human ILC2s, suggesting that ICOS-ICOSL interaction among ILC2s could 
influence their homeostasis (Paclik et al., 2015, Maazi et al., 2015).  Furthermore, it 
was found that ICOSL on ILC2s binds to ICOS expressed on inducible regulatory T 
cells and this binding has an inhibitory effect on ILC2 function both in vitro and in  
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 Aims 
IL-33 dependent responses in ILC2s have been implicated in a number of 
pathological conditions such as asthma, atopic dermatitis and helminth infections. 
Therefore, the first aim of this study was to investigate the role of IL-33 signalling 
pathway in type two innate lymphoid cells (ILC2s). Due to the implication of 
MAPKAPKs MK2/3 in regulating IL-33 dependent cytokine production in mast cells, 
another aim was to characterise ILC2s in mice deficient of these kinases and to 
understand if they are important for regulation of the cytokine production in ILC2s.  
In addition, initial data indicated that IL-33 induces major changes in size and 
proliferation of ILC2s. Consequently, the IL-33 mediated metabolic changes were 
investigated, including upregulation of nutrient transports, mTOR and c-Myc 
activation and amino acid uptake. The role of the amino acid transporter Slc7a5 was 
also studied using Slc7a5fl/flVav-iCre+/- mice. 
As part of this work, ABIN1[D485N] knockin mice, which spontaneously 
develop a Lupus-like autoimmune condition, were examined to see if they had normal 
numbers of ILC2s.  This revealed the presence of a greatly expanded population of 
patrolling monocytes in the tissues of these mice, and this became focus of study 
during my PhD.  
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II. Materials and methods 
 Animals 
MK2/3 (Mapkapk2tm1mgl / Mapkapk3tm1mgl) knock out mice were obtained from Prof. 
Matthias Gaestel (Hannover Medical School) (Kotlyarov et al., 1999b, Zaru et al., 
2007). To generate a conditional MK2 mice, Mapkapk2tm1a(EUCOMM)Hmgu were 
purchased from the International Mouse Phenotyping Consortium. 
Mapkapk2tm1a(EUCOMM)Hmgu were crossed to Flpe transgenic mice (TaconicArtemis) to 
remove the LacZ and marker cassette.  The conditional MK2 allele was then crossed 
away from the Flpe transgene and further crossed to Vav-iCre mice (de Boer et al., 
2003), to selectively delete MK2 in immune cells. ABIN1[D485N] (Tnip1tm1Pcoh) 
(Nanda et al., 2011), IRAK1[D359A] (IRAK1tm1Pcoh) (Goh et al., 2012), 
IRAK4[D329A] (IRAK4tm1Pcoh) (Nanda et al., 2016) and IRAK2[E525A] 
(IRAK2tm1Pcoh) (Pauls et al., 2013a) knock in mice were obtained from Professor Philip 
Cohen (University of Dundee).  Slc7a5fl/fl (Slc7a5tm1Daca) bred to Vav-iCre+/- mice were 
obtained from Professor Doreen Cantrell (University of Dundee) (Poncet et al., 2014). 
TLR7 (B6.129S1-Tlr7tm1Flv/J,) and IL-6 (B6;129S2-IL6tm1Kopf/J) knock out mice 
were purchased from Jackson Laboratory (Lund et al., 2004, Kopf et al., 1994). 
MyD88 (Myd88tm1Aki) knock out mice were provided by S. Akira (Adachi et al., 1998). 
All mice were bred on a C57Bl/6J background and wild type mice for backcrossing 
obtained from Charles River Laboratories UK.  Animals were maintained in specific 
pathogen-free conditions according with EU and UK regulations. Non breeding mice 
were housed in same-sex groups, in individually ventilated sterile cages and were 
given standard diet R&M1 or R&M3 (SDS, Special Diets Services).  Animals were 
maintained in rooms with controlled 12h/12h light/dark cycle (lights on at 7:00 AM), 
21°C temperature, and relative humidity of 45%–65%. All the work was performed 
under a UK Home Office project license and subject to local ethical review. 
Colony maintenance, PCR genotyping and breeding of MK2/3 KO and conditional 
MAPKAPK2 (Vav-cre) was done by Tsvetana Petrova and Simon Arthur.  Colony 
mainatince for the ABIN1 crosses was carried out by Sambit Nanda (MRC PPU) and 
genotyping carried out by the Genotyping Service in the MRC PPU.  Routine welfare 
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checks and cage changing was carried out by Biological Services, University of 
Dundee. 
 
 Genotyping 
Mice were genotyped from ear biopsy.  DNA was extracted by digestion in buffer 
containing 10 mg/ml Proteinase K in 28 mM NaCl, 55 mM Tris HCl, pH 8.0, 0.1% 
SDS.  Samples were incubated at 55oC for 6h, 96oC for 10 min (to kill the Proteinase 
K) and then stored at -20oC until use. PCR reaction mix is shown in Table 2.1, primers 
used for the genotyping are listed in Table 2.2 and the PCR program in Table 2.3.  
Samples were run on 2% Agarose gels made in TAE buffer and bands visualized using 
Syberafe DNA dye (Invitrogen). 
Table 2.1. PCR reaction mix 
Reagent Stock 
concentration 
Final 
concentration 
Volume 
Taq Buffer 
(Promega) 
5x 1x 5 
dNTP 2 mM 0.2 mM 2.5 
Fwd primer 10 µM 0.2 µM 0.5 
Rev Primer 10 µM 0.2 µM 0.5 
Go-Taq (Promega)   0.1 µl 
H20   14.4 µl 
DNA   2 µl 
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Table 2.2. Primer sequences for genotyping 
Mouse line Target 
sequence 
Primer sense 
MK2 Vav Cre Loxp 
forward 
 5’ TGTCATCATGTATATTTTGTAAGTGGGCTG 
3’ 
MK2 Vav Cre Loxp reverse 5’ GGCTAGCCCATTAGCTAGTTTCTAC 3’ 
MK2 Vav Cre 5’ Arm 
forward 
5’ GTCCAGCTTGACTTCATGCTCCTG 3’ 
 
MK2 Vav Cre CSD-
Neomycin 
cassete 
forward 
5’ GGGATCTCATGCTGGAGTTCTTCG 3’ 
 MK2 Vav Cre Floxed 
region 
reverse 
5’ CAACTCTCATTCCATCAGCTAAGAGC 3’ 
 
MK2 Vav Cre Cre forward 5' AAA TGG TTT CCC GCA GAA CC 3' 
MK2 Vav Cre Cre reverse 5' TAG CTG GCT GGT GGC AGA TG 3' 
 
MK2/3 double 
knock out 
Mapkap2 
(for) 
5’ CGTGGGGGTGGGGTGACATGCTGGTTGAC 3’ 
MK2/3 double 
knock out 
Mapkap2 
(rev WT) 
5’ GGTGTCACCTTGACATCCCGGTGAG 3’ 
MK2/3 double 
knock out 
Mapkap2 
(rev NEO) 
5’ TGCTCGCTCGATGCGATGTTTCGC 3’ 
MK2/3 double 
knock out 
Mapkap3 
(for WT) 
5’ TTAGTTGTTTGGCCATGACCTCCAGCTTTC 3’ 
MK2/3 double 
knock out 
Mapkap3 
(for NEO) 
5’ TGCTTTACGGTATCGCCGCTCCCGATTC 3’ 
MK2/3 double 
knock out 
Mapkap3 
(rev) 
5’ ATAGCTGGTCCTCGAATGGGCCAGCCTG 3’ 
 
Table 2.3. PCR program for genotyping  
Step Temperature Time 
1 95°C 2 min 
2 95°C 30s 
3 60°C 30s 
4 72°C 30s 
5  Go to step 2, repeat 36 times   
6 72°C 5 min 
7 10° Forever 
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 Media and Buffers 
 
Table 2.4. Media and Buffers 
Solution Recipe 
Complete RPMI RPMI-1640 medium with 10% heat-inactivated FBS, 50 U/ml 
penicillin-streptomycin, 5mM L-glutamine, 10mM HEPES 
buffer, 1mM sodium pyruvate, 50 µM 2-mercaptoethanol 
R20F Eosinophil 
media 
RPMI containing 20% FCS, 100 IU/ml penicillin, 10 mg/ml 
streptomycin, 5mM L-glutamine, 1x non-essential amino acids, 
1 mM sodium pyruvate and 50µM 2-mercaptoethanol 
BMDM media  DMEM containing 10% FBS, 5mM L-Glutamine, 50 U/mL 
Penicillin, 100 mg/mL Streptomycin , 0.25 mg/mL amphoceterin 
(Life Technologies) and 5 ng/mL M-CSF 
(R&D Systems) 
MACS buffer PBS with 0.5% BSA  and 2mM EDTA 
FACS buffer PBS with 1% BSA   
Blood collection 
buffer 
10% FBS, 10% RBC lysing buffer (Sigma) and 2mM EDTA in 
RPMI 
ELISA Coating buffer 0.1M NaHCO3, pH 8.2 in MilliQ H2O 
ELISA Coat Wash 
buffer 
1M KPO4 and 0.05% Tween 20 in MilliQ H2O 
ELISA Assay wash 
buffer 
NaCl, 1M NaPO4, 2.7M KCl and 0.05%     Tween 20 in MilliQ 
H2O 
EAR digestion buffer 28mM NaCl, 55mM Tris HCl, ph 8.0, 0.1% SDS, MilliQ H2O 
TAE buffer 10x 40 mM Tris-acetate, 1mMof EDTA, disodium salt. 
 
 
 Isolation of cells from spleen and mesenteric lymph nodes 
Single cell suspensions from spleens were obtained by gently mashing the spleen 
through 40 µm nylon cell strainer (VWR) in 5 ml of complete RPMI media. 
Suspensions were centrifuged at 450g for 5 minutes at room temperature (RT), 
supernatant was removed and red blood cells were lysed by resuspending the pellet in 
1 ml of RBC lysing Buffer (Sigma) for 2 min at RT. Cells were washed by adding 10 
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mL ice cold PBS, pelleted by centrifugation at 450g for 5 minutes and resuspended in 
10 ml complete RPMI media. Cell suspensions were filtered through 40 µm nylon cell 
strainer to remove any clumps.  
 
 Isolation of cells from lungs, mesenteric fat and eWAT 
Lung and mesenteric fat digestion was performed as previously described (Moro 
et al., 2015a). Briefly, lungs were placed into a 40 µm cell strainer (VWR) in a 58 mm 
cell culture dish (Nunclon, Thermo Scientific) and cut into small segments. 7 ml of 
RPMI containing 50 µg/ml Liberase TM (Sigma Aldrich) and 10 µg/ml DNaseI 
(Roche/Sigma Alderich) were added to the lung segments and they were incubated for 
45 min at 37°C. Lung segments were mashed through 40 µm cell strainers and washed 
with 13 ml of 5% FBS in HBSS. Cell suspensions were centrifuged (450g for 5 
minutes at RT) and red blood cells were lysed as described above. Cell pellets were 
resuspended in 5ml complete RPMI media and filtered through a 40 µm cell strainer. 
Single cell suspensions from mesenteric fat or epididymal white adipose tissue 
were obtained by dissecting and placing the tissue into a 15ml falcon tube containing 
7 ml of 4% BSA in DMEM. For isolation of cells from multiple mice, mesenteric fat 
from up to 6 mice was placed into a 50 ml falcon tube containing 25 ml of 4% BSA 
in DMEM. The fat tissue was cut into small segments, LiberaseTM (50 µg/ml) and 
DNaseI (10 µg/ml) were added to the tubes and they were incubated for 1 hour at 37°C 
in water bath. Tubes were vigorously shaken every 15 minutes. Following the 
incubation red blood cells were lysed as described above.  Cells were resuspended in 
RPMI media and filtered through 40 µm cell strainer.  
 
 Isolation of blood leukocytes 
For phenotyping blood, mouse tail was cut superficially and 4-5 drops of blood 
were collected in 1mL ice cold blood collection buffer.  Collection of blood was 
carried out by staff in Biological Services, University of Dundee or Dr Sambit Nanda.   
Alternatively, blood was collected from the heart via cardiac puncture and placed in 
heparin coated tubes. 50 µl from the blood were added to 1mL ice cold blood 
collection buffer. Tubes were centrifuged at 450g for 5 minutes at 4°C, pellets were 
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resuspended in 1ml of RBC lysis buffer and incubated for 5 minutes at room 
temperature. Cells were centrifuged as above, supernatant was aspirated and cells were 
resuspended in 1 mL FACS buffer and kept on ice before flow cytometry analysis.  
 
 Isolation of bone marrow 
Femurs and tibias were dissected under sterile conditions. The epiphyses were 
cut, the bone marrow was flushed with sterile 20 mL of PBS and the suspension was 
passed through a 100 µm cell strainer (VWR). Cells were centrifuged at 450g for 
5mins at RT, red blood cells were lysed as previously described and cell pellets were 
resuspended in PBS. 
 
 Cell culture and stimulation 
 Purification and cell culture of type two innate lymphoid cells 
 ILC2 cells were purified from mesenteric fat cell suspensions using magnetic 
sorting. Cells were counted on haemocytometer and up to 1x107  cells were incubated 
in 100 µl of CD16/CD32 Fc block (1:50 in MACS buffer) (BD Biosciences) for 20 
minutes at 4°C. To deplete other immune cells, a cocktail of biotinylated anti-CD3, 
anti-CD11b, anti-CD11c, anti-Ly6C/Ly6G, anti-F4/80, anti-CD19, anti-B220, anti-
NK1.1 and anti-TER119 antibodies (antibody dilutions are listed in Table 2.5) was 
added to the mesenteric cells and they were incubated for further 20 minutes at 4°C. 
Unbound antibodies were removed by adding 10 ml of MACS buffer and the cell 
suspension was centrifuged at 450g for 5 mins.   Supernatant was aspirated away and 
cells were incubated with streptavidin conjugated magnetic microbeads (Miltenyi 
Biotec) for 10 minutes at 4°C according to manufacturer’s instruction. After 
incubation cells were washed with MACS buffer and centrifuged (450g for 5 minutes).  
The cell pellet was then resuspended in 1 ml of MACS buffer and passed through a 
LD depletion column (Miltenyi Biotec) that had been pre-wetted in MACS buffer and 
placed on a magnetic separator. The column was washed two times by adding 1 ml of 
MACS buffer. The flow through and washes were collected in a 15 ml falcon, cells 
were centrifuged (450g for 5 minutes), resuspended in 100 µl of biotinylated anti-
CD45 antibody  diluted 1:200 in MACS buffer and incubated for 20 minutes at 4°C.  
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Cells were washed with MACS buffer and incubated with streptavidin microbeads for 
10 minutes at 4°C. After the incubation, the cells were washed in MACS buffer, 
resuspended in 1 ml of MACS buffer and passed through a pre-wetted MS column 
(Miltenyi). The column was washed twice with 1ml of MACS buffer. The flow 
through was discarded, the column was removed from the magnetic separator and 
placed into a new 15 ml falcon tube. The cells bound to the column were eluted by 
adding 2 ml of MACS buffer and using the column plunger. Cells were counted on 
haemocytometer and cultured at 0.5-1x105 density in 200 µl of complete RPMI media 
supplemented with IL-2 (20 ng/ml) and IL-7 (10 ng/ml) in 96-well plate for 5 days at 
37°C and 5% CO2. On day 3 half of the media was replaced with fresh media 
containing IL-2 (20 ng/ml) and IL-7 (10 ng/ml).  
 
Table 2.5. Biotinylated antibodies for depletion of Lineage positive cells 
Antigen Clone Concentration  Company 
CD3ε 145-2C11 0.5 µl for 1x106 cells Biotin BioLegend 
CD11b M1/70 0.5 µl for 1x106 cells Biotin BioLegend 
Ly-6G/Ly-6C (Gr-1) RB6-8C5 0.5 µl for 1x106 cells Biotin BioLegend 
TER-119 Ter-119 0.5 µl for 1x106 cells Biotin BioLegend 
CD45R/B220 RA3-6B2 0.5 µl for 1x106 cells Biotin BioLegend 
NK 1.1 PK136 0.5 µl for 1x106 cells Biotin BioLegend 
CD19 6D5 0.5 µl for 1x106 cells Biotin BioLegend 
CD11c N418 0.5 µl for 1x106 cells Biotin BioLegend 
F4/80 BM8 0.5 µl for 1x106 cells Biotin BioLegend 
CD45 30-F11 1:200 Biotin BioLegend 
 
 
 Stimulation of ILC2 cells 
Cultured ILC2 cells were plated in 96 well plates at a density of 2500-5000 cells 
in 100 µl of complete RPMI media for stimulation (without IL-2 and IL-7). ILC2 cells 
were pre-incubated with inhibitors (listed in Table 2.6) for 1 hour before stimulation. 
The agonists used are listed in Table 2.7. Following the stimulation, 50 µl from the 
culture media was carefully collected at the times indicated in the figure legends 
without disturbing the cells to measure cytokine production. At the end of the 
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stimulation, cells were stained by adding 150 µl of PBS with DAPI (0.5 µg/mL) in 
each well. Plates were analysed on BD FACSVerse to determine absolute counts of 
live DAPI negative cells. For time course stimulations of ILC2, cells were plated in 
100 µl of media and stimulated with 100 ng/mL IL-33.  50 µl of the culture media 
were collected on day 1 and day 3 and replaced with fresh 50 µl media with the 
corresponding stimuli and inhibitors. On day 5 the media was collected and cells were 
counted as described above.  
Table 2.6. Small molecule inhibitors 
Name Target Concentration Reference 
VX-745 p38α/β 1 µM (Tsai et al., 2013) 
PD-184352 MKK1/2 2 µM (Mayes et al., 2013) 
JNK-in8 JNK1/2 3 µM (Zhang et al., 2012) 
PF-3644022 MK2/3 5 µM (Mourey et al., 2010) 
Akti-1/2 Akt 1 µM (Logie et al., 2007) 
Dasatinib c-kit/Bcr-Abl 10 nM (Kitagawa et al., 2013) 
Cmp2s MK2/3 5 µM (Xiao et al., 2013) 
Rapamycin mTORC1 20 nM (Bain et al., 2007) 
 
Table 2.7. Agonists 
Name Target Concentration Source 
IL-33 ST2 100 ng/mL Peprotech 
IL-2 CD25 20 ng/mL Peprotech 
IL-25 IL-17RB 10 ng/mL Peprotech 
R837 TLR7 1 µg/mL Invivogen 
LPS TLR4 100 ng/mL Sigma 
PMA multiple targets 
including activation of 
PKC and ERK1/2 
50 ng/mL Merck Millipore 
Ionomycin Elicits Ca2+ influx 1 µg/mL Merck Millipore 
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 Flow cytometry  
 Cell counting 
Cell suspensions obtained from bone marrow, lungs, spleens, lymph nodes were 
diluted 1:10 or 1:20 in total volume of 1 ml of PBS with 0.5 µg/ ml of DAPI 
(BioLegend) and analysed on BD FACSVerse. Absolute numbers were calculated 
using FlowJo software (Tree Star). Alternatively, cells were counted using Precision 
Count Beads (BioLegend) according to manufacturer’s instruction. Briefly, cells were 
diluted 1:10 in PBS with 0.5 µg/ ml of DAPI to a total volume of 950 µl. 50 µl count 
beads were added to the cell suspension and cells were acquired on a BD FACSCanto. 
Data were analysed using FlowJo software to obtain event numbers in the beads and 
live cell gates. Beads were gated based on autofluorescence in the FITC and APC/Cy7 
channels and the absolute number of DAPI negative live cells was calculated using 
the formula: 
Absoluite	cell	count
cells
μl
	 	 	 	 	
	 	 	 	
	 	  
 
 Extracellular staining 
Staining for flow cytometry analysis was performed using standard techniques. 
Briefly, cells were blocked with 50 µl rat anti-mouse CD16/CD32 Fc block (BD 
Pharmigen) (1:50 in FACS buffer) and incubated for 20 minutes at 4°C. For detection 
of surface antigens cells were stained with the appropriate fluorophore conjugated 
antibodies (listed in Table 2.8) for 20 minutes at 4°C. Cells were then washed by 
adding 1 ml of FACS buffer and centrifuged at 450g for 5 minutes at 4°C. Pellets were 
resuspended in 400 µl of FACS buffer.  For dead cell exclusion 0.5 µg/ ml of DAPI 
(Biolegend) or 0.25 µg of 7-AAD (eBioscience) were added to the tubes before 
acquiring.  Samples were analysed using FACSCanto or BD LSRII Fortessa (BD 
Bioscience) and results were further analysed by FlowJo software (Tree Star). 
 
 Intracellular staining 
To measure TNF-α and IL-6 production by flow cytometry, 1x106 cells isolated 
from spleen and lungs were stimulated in 1 ml of complete RPMI media in the 
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presence of 5 µg/ml Brefeldin and/or 2µM Monensin (BioLegend). Media was washed 
and cells were resuspended in 100 µl of FACS buffer.  To measure IL-13 production 
in ILC2 cells, 20 000 cells were stimulated in 200 µl of RPMI media for 28 hours, in 
the last 4 hours of the stimulation 2µM Monensin were added to the cells. Following 
the stimulation, cells were fixed by adding 100 µl of IC Fixation Buffer (eBioscience) 
and 20 minutes incubation at 4°C. Cells were washed and supernatants were discarded. 
300 μl of 1x Permeabilisation buffer (eBioscience) were added into the tubes and the 
cells were incubated for 20 min at 4°C. Cells were then blocked and stained as 
described above.m  
Table 2.8. Flow cytometry antibodies  
Target Fluorophore Clone Dilution Stock conc Source 
Lieange PE mixed 1:50  BioLegend 
CD45 APC-eFluor 780 30-F11 1:200 0.2 mg/ml ThermoFisher 
CD3ε FITC 17A2 1:200 0.5 mg/ml BioLegend 
CD19 FITC 6D5 1:200 0.5 mg/ml BioLegend 
CD8 FITC 53-6.7 1:200 0.5 mg/ml BioLegend 
F4/80 FITC BM4 1:200 0.2 mg/ml BioLegend 
CD11b FITC M1/70 1:200 0.5 mg/ml BioLegend 
CD11c FITC N418 1:200 0.5 mg/ml BioLegend 
NK1.1 FITC PK136 1:200 0.5 mg/ml BioLegend 
c-Kit PE/Cy7 2B8 1:200 0.2 mg/ml BioLegend 
KLRG1 APC 2F1 1:200 0.2 mg/ml BD Biosciences 
Sca1 APC/Cy7 D7 1:200 0.5 mg/ml BD Biosciences 
ST2 PerCP-
eFluor710 
RMST2-2 1:200 0.2 mg/ml ThermoFisher 
ST2 BV421 DIH9 1:200 0.2 mg/ml BioLegend 
CD45.1 BV510 A20 1:200 0.2 mg/ml BioLegend 
CD45.2 PerCp/Cy5.5 104 1:200 0.2 mg/ml BioLegend 
CD45 BV510 30-F11 1:200 0.2 mg/ml BioLegend 
NK1.1 APC/Cy7 PK136 1:200 0.5 mg/ml BioLegend 
CD11c PE/Dazzle594 N418 1:200 0.2 mg/ml BioLegend 
CD11b PE/Cy7 M1/70 1:600 0.2 mg/ml BioLegend 
Ly-6G/Ly-6C (Gr-
1) 
PerCp/Cy5.5 RB6-8C5 1:400 0.2 mg/ml BioLegend 
Ly-6G/Ly-6C (Gr-
1) 
FITC RB6-8C5 1:400 0.2 mg/ml BioLegend 
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Ly-6C FITC HK1.4 1:400 0.5 mg/ml BioLegend 
Ly-6C BV421 HK1.4 1:400 0.5 mg/ml BioLegend 
CX3CR1 PE SA011F11 1:200 0.2 mg/ml BioLegend 
CD115 APC AFS98 1:200 0.2 mg/ml BioLegend 
I-A/I-E (MHC II) AlexaFluor700 M5/114.15
.2 
1:200 0.5 mg/ml BioLegend 
CD45R (B220) APC RA3-6B2 1:200 0.2 mg/ml ThermoFisher  
CD95 (Fas) PE SA367H8 1:400 0.2 mg/ml BioLegend 
Gl7 FITC GL7 1:400 0.5 mg/ml BioLegend 
TCR-β FITC H57-597 1:50 0.5 mg/ml BioLegend 
CD4 PerCp/Cy5.5 GK1.5 1:200 0.2 mg/ml BioLegend 
CXCR5 APC L138D7 1:100 0.2 mg/ml BioLegend 
PD-1 BV421 29F.1A12 1:100 0.2 mg/ml BioLegend 
TNF-alpha APC MP6-
XT22 
1:400 0.2 mg/ml BioLegend 
IL-6 PE MP5-20F3 1:100 0.2 mg/ml ThermoFisher 
IL-13 PE eBio13A 1:200 0.2 mg/ml ThermoFisher 
IL-5 APC TRFK5 1:100 0.2 mg/ml BioLegend 
IL-4 PE/Cy7 11B11 1:100 0.5 mg/ml BioLegend 
TLR7 PE 58557 1:100 0.2 mg/ml BDPharmigen 
Phospho-p38 
(Thr180/Tyr182) 
Alexaflour647 3D7 1:100  Cell Signalling 
Phospho-S6 
(Ser235/236) 
Alexaflour647 D57.2.2E 1:100  Cell Signalling 
Phospho ERK1/2 
(Thr202/Tyr204) 
Antibody 
BV421 6B8B69 1:100  BioLegend 
 
 Detection of protein phosphorylation 
ILC2 cells were seeded in 500 µl complete RPMI media in sterile 4 ml polystyrene 
round-bottom flow cytometry tubes.  Cells were rested for 3 hours in complete RPMI 
media before pre-incubation for 1 hour with inhibitors listed in Table 2.6. Cells were 
stimulated with 100 ng/ml IL-33 for the indicated time. After the stimulation, ILC2 
cells were fixed by adding 500 µl of ice cold 4% PFA and 20 mins incubation on ice.  
Tubes were centrifuged (450g for 5 minutes) and supernatant was removed.  Cells 
were permeabilised by adding 1 ml of ice cold 90% methanol while vortexing. Tubes 
were incubated overnight in the freezer at -20 °C. On the next day tubes were left for 
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30 mins on the bench. Cells were then washed with 2 ml of FACS buffer and stained 
as described above in 2.9.3.  
 
 Kynurenine uptake assay  
ILC2 cells were left untreated or stimulated for 24 hours with 100 ng/ml of IL-33.  
Following the stimulation the cells were centrifuged at 450g for 5 min, supernatant 
was discarded and cells were resuspended in 0.5 ml of HBSS (37°C). Data were 
collected on BD FACS canto with the violet laser.  To determine the baseline uptake 
of kynurenine, each sample was acquired initially for 2 minutes before adding the 
kynurenine to a final concentration of 200 µM. The samples were then collected for 
further 5 min. Data were analysed in FlowJo by plotting the fluorescence in the V450 
channel against time.  
 
   Cell sorting 
 Sorting of ILC2 cells 
Lineage negative cells were depleted as described above in 2.8.1 from mesenteric 
cell suspensions. Cells were then stained with anti-Lineage (PE), anti-CD45 
(APCeFlour780), anti-Sca1 (FITC), anti-KLRG1 (APC) and anti-ST2 (PerCP-
eFluor710) diluted in MACS buffer. ILC2 cells were defined as  
DAPI-veLineage-veCD45+KLRG1+Sca1+ST2+ and sorted on BD Influx™ cell sorter. 
 
 Sorting of neutrophils, Ly6C+ve and Ly6C-ve monocytes 
Neutrophils, Ly6C+ve and Ly6C-ve monocytes were sorted from spleens of WT and 
ABIN1 knock in mice. Splenocytes were resuspended in 500 µl CD16/32 Fc block 
(1:50 in MACS buffer) and incubated on ice for 20 mins. Cells were incubated for 
another 20 mins at 4°C with biotinylated antibodies against TER119, CD3, CD19 and 
NK.1.1 (0.5 µl per 1x106 cells from each antibody) to deplete red blood cells, T, B and 
NK cells.  Unbound antibodies were removed by adding 10 ml of MACS buffer and 
centrifuging the tubes at 450g for 5 minutes.  Pellets were resuspended in Streptavidin 
Microbeads (Miltenyi) diluted in MACS buffer according to manufacturer’s 
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instructions and passed through LD columns. The cells in the flow through were 
collected and stained with antibodies against CD45 (BV510), NK1.1(APCCy7), 
CD11b(PeCy7), Ly6C(FITC), CX3CR1(PE) and CD115 (APC). Neutrophils (DAPI-
veCD45+veNK1.1-veCD11b+veLy6CmidGr1high), Ly6C+ve inflammatory (DAPI-
veCD45+veNK1.1-veCD11b+veLy6ChighCX3CR1+veCD115+ve) and Ly6C-ve patrolling 
monocytes (DAPI-veCD45+veNK1.1-veCD11b+veLy6C-veCX3CR1+veCD115+ve) were 
sorted on BD Influx™ cell sorter. 
 
 RNA extraction 
Lung tissues were ground to a fine powder in the presence of liquid N2 using 
cellcrusher (Stratech). 20-30 mg of the powder were lysed in 350 µl of LBP lysis 
buffer (Macherey-Nagel) and RNA was extracted using NucleoSpin® RNA Plus kit 
according to manufacturer instruction (Macherey-Nagel). RNA concentration was 
determined using a Nanodrop 1000 spectrophotometer.  RNA samples were stored at 
-80°C. cDNA was synthesised from 200 ng of RNA in a 20 µl reaction volume 
containing 4 µl iScript Reaction buffer and 1 µl iScript reverse transcriptase (Bio-
Rad). Samples were incubated in a thermal cycler, at 25°C for 5 minutes, 42°C for 30 
minutes and 85°C for 5 minutes. cDNA samples were diluted 1:10 in nuclease-free 
water and stored at -20°C. 
 
 Real-time quantitative PCR 
Quantitative PCR was performed in 384 well plate (Bio-rad) using Syber®Premix 
Ex TaqTM II (Takara) and CFX 384 thermal cycler (Bio-Rad). Reaction mix is shown 
in Table 2.9 and primers are listed in Table 2.10.  
  
51 
 
Table 2.9. Quantitative PCR reaction mix 
Reagent Amount Final concentration 
Syber®Premix Ex TaqTM II (2x) 7 µl 1x 
Forward Primer (10 µM) 0.28 µl 0.4 µM 
Reverse Primer (10 µM) 0.28 µl 0.4 µM 
cDNA 4 µl  
H2O (nuclease-free water) 2.44 µl  
 
Table 2.10. Quantitative PCR primers 
Gene Forward primer Reverse primer 
18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
GAPDH ACAGTTCTTATGTGGTGACCC TGCACCACCAACTGCTTAG 
IL4 AATGCCGATGATCTCTC CTTGATAAACTTAATTGTCTCTC 
IL5 AGGCTTCCTGTCCCTACTCA CCCCCACGGACAGTTTGATT 
IL6 TTCCATCCAGTTGCCTTCTTG AGGTCTGTTGGGAGTGGTATC 
IL13 GCAGCAGCTTGAGCACATTT GCAGACAGGAGTGTTGCTCT 
IL33 CAATGACCAATCTGTTAGT CATAGTAGGGTAGTAGCA 
Arg1 CTCCAAGCCAAAGTCCTTAGAG AGGAGCTGTCATTAGGGACATC 
Eotaxin  GCAGAGCTCCACAGCGCTTCTATTCCT GTTTTTGGTCCAGGTGCTTTGTGGCATCC 
Ym1 GGCAATTCTTCTGAACGTACAGCTGGG GAAGTCATCCATGTCCAGGGGCCAG 
 
PCR conditions were as follows: Initial denaturation was done at 95ºC for 30 seconds, 
followed by 60 cycles of 95ºC for 1 second and 60ºC for 25 seconds. The melting 
curve analysis of the PCR products was done at 95ºC for 1 minute, 65ºC for 1 minute, 
followed by an increase in 0.5ºC increments every 5 seconds.18S and GAPDH mRNA 
were used as housekeeping genes for normalisation of the input. The mRNA levels 
were calculated using the following equation: 
	 	  
where E is the efficiency of the PCR primer pair, Ct is the threshold cycle, i is the 
mRNA of interest, h is the housekeeping gene, s is the sample and c is the unstimulated 
control. 
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 Histology 
 Fixation and paraffin embedding of lung tissues 
Freshly dissected lungs were fixed in 4% PFA for 48 hours at room temperature. 
Samples were then transferred in embedding cassettes (Simport- M490-2) in 70% 
ethanol for 3-4 hours. Immediately prior to embedding, the cassettes were rinsed in 
PBS for 5 minutes. The cassettes were placed in Citadel Tissue processor (Thermo 
Shandon) and run on the program shown in Table 2.11. Tissues were then embedded 
into paraffin blocks.  
Table 2.11. Citadel program 
Solution Time 
50% Ethanol 1 hours 
70% Ethanol 2 hours 
80% Ethanol 2 hours 
90% Ethanol 2 hours 
100% Ethanol 2 hours 
100% Ethanol 2 hours 
100% Ethanol 2 hours 
Xylene 1 hours 
Xylene 2 hours 
Xylene 2 hours 
Paraffin wax 3 hours 
Paraffin wax 3 hours 
 
 Slide preparations and staining 
5 µM sections were cut using microtome and mounted on slides. Slides were left to 
air dry for 1 hour at room temperature and then further dried in a 60°C oven overnight. 
Slides were deparaffinised and dehydrated and stained with haematoxylin and eosin 
using standard technics as shown in Table 2.12.  
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Table 2.12. Deparaffinised and dehydrated and H&E staining. 
Deparaffinised and Dehydrated Haematoxylin and Eosin 
Xylene 5 min Haematoxylin 1 min 
Xylene 5 min Running tap water 10 min 
100% Ethanol 2 min 80% EtOH 2 min 
100% Ethanol 2 min Eosin  10s 
95% Ethanol 2 min 95% EtOH 2 min 
95% Ethanol 2 min 95% EtOH 2 min 
75% Ethanol 2 min 100% EtOH 2 min 
50% Ethanol 2 min 100% EtOH 2 min 
dH2O 2 min Xylene 2 min 
  Xylene 2 min 
 
 
 Enzyme-linked immunosorbent assay  
 Preparation of mouse serum 
Mouse blood was obtained by superficial tail cut or by cardiac puncture. Blood was 
collected in eppendorf tubes, left at 4°C for 30 minutes to allow blood clotting and 
centrifuged at 6797g for 5 minutes at 4°C. Serum was carefully collected and 
transferred into a new tube. Samples were stored at -20°C before analysis.  
 
 Detection of anti-dsDNA and anti-nuclear antibodies (ANA) 
Autoantibodies to dsDNA and antinuclear antibodies (total Ig; Alpha Diagnostics 
International) were measured according to manufacturer’s instruction. Serum samples 
were diluted 50x times in the corresponding buffers provided in the kit.  
 
 Multiplex assay for cytokines and chemokines detection 
Supernatants from cell cultures were collected and stored at -80°C prior to 
analysis. Cytokines in supernatants were measured using a Luminex-based Bio-Plex 
assay (Bio-Rad Laboratories) using manufacturer’s instructions. Standards were 
reconstituted in the cell culture medium and used to determine cytokine 
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concentrations. Plates were read using a Luminex 100/200 machine and Bio-Rad’s 
Bio-Plex manager software. 
 
 In vivo experiments 
  
 Alternaria Alternata asthma model 
WT mice (10-12 weeks old) were treated intranasally with 10 or 20 µg of a sterile 
extract of Alternaria alternata (Stallergenes Greer) diluted in 25ul of PBS or PBS 
alone 3 times a week for 5 weeks. The mice received one final dose at week 6 and 
were culled 24 hours after the last treatment. Bronchoalveolar lavage fluid (BALF), 
lung tissue and blood samples were collected post mortem to investigate immune cell 
infiltration within the tissues, cytokine production and levels of serum IgE.  Half of 
the lungs were fixed and analysed for tissue remodelling and mucus production.  
Administration of the Alternaria alternata was done by Dr Sarah Thomson.  
 
 Bone marrow chimera experiment 
CD45.1 WT (120 days old) mice were lethally irradiated with two doses of 4.5 Gy 
and 5 Gy given 3 hours apart. Mice were irradiated one at a time, in the middle 
compartment of the irradiator. The recipient mice were split into two groups and each 
mouse was injected with 2.5x106 bone marrow cells in 200µl PBS through the tail 
vein. i.v. injection was carried out by staff in Biological Services, University of 
Dundee.  The two groups were reconstituted with either CD45.2 WT or CD45.1 WT 
and CD45.2 ABIN1 KI bone marrow cells mixed in 1:1 ratio.  The antibiotic 
Levofloxacin (0.67g/L) was added to the drinking water during the first two weeks 
after the irradiation to reduce the risk of infection. Wet mash, jelly and baby food were 
given to the mice as supportive measure. Mouse weight was monitored during the 
length of the study. Mice were culled 4 months after the irradiation by a schedule 1 
procedure. Spleen, lungs, and kidneys were harvested for FACS analysis and histology 
analysis. Serum obtained from the blood was tested for presence of autoantibodies. 
Intravenous injection into the tail vein was done by Dr Sarah Thomson. Tail bleeds 
were done by Dr Sambit Nanda.  
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 In vivo stimulation with imiquimod (TLR7 agonist) 
WT mice (10-13 weeks old) were treated with 60 mg experimental cream 
containing 5% of the TLR7 agonist imiquimod (Aldara). The cream was applied 
topically, once per day on both ears. Mice were split into 5 groups, each with different 
duration of treatment: 0, 2, 3, 4 and 5 days. Mice were culled 4 hours after the last 
administration and blood, spleen and lungs were harvested for flow cytometry 
analysis. Application of the cream was done by Dr Manuel Van Gijsel Bonnello.  
 
 In vivo administration of IRAK4 inhibitor 
ABIN1[D485N] (6 weeks old) mice were split in control and experimental 
groups. The control mice were fed with normal R&M3 diet and the experimental group 
was fed with R&M3 containing 1000 mg per kg of the IRAK4 inhibitor PF-06426779 
(Pfizer). An additional control group of age matched WT animals was included in the 
study. WT mice were given normal R&M3. Blood samples were collected from the 
tail vein at the start of the study and at week 5. Mice were culled after 10 weeks and 
tissues were analysed. Welfare monitoring and tail bleeds were done by Dr Sambit 
Nanda. 
 
 Statistical analysis 
Statistical significance was determined using two-tailed, unpaired Student t-test 
or ANOVA with post hoc Tukey HSD testing was carried out in RStudio.  Plots with 
the indicated mean values ± standard deviation (SE) were made in RStudio using 
ggplot2, ggpubr, ggpubsci packages.  
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III. Investigating the role of MAPKs and 
MAPKAPKs in IL-33-dependent ILC2 
responses 
 
 Flow cytometry characterisation of ILC2 cells and in 
vitro culture system 
ILC2s do not express lineage-defining surface markers (CD3e, CD8, CD19, 
CD11b, CD11c, F4/80, Gr-1 and NK1.1), however they do express KLRG1 and Sca-
1 and the cytokine receptors CD25, CD127 (IL-7 receptor) and ST2 (IL-33 receptor) 
(Halim, 2015). ILC2 cells are tissue resident cells found in the fat-associated lymphoid 
clusters (FALC), mesentery, spleen, liver, small intestine and lungs. To identify 
ILC2s, cell suspensions from lungs, mesenteric lymph nodes, mesenteric fat and white 
adipose tissues were stained for expression of Lineage markers, CD45, KLRG1, Sca1, 
ST2 and c-Kit and gating strategies are illustrated in Figure 3.1. Briefly, ILC2s were 
defined as the Sca1 and KLRG1 double positive cells in the CD45+veLineage-ve gate. 
While most of the ILC2s in the mesenteric fat and white adipose tissue were positive 
for the IL-33 receptor ST2, ILC2s from the lungs and mLN expressed very low levels 
of ST2. Expression of c-Kit was low in all stained tissues. Similar observations were 
made in other studies, showing that ST2 and c-kit expression in ILC2 cells varies in 
different tissues (Bartemes et al., 2012, Moro et al., 2015). 
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Figure 3.1 Gating strategy for identifying ILC2s.  
Single cell suspensions from lungs, mesenteric fat, mesenteric lymph nodes (mLN) and 
epididymal white adipose tissue (eWAT) were stained with antibodies against CD45 (BV510), 
Lineage markers (CD3e, CD8, CD19, CD11b, CD11c, F4/80, Gr-1 and NK1.1, all conjugated 
to FITC), KLRG1 (APC), Sca-1 (APC/Cy7), c-kit (PE/Cy7) and ST2 (PerCP-eFluor710) and 
analysed by flow cytometry. Doublets and were excluded using FSC-A and FSC-W and live 
cells were gated as DAPI negative. ILC2 cells were characterised as  
Lineage-veCD45+veKLRG1+veSca1+ve. The Lineage-veCD45+veKLRG1+veSca1+ve population 
was further analysed for expression of ST2 and c-kit.  
 
Studying ILC2s function in vitro has been challenging due to their low 
abundance and most of the investigators use flow cytometry based cell sorting to 
isolate pure populations. This can be time consuming, costly and there is a 
considerable cell loss during the staining procedure and sorting. Although, there are 
commercially available kits for enrichment of the ILC2 cells using magnetic sorting, 
these kits do not provide completely purified ILC2s populations. In the mesenteric fat 
ILC2s are the major population of innate lymphoid cells consisting of around 90% of 
the lineage negative immune cells. In addition, mesenteric ILC2s have high expression 
of the IL-33 receptor (Figure 3.1). As the primary aim of this work was to examine 
IL-33 signalling in ILC2s, for these reasons the mesenteric fat was selected as a source 
of ILC2s.  To study ILC2s in vitro, I first optimised a protocol for depletion of other 
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immune cell using a cocktail of biotinylated antibodies recognising CD3ε, B220, 
CD19, Ly-6G/Ly-6C (Gr-1), CD11b, TER-119, NK1.1 and F4/80 and streptavidin-
conjugated magnetic beads. Flow cytometry analysis of the depleted mesenteric cells, 
showed that most of the other immune cells were effectively depleted and the majority 
of the CD45+ve cells were lineage negative (Figure 3.2). Furthermore, around 90% of 
the Lineage-veCD45+ve population expressed the ILC2s markers KLRG1 and Sca1. 
Although most of the cells after the depletion were CD45-ve cells, these non-
haematopoietic cells did not express high levels of the  ST2 chain of the IL-33 
receptor, in contrast to the ILC2s which did express high levels of ST2 (Figure 3.3). 
 
 
Figure 3.2 Depletion of lineage positive immune cells from mesenteric fat.   
CD3ε, B220, CD19, Ly-6G/Ly-6C (Gr-1), CD11b, TER-119, NK1.1 and F4/80 positive 
immune cells were depleted from mesenteric fat cell suspension by magnetic sorting. Cells 
were stained with antibodies against CD45 (APC-eFluor780), Lineage (PE), KLRG1 (APC) 
and Sca1 (FITC) and ST2 (PerCP-eFluor710) and analysed on BD FACSCanto. The 
representative FACS plots show the purity of the cultures after the magnetic sorting. 
 
 
Figure 3.3 Expression of ST2 in CD45- and ILC2 cells.   
CD3ε, B220, CD19, Ly-6G/Ly-6C (Gr-1), CD11b, TER-119, NK1.1 and F4/80 positive 
immune cells were depleted from mesenteric fat cell suspension by magnetic sorting. Cells 
were stained as in Figure 3.2. The histogram represents expression of ST2 in CD45-ve cells 
and in ILC2 cells.  
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ILC2s respond to the epithelial derived cytokines IL-33, IL-25 and TSLP. IL-
33 has been shown to drive production of IL-5, IL-9 and IL-13 (Furusawa et al., 2013). 
Therefore, I stimulated cells obtained after lineage depletion with IL-33 to measure 
cytokine production.  IL-33 induced secretion of IL-9, IL-13, GM-CSF and IL-10 in a 
time dependent manner (Figure 3.4). Production of IL-5 was also increased following 
the stimulation, however appreciable levels of IL-5 were also produced by 
unstimulated cells.  On day 1, similar levels of IL-6 were detected in the media of both 
unstimulated and IL-33 stimulated cells.  In the IL-33 stimulated cultures IL-6 levels 
did not change dramatically between day 1 and 5, however the levels did decrease over 
time in the unstimulated cultures (Figure 3.4).    
To understand better what is the source of the IL-33 independent IL-5 and IL-
6 production, lineage positive cells were depleted from mesenteric cell suspension, the 
cells were then stained with fluorescent conjugated antibodies and ILC2 cells  
(DAPI-veCD45+veLin-veKLRG1+veSca1+ve) were sorted using fluorescent activated cell 
sorting. The FACS sorted ILC2s produced IL-9, IL-13 and GM-CSF similar to the 
lineage depleted mesenteric cells, but the high levels of IL-5 and IL-6 were not 
observed in unstimulated cells and production of IL-5 and IL-6 were detected only in 
the supernatants from cells stimulated with IL-33 (Figure 3.5). In addition, IL-6 
production was increased over time, which was not observed in the mixed cultures. 
Taken together, these data indicated that although the CD45 negative cells are not 
expressing high levels of the IL-33 receptor, their presence can influence the cytokine 
production measured in the cultures. Moreover, comparing responses between mice 
from different genotypes using the mixed cultures would not be reliable as it would 
not be possible to determine if an effect of genotype was intrinsic to the ILC2s or due 
to a phenotype in the CD45-ve cells.  
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Figure 3.4 IL-33 dependent cytokine production in lineage depleted ILC2 cells 
CD3ε, B220, CD19, Ly-6G/Ly-6C (Gr-1), CD11b, TER-119, NK1.1 and F4/80 positive 
immune cells were depleted from mesenteric fat by magnetic sorting. 5x103 cells per well 
were cultured with or without IL-33 (100 ng/ml). Supernatants were collected 1, 2 and 5 days 
after the stimulation and analysed by multiplex cytokine assay. The stimulation was done in 
triplicate and error bars show the average value ± standard error of the mean. Symbols 
represent individual measurements. Results are representative from 2 experiments.  
 
61 
 
 
Figure 3.5 IL-33 dependent responses in FACS sorted ILC2s.  
Lineage-veCD45+veKLRG1+veSca1+ve cells were sorted by FACS from mesenteric fat cell 
suspensions (pulled from 11 WT mice) and 5x103 cells per well were cultured with or without 
IL-33 (100 ng/ml). Supernatants were collected 1, 2 and 5 days after the stimulation and 
analysed by multiplex cytokine assay. The stimulation was done in quadruplicate and error 
bars show the average value ± standard error of the mean. Symbols represent individual 
measurements. Results are representative from 2 experiments.  
 
To further optimise the ILC2s in vitro cultures, following the depletion of 
lineage positive cells, the ILC2 were further purified by another round of magnetic 
sorting consisting of positive selection of CD45+ve cells. The cells were then cultured 
in IL-2 and IL-7 for 5-7 days.  Culturing of ILC2s in IL-2 or IL-7 has been used to 
maintain or grow ILC2s at a gradual rate, whereas combination of IL-25 and IL-7 or 
IL-2 and IL-33 leads to rapid growth and activation (Moro et al., 2015, Huang et al., 
2014). Although there is a considerable enrichment after the 2 rounds of magnetic 
sorting, not all of the CD45 negative cells are removed by these steps and the ILC2s 
represent around 50-60% of all live cells (not shown). The culture conditions with IL-
2 and IL-7 are favorable for the ILC2s, but not for the non-immune cells, resulting in 
more than 95% purity of the ILC2s cultures and yield of 10 000 - 20 000 cells per 
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mouse depending on the age of the mice.  The purity of the cultures is shown in Figure 
3.6.  
 
Figure 3.6 Purification of ILC2 cells from mesenteric fat.   
ILC2 cells were purified from mesenteric fat by magnetic depletion of Lineage positive cells 
and positive selection of CD45+ve cells. Cells were cultured in IL-7 (10ng/mL) and IL-2 
(20ng/mL) for 5 days and stained with antibodies against CD45(BV510), Lineage markers 
(CD3e, CD8, CD19, CD11b, CD11c, F4/80, Gr-1 and NK1.1 all conjugated to FITC), KLRG1 
(APC) and Sca1(PE/Cy7) and analysed on BD FACSCanto. Flow cytometry plots show the 
purity.  
 
Administration of IL-33 or IL-25 leads to expansion of ILC2 cells in mice 
(Barlow et al., 2013, Huang et al., 2015, Klein Wolterink et al., 2012). Whereas IL-33 
drives cytokine production in ILC2s, stimulation of ILC2s with IL-25 alone is not able 
to induce cytokine release in ILC2s (Klein Wolterink et al., 2012, Camelo et al., 2017, 
Salimi et al., 2013). Similarly, IL-2 does not induce cytokine in ILC2s, but augments 
IL-33 dependent cytokine production (Roediger et al., 2015). To confirm these 
findings, ILC2s cultured using the above described method were stimulated with IL-
25, IL-33 or IL-33 in combination with IL-2 or IL-25. Stimulation of ILC2s with IL-
33 led to a significant increase in the production of IL-5, IL-6, IL-9, IL-13 and GM-
CSF. In contrast, IL-25 did not induce responses in ILC2s, neither did it amplify IL-
33 dependent responses. Addition of IL-2 only affected IL-33 dependent IL-13 
secretion, but not the production of other cytokines (Figure 3.7).  These data were in 
line with previous reports in the literature and confirmed that IL-33 is a potent 
activator of ILC2s. Interestingly, the amounts of cytokines produced from the in vitro 
grown ILC2s following 24 hours stimulation with IL-33 were higher in comparison to 
the cytokines production from FACS sorted ILC2s after 24 hours, suggesting that 
priming the cells in IL-2 and IL-7 is driving a faster ILC2s response.  
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Figure 3.7 IL-33 activates mesenteric ILC2s.   
Cultured ILC2 cells were plated at 5x103 per well and stimulated with the indicated 
combinations of IL-25 (10ng/mL), IL-33 (100ng/ml) and IL-2 (20ng/ml) for 24h. Cells were 
stained with DAPI (0.5 µg/mL) and analysed on BD FACSVERSE to determine absolute 
numbers of live cells Supernatants were analysed for IL-5, IL-6, IL-9, IL-13 and GM-CSF by 
multiplex cytokine assay. The stimulation was done in triplicate and error bars show the 
average value ±SEM. Significance was calculated relative to IL-33 stimulated by two-tailed 
unpaired Student’s t-test; * denotes p<0.05, ** denotes p<0.01 and **** denotes p<0.0001.  
 
 Investigating the role of c-Kit in IL-33 dependent ILC2 
response. 
The production of IL-13 by ILC2 cells was strongly dependent on the duration 
of the stimulation with IL-33, with more than 100 fold difference between day 1 and 
day 5 (Figure 3.5), suggesting that there is a feedback mechanism leading to the 
amplified cytokine production. Interestingly, in mast cells c-Kit has been suggested to 
interact with the IL-1RAcP constitutively from the IL33-ST2 receptor complex 
leading to enhanced signalling and IL-6 production (Drube et al., 2010). Although 
mesenteric ILC2s express very low levels of c-Kit (Figure 3.8A), stimulation with IL-
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33 led to an increase in c-Kit expression (Figure 3.8A). Moreover, ILC2s stimulated 
with IL-33 in the presence of dasatinib, which inhibits a number of tyrosine kinases 
including c-kit, led to a significant reduction in the secretion of IL-13 (Figure 3.8B). 
However, dasatinib has several targets including Abl and Src family tyrosine kinases. 
Hence, there is a possibility that it blocks IL-13 production in ILC2s independent of 
c-kit. Since most of the available c-kit inhibitors also have other targets, it would be 
interesting to confirm these finding using ILC2s isolated from c-Kit deficient mice 
(Furusawa et al., 2013). 
 
 Figure 3.8 c-Kit is involved in regulating IL-33 dependent responses in ILC2s.  
A. Cultured ILC2s were stimulated with or without IL-33 for 24 hours. Following the 
stimulation, cells were analysed on BD FACSCanto to determine expression of c-Kit. The 
representative histogram plot shows c-Kit expression in control and IL-33 stimulated ILC2. 
B.  Purified ILC2 cells were cultured at 2.5x103 per well and stimulated with DMSO, IL-33 
(100ng/ml) alone or IL-33 with in the presence of c-kit inhibitor dasatinib (10nM). Cells were 
stained with DAPI (0.5 µg/mL) and analysed on BD FACSVERSE to determine absolute 
numbers of live cells. Culture media was analysed for IL-5, IL-6, IL-9, IL-13 and GM-CSF 
by multiplex cytokine assay. The stimulation was done in triplicate and error bars show the 
average value ±SEM. Significance between the stimulated samoles ± dasatinib (10nM) was 
calculated by two-tailed unpaired Student’s t-test; * denotes p<0.05, ns denotes not significant. 
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 Importance of p38/MK2/3 axis in IL-33 signalling 
pathway in ILC2  
IL-33 signal transduction leads to activation and phosphorylation of the 
MAPK kinases p38 and ERK1/2 in different immune cells such as Th2 cells, mast 
cells, eosinophils. (Schmitz et al., 2005, Park et al., 2016, Drube and Kraft, 2016, 
Chow et al., 2010, McCarthy et al., 2018). To confirm if these pathways were activated 
in ILC2s, intracellular staining and flow cytometry was used to examine ERK1/2 and 
p38 phosphorylation.  Stimulation with IL-33 induced rapid phosphorylation of both 
p38 and ERK1/2 in ILC2 cells, suggesting that these kinases are involved in the 
regulation of IL-33 induced responses in ILC2 cells.  
 
Figure 3.9 IL-33 induces activation of p38 and ERK1/2 in ILC2s.   
Cultured ILC2 cells were rested for 2 hours before stimulation with 100ng/ml of IL-33 for the 
indicated time points. Cells were fixed, permeabilised and acquired on BD FACSCanto. 
Representative histograms of p-p38 and p-ERK at 0 and 20 are shown.  Unst shows unstained 
cells.   Bar plots show average of the median fluorescence intensity (MFI) of p-p38 and p-
ERK1/2 from 3 biological replicates. Error bars show standard error of the mean. 
 
The p38 MAP kinase has been previously found to regulate production of IL-
5 and IL-13 in ILC2s, however the role of downstream of p38 kinases MK2/3 has not 
been studied in the context of ILC2s (Furusawa et al., 2013). Our lab and others have 
shown that MK2/3 play important role in regulation of mast cell responses to IL-33. 
(Drube et al., 2016, Gopfert and Andreas, 2018, McCarthy et al., 2018). Therefore, to 
further elucidate the role of MAPKs in regulating ILC2s function, ILC2s were 
stimulated with IL-33 in the presence of p38, ERK1/2 and two different MK2/3 
inhibitors. Following stimulation, the cells were counted on day 5 to assess viability. 
The samples only cultured with DMSO and no IL-33 had very low numbers of live 
cells, suggesting that the presence of either IL-33 or IL-2 and IL-7 is required for the 
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maintenance of the ILC2s (Figure 3.10). The cell numbers in the samples stimulated 
with IL-33 were around 2-3 fold higher than the initially plated cells, whereas the cell 
counts with inhibitors were similar to the counts at the start of the stimulation. This 
suggested that the presence of inhibitors is either blocking proliferation or having a 
cytotoxic effect.   
 
Figure 3.10 Regulation of cytokine production in ILC2 by p38, ERK1/2 and MK2/3.   
ILC2 cells were cultured at 5x103 cells per with IL-33 (100ng/ml) in the presence of either 
DMSO, p38 inhibitor VX745 (1µM), MEK1/2 inhibitor PD184352 (5 µM), or the MK2/3 
inhibitors Cmp2s (5µM) and PF3644022 (5µM).  Control cells were incubated in DMSO but 
no IL-33. Culture media was sampled at 1, 3 and 5 days after the stimulation and cell numbers 
were determined at day 5. Bar plots represent the average value of 4 biological replicates (each 
biological replicate was made by pulling cells from 4 mice). Error bars represent the standard 
error of the mean. Statistical significance was determined by two way ANOVA with Tukey’s 
test for posthoc analysis.  Comparisons of IL-33 vs IL-33 with inhibitors are shown.  p < 0.05 
is indicated by *, p < 0.01 by ** and p < 0.001 by *** 
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Secretion of IL-6, IL-9 and IL-13 was blocked in the presence of all inhibitors.  
IL-5 was partly reduced in the presence of the p38 inhibitor VX475, but not by the 
other inhibitors. Production of GM-CSF was also blocked by inhibition of p38 and 
significantly reduced in the presence of MK2/3 inhibitors at the early time point only. 
In contrast to the FACS sorted ILC2s, where there was an increase in the production 
of IL-10 after 5 days stimulation, the magnetically sorted and cultured ILC2s did not 
secrete measurable amounts of IL-10 (not shown). 
The above data could be explained by either a direct role of ERK1/2 and p38 
in cytokine production or an indirect role in controlling cell survival/proliferation.  To 
examine this, ILC2s were stimulated with IL-33 in the presence of p38, ERK1/2 and 
JNK inhibitors for 24 hours.  After the stimulation the cells were counted to assess 
viability (Figure 3.11).  The presence of the inhibitors did not have cytotoxic effect 
and the ILC2s numbers were similar to the numbers in the cultures stimulated with IL-
33 alone. Consistent with Figure 3.10, the p38 inhibitor VX745 had the most 
prominent effect on the cytokine production in ILC2s and supressed production of all 
measured cytokines (Figure 3.11). Hence, p38 regulates cytokine production not only 
by supressing IL-33 dependent ILC2s proliferation, but also has a direct effect either 
on the production or the secretion of cytokines. Inhibition of ERK1/2 also had an effect 
on the production of IL-9 and IL-13 and led to a modest decrease in GM-CSF. In 
contrast JNK do not seem to play a major role in regulating IL-33 responses in ILC2s 
as JNK inhibition only led to a partial reduction of IL-6. 
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Figure 3.11 Regulation of cytokine production in ILC2s by MAPKs.   
Cultured ILC2 cells were stimulated with DMSO, IL-33 (100ng/mL) or IL-33 and p38 
inhibitor VX-745 (1µM), MEK1/2 inhibitor PD184352 (5 µM) and JNK1/2/3 inhibitor JNK-
IN-8 (3 µM). Following the stimulation cells were stained with DAPI (0.5 µg/mL) and 
analysed on BD FACSVERSE to determine absolute numbers of live cells. Supernatants from 
the cell cultures were analysed for IL-5, IL-6, IL-13 and GM-CSF by multiplex cytokine assay. 
The stimulation was done in triplicate and error bars show the average value ± standard error 
of the mean. Significance between IL-33 alone and inhibitor treated samples was calculated 
by two-tailed unpaired Student’s t-test; * denotes (p<0.05), ** denotes (p<0.01), ns denotes 
not significant. 
 
MK2/3 are directly activated by p38 and are known to mediate some of the 
effects of p38 on cytokines production in macrophages and mast cells (McCarthy et 
al., 2018). 24 hours stimulation of ILC2s in the presence of the MK2/3 inhibitor 
Cmp2s did not influence the cell viability, but led to a significant reduction in the 
production of IL-13 (Figure 3.12).   
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Figure 3.12 Regulation of cytokine production in ILC2s by MK2/3.  
Cultured ILC2 cells were stimulated with DMSO, IL-33 (100ng/mL) or IL-33 and MK2/3 
inhibitor 1 Cmp2s (5µM). Following the stimulation cells were stained with DAPI (0.5 
µg/mL) and analysed on BD FACSVERSE to determine absolute numbers of live cells. 
Supernatants from the cell cultures were analysed for IL-5, IL-6, IL-13 and GM-CSF by 
multiplex cytokine assay. The stimulation was done in triplicate and error bars show the 
average value +/- standard error of the mean. Significance between IL-33 alone and inhibitor 
treated samples was calculated by two-tailed unpaired Student’s t-test; **** denotes 
(p<0.0001), ns denotes not significant. 
 
To address the question if loss of MK2/3 results in regulating the IL-33 
induced IL-13 production by blocking its secretion from the cells, ILC2 cells were 
stimulated with IL-33 in the presence of the Golgi complex inhibitor Monensin. 
Similarly, IL-33 induced production of IL-13 in ILC2s following stimulation, which 
was reduced by both MK2/3 inhibitors Cmp2s (5µM) and PF3644022 (5µM) (Figure 
3.13). These data suggested that inhibition of MK2/3 is not regulating IL-13 
production by blocking its secretion, but most likely is involved in IL-13 regulation at 
transcriptional or post-transcriptional level.  
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Figure 3.13 IL-33 activates mesenteric ILC2s.   
Purified ILC2 cells were cultured in the presence of DMSO, IL-33 (100ng/ml), or IL-33 with 
either of the MK2/3 inhibitors AZ71 (5µM) and PF3644022 (5µM). 24 hours after the stimulation 
monensin (2nM) was added to the cell cultures and the cells were incubated for another 4 
hours. Cells were fixed and permeabilised and analysed on BD FACSCanto for expression of 
Lineage markers (FITIC), KLRG1 (APC), Sca1 (PE/Cy7) and IL-13(PE). Plots shows Sca1 
and IL-13 expression in Lineage-ve KLRG1+ve cells.  
 
 Characterisation of ILC2s in MK2/3 double knock out 
mice. 
The in vitro data in Figure 3.10 suggested that MK2/3 have a role in ILC2s 
proliferation, as well as in the production of IL-13. Therefore, next I characterised the 
ILC2s populations in the lungs, mesenteric lymph nodes, mesenteric fat and 
epididymal white adipose tissue (eWAT) of MK2/3 double knock out mice. Although, 
there was an increase of the Lineage negative CD45+ve immune cells in the lungs, 
mesentery and eWAT in the knock out mice, the percentages of KLRG1+veSca1+ve 
cells was lower and ILC2s total cell numbers were not different from those in the WT 
mice (Figure 3.14). ILC2s in the mLN of the MK2/3 mice were significantly reduced. 
Interestingly, the expression of KLRG1 was lower in the eWAT of MK2/3 knock out 
ILC2s (Figure 3.15). Although KLRG1is an inhibitory ITIM motif containing 
receptor, the upregulation of KLRG1+ve expression has been associated with the 
activation of ILC2s (Wallrapp et al., 2017). Hence, MK2/3 deficient ILC2s in the 
eWAT might have a less activated phenotype than WT ILC2s.  
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Figure 3.14 ILC2s in MK2/3 knock out mice.  
Cells obtained from lungs, mesenteric lymph nodes, mesenteric fat and epididymal white 
adipose tissue (eWAT) from WT (n=4) and MK2/3 DKO (n=4) were analysed for expression 
of Lineage markers (FITC), CD45 (BV510), KLRG1 (APC) and Sca1(Pe/Cy7) and DAPI and 
analysed on BD LSRFortessa. Representative plots are showing percentage of Lineage-ve 
CD45+ve cells from all live single cells and percentage of KLRG1+ve Sca1+ve ILC2 cells within 
the Lineage-veCD45+ve  population in lungs (A) mLN (B), mesentery (C) and eWAT (D). Bar 
plots represent absolute numbers of ILC2 cells in the lungs, mLN, mesentery and eWAT. 
Symbols represent individual biological replicates. (E). Error bars represent the standard error 
of the mean. Significance between WT and MK2/3 knock out samples was calculated by two-
tailed unpaired Student’s t-test; * denotes (p<0.05), ** denotes (p<0.01), ns denotes not 
significant.  
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Figure 3.15 KLRG1 expression is decreased in ILC2s from the eWAT. 
Samples were stained and analysed as in figure 3.14. Representative plots are showing the 
expression of KLRG1 in WT and MK2/3 KO ILC2s isolated from eWAT. Bar plots represent 
the median fluorescence intensity of KLRG1. Symbols represent individual biological 
replicates and error bars represent the standard error of the mean. Significance between WT 
and MK2/3 knock out samples was calculated by two-tailed unpaired Student’s t-test; ** 
denotes (p<0.01). 
 
To confirm the data obtained using MK2/3 inhibitors showing a role of MK2/3 
in regulating IL-33 dependent cytokine production in ILC2s, in vitro cultured ILC2s 
isolated from mesenteric fat of WT and MK2/3 mice were stimulated with IL-33 for 
24 hours. Live cells were counted and cytokine production was normalised for 1000 
cells.  Similar to the data obtained with the MK2/3 inhibitors, the MK2/3 knock out 
ILC2 cells produced significantly less IL-13 in response to IL-33 (Figure 3.16). In 
addition IL-6 production was also significantly reduced in the knock out cells.  IL-5, 
IL-9 and GM-CSF production in response to IL-33 was not affected by MK2/3 
knockout. Both IL-6 and IL-13 are implicated in diseases such as asthma and atopic 
dermatitis (Eder et al., 2011, Rincon and Irvin, 2012, Neveu et al., 2010). IL-13 
activity leads to increased bronchial hyperresponsiveness and promotes the switching 
of B cells antibody production from IgM to IgE (Corren, 2013).  IL-6 is a pleotropic 
cytokine, which in the context of allergic airway inflammation has been found to 
regulate mucus production (Neveu et al., 2009). Therefore, targeting MK2/3 could be 
potentially used for developing therapies for treating allergic airway inflammatory 
diseases. 
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Figure 3.16 Regulation of cytokine production ILC2s by MK2/3.   
Cultured ILC2 cells from WT and MK2/3 KO mice were cultured with or without IL-33 
(100ng/ml) for 24 hours. Supernatants were analysed for IL-5, IL-6, IL-9, IL-13 and GM-CSF 
by multiplex cytokine assay. Following the stimulation cells were stained with DAPI 
(0.5µg/mL) and absolute counts were obtained by BD FACSVerse. Supernatants were 
analysed by multiplex cytokine assay. Values were normalised for 1000 cells. Bar plots 
represent the average value of 4 biological replicates (each biological replicate was made by 
pulling cells from 4 mice). Error bars represent the standard error of the mean. Significance 
between IL-33 stimulated WT and MK2/3 knock out samples was calculated by two-tailed 
unpaired Student’s t-test; ** denotes (p<0.05). 
 
 Alternaria alternata induced airway inflammation mouse 
model 
The in vitro data from this study supported the hypothesis that MK2/3 are 
important for regulating the production of IL-13 and IL-6 in ILC2 cells in response to 
IL-33. In addition our lab has shown that inhibition or loss of MK2/3 in mast cells 
leads to complete blockade of cytokine induction in response to IL-33. Loss of MK2 
has been previously reported to have a protective phenotype during OVA-induced 
airway inflammation (Gorska et al., 2007). OVA treated MK2 knock out mice had 
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significantly reduced airway remodelling, immune cell infiltration and type two 
cytokine induction, which the authors suggested is due to loss of MK2/3 in non-
immune cells. (Gorska et al., 2007).  
To expand these findings and study the effect of MK2 deletion specifically in 
immune cells, we set up another model of allergic lung inflammation induced by 
treatment with Alternaria alternata spores. Alternaria alternata is a fungal 
aeroallergen which has a long history of association with respiratory allergy (Denning 
et al., 2006).  Infection of mice with Alternaria leads to increased production of IgE, 
airway inflammation, airway hyperactivity and it is used as an asthma model in mice 
(Havaux et al., 2005). Alternaria induces release of IL-33 and TSLP that promotes the 
production of IL-13 and IL-5 by ILC2s and Th2 cells (Snelgrove et al., 2014, Löser et 
al., 2017). Studies with ST2 deficient mice showed that the response to Alternaria is 
strongly dependent on IL-33 signalling, since ST2 knock out mice are rescued from 
Alternaria induced inflammation (Snelgrove et al., 2014).  Immune cell infiltration 
occurs rapidly after the administration of Alternaria, however tissue remodelling of 
the respiratory system requires longer time. To set up the model we stimulated mice 
with two different concentrations of Alternaria intranasal. The mice received a total 
of 16 doses and were culled 24 hours after the last administration to analyse airway 
inflammation (Figure 3.17).  Treatment with both doses induced airway remodelling, 
thickening of the bronchial bed and immune cell infiltration (Figure 3.17).   
 
Figure 3.17 Alternaria induced allergic asthma model.   
10-12 weeks old mice were treated intranasal with PBS, 10 µg or 20µg purified Alternaria 
alternata extract 3 days a week for 5 weeks and one final dose on week six. The mice were 
culled and lungs were harvested for analysis. The representative microscopy images show 
Alternaria-induced pulmonary inflammation in lungs tissue sections (H&E staining). 
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The Alternaria treatment induced a significant increase in eosinophil numbers 
both in the lungs and the bronchoalveolar lavage fluid (BAL) and this was independent 
of the Alternaria concentration used (Figure 3.18). ILC2 cells were also significantly 
increased. In the lungs this increase was dependent on the dose of Alternaria (Figure 
3.19).  
A.
 
B. 
 
Figure 3.18 Alternaria induces eosinophilia in the lungs and bronchoalveolar lavage.   
10-12 week old mice were treated intranasally with PBS, 10 µg or 20µg purified Alternaria 
alternata extract 3 days a week for 5 weeks. The mice received one final dose on week six 
and were culled 24 hours after the last administration. Lungs and bronchoalveolar lavage fluid 
were harvested for analysis. Single cell suspensions were stained with DAPI, anti-CD11c and 
anti-SiglecF to characterise eosinophils and alveolar macrophages and analysed on BD 
LSRFortessa. A. Representative FACS plots showing percentage of Eosinophils (Siglec-
F+veCD11c-ve) in lungs and BAL from DAPI negative single cells. B. Total eosinophil numbers 
in BAL and lungs. Symbols represent individual mice. Bar plots show average and standard 
error of the mean. Significance relative to PBS was calculated by two-tailed unpaired 
Student’s t-test; * denotes (p<0.05), ** denotes (p<0.01). 
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Figure 3.19 Alternaria induces increase in the ILC2 numbers in the lungs in a dose 
dependent manner.   
Mice were treated as described in Figure 3.17.  Single cell suspensions from the lungs were 
analysed for expression of Lineage markers (FITC), CD45 (BV510), KLRG1 (APC) and Sca1 
(APC/Cy7) and DAPI and analysed on BD LSRFortessa. Representative plots are showing 
percentage of Lineage-ve and CD45+ve cells from all live single cells and percentage of 
KLRG1+ve Sca1+veILC2 cells within the Lineage-veCD45+ve population in lungs. The bar graph 
shows absolute numbers of ILC2s in the lungs. Significance between PBS and Alternaria 
treated mice was calculated by two-tailed unpaired Student’s t-test; * denotes (p<0.05), ** 
denotes (p<0.01). 
 
The Alternaria treatment led to an increased mRNA levels of the type 2 
cytokines IL4, IL5 and IL13 (Figure 3.20). Significant induction for most of the 
cytokines was observed only in the lungs of animals treated with the higher dose, with 
the low dose giving intermediate values. Induction of IL6 and IL33 mRNA was also 
observed. The eosinophil chemoattractant Eotaxin (CCL11) mRNA was also strongly 
induced in the treated animals, which was in line with the observed eosinophilia in the 
lungs and the BAL (Figure 3.20). Interestingly, IL-33 mRNA levels were only 
increased following treatment with 20 µg of Alternaria.  In addition to the cytokine 
induction, induction of Arg1 and Ym1 mRNA was also observed (Figure 3.20). 
Arginase-1 and YM1 are markers for alternatively activated murine macrophages or 
M2 macrophages (Raes et al., 2005, Raes et al., 2002). The M2 macrophages are 
important regulators of the pathology of asthma, contributing to the eosinophilia and 
collagen deposition around the airways (Draijer et al., 2018).  Taken together, the 
treatment with 20µg Alt extract provides more reliable read outs for studying 
Alternaria dependent lung inflammation in mice.  
77 
 
 
Figure 3.20 Increased expression of genes regulating type two immunity following 
Alternaria in vivo administration.  
10-12 weeks old mice were treated intranasally with PBS, 10 µg or 20µg purified Alternaria 
alternata extract 3 days a week for 5 weeks and one final dose on week six. The mice were 
culled 24 hours after the last administration. Lung tissues were lysed in RLT buffer and total 
RNA was purified (Takara RNA isolation kit). Total RNA was reverse-transcribed using 
iScript (Bio-Rad) and qPCR was carried out using SYBR green based methods. 18S and 
GAPDH were used as a normalisation control and fold induction was calculated for IL-4, IL-
5, IL-6, IL-13, IL-33, Arg1, Eotaxin and Ym1. Symbols represent individual mice, bars show 
average and standard error of the mean values. Significance between PBS and Alternaria 
treated mice was calculated by two-tailed unpaired Student’s t-test; ns denotes (p>0.5)* 
denotes (p<0.05), ** denotes (p<0.01). 
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 Discussion 
 
An increasing number of studies indicate the importance of innate lymphoid 
cells in regulating inflammatory diseases (Poposki et al., 2017, Nechama et al., 2018, 
Miller et al., 2010a). ILC2s cells are strategically located at the barrier site, where they 
can communicate with epithelial and endothelial cells to respond to environmental 
stimuli. ILC2s have very low abundance, but they are potent producers of cytokines 
and can modulate the function and recruitment of other immune cells during 
inflammation. To study ILC2s function in vitro, first I have optimised a method for 
enrichment of the ILC2s population by depleting other immune cells. This resulted in 
generation of mixed cultures, with ILC2s and CD45-ve non-immune cells (Figure 3.2). 
Although the CD45-ve cells were not expressing the IL-33 receptor, high levels of IL-
5 and IL-6 were detected in the supernatant of control unstimulated samples, which 
were not detected in supernatants from FACS sorted ILC2s (Figure 3.4 and 3.5 ). This 
could be explained by the fact that adipocytes and adipose tissue have been shown to 
be a source of IL-6 both in humans and mice (Antunes et al., 2006, Harkins et al., 
2004).  The effect of IL-6 on ILC2s has not been studied, however IL-6 has been found 
to modulate function of lineage negative cells in the gut and promote IL17A and IL-
22 production (Powell et al., 2015).  These data implicate that cross talk between the 
ILC2s and adipocytes could influence responses in both cell types, therefore the purity 
of the cultures plays an important role in studying ILC2s.  
Consequently, I have further optimised the magnetic purification by doing an 
additional step of positive selection with anti-CD45 antibody and culturing the cells 
in IL-2 and IL-7, which greatly improved the purity of the ILC2s cultures (Figure 3.6). 
Moreover, ILC2s sorted using this method responded in a very similar way to FACS 
sorted cells, secreting IL-5, IL-6, IL-9, IL-13 and GM-CSF, but with slightly different 
kinetics. Whereas the FACS sorted ILC2s had very low response following a 24 hours 
stimulation with IL-33 and cytokines were detected after 3 and 5 days of stimulation, 
the magnetically sorted ILC2s secreted higher levels of the type two cytokines even at 
24 hours (Figure 3.6 and 3.10). This effect is most likely a result from the priming of 
the cells in IL-2.  In vivo stimulation of mice with IL-2 leads to expansion of ILC2 
cells (Roediger et al., 2015). IL-2 has been shown to induce IL-9 production in ILC2s 
isolated from papain-treated mice independent of stimulation with IL-33 (Wilhelm et 
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al., 2011). In contrast, here IL-2 did not have any effect on IL-9 production in IL-33 
stimulated ILC2 cells, but led to an increase production of IL-33 dependent IL-13 
(Figure 3.7).  This may be due to the culture in IL-2 and IL-7 downregulating their 
ability to respond to IL-2 in the acute stimulation or that the primary effect of IL-2 is 
already maximal. 
Surprisingly, IL-10 production was only detected in FACS sorted ILC2s after 
5 days of stimulation, but not in the supernatants of the magnetically sorted and 
cultured ILC2s in IL-2 and IL-7 (data not shown). This was not expected as IL-2 is 
known to induce IL-10 production in regulatory T cells in a STAT5 dependent manner 
and IL-2 is required for the immune suppressive function of Tregs (Tsuji-Takayama 
et al., 2008) (Cheng et al., 2013).  IL-2 was also found to induce IL-10 production in 
IL-33 and IL-7 expanded ILC2 and the addition of retinoic acid further amplified the 
induction of IL-10 (Seehus et al., 2017). These findings suggest that the culture 
conditions could influence cytokine production in ILC2 and they can adopt different 
phenotype depending on the environment.  
ILC2 express low levels of c-Kit, however IL-33 stimulation led to an 
increased expression of c-Kit. The receptor tyrosine kinase c-Kit has been shown to 
co-immunoprecipitate with the IL-33-ST2 receptor complex (Drube et al., 2010). SCF 
ligation with c-Kit triggers receptor dimerisation and autophosphorylation of the 
receptor leading to recruitment of proteins containing Src homology 2 (SH2 domains) 
including Shc, the growth factor receptor-bound protein 2 (Grb2) and the Ras 
guanylnucleotide exchanging factor Sos (son of sevenless). Sos mediates the exchange 
of GDP for GTP on Ras, Ras then interacts with Raf1 leading to the activation of 
cascade of multiple protein kinases, including MEK1 and ERK1/2 (Moodie et al., 
1993) (Taylor and Metcalfe, 2000). Addition of SCF to BMMC culture media leads 
to a hyper responsive mast cell phenotype (Ito et al., 2012). Here, I demonstrated that 
the tyrosine kinase inhibitor dasatinib significantly downregulates production of  
IL-13 (Figure 3.8). Similar effect was also observed using the MEK1/2 inhibitor which 
blocks ERK1/2 phosphorylation. Therefore it will be interesting to understand if SCF 
leads to ERK1/2 activation in ILC2. One study suggests that ILC2 isolated from  
KitW-sh, carrying a mutation in regulatory elements upstream of the c-kit gene, have 
normal cytokine production and SCF is not amplifying IL-33 dependent production of 
IL-5, IL-6 and IL-13 in ILC2s (Furusawa et al., 2013a). However, there are not any 
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other reports in the literature looking at c-Kit role in ILC2 cells and more research is 
needed to understand the role of c-Kit in modulating ILC2s responses.  
The role for c-Kit in regulating airway inflammation and type two immunity 
has been shown in an OVA experimental model of allergic asthma, where 
administration of the tyrosine kinase inhibitor dasatinib led to a significant reduction 
in the airway hyperresponsivness, leukocyte infiltration in the lungs and BAL and 
decreased production of IL-13 and an increase in the anti-inflammatory cytokine IL-
10 (Silva et al., 2016). The authors did not look at the effect on dasatinib on ILC2s 
expansion, however it will be interesting to understand if the effect of dasatinib was 
due to supressing ILC2s function. Another tyrosine kinase inhibitor bosutinib was also 
found to have a protective role during experimental model of lung fibrosis induced by 
silica particles (Carneiro et al., 2017). These inhibitors are not specific for c-Kit only, 
but also for other tyrosine kinases. Therefore it is possible that their effect is mediated 
through another mechanism independent of c-Kit. However studies using the KitW-sh 
mice, showed that these mice exhibit decreased eosinophilia and IgE production in 
house dust mite induced lung inflammation, but did not rescue lung pathology and 
mucus production. Hence, c-Kit signalling has a potential role in regulating allergic 
asthma (de Boer et al., 2014). 
Male SJL-KitW-sh mice have been shown to have an exacerbated phenotype in 
experimental autoimmune encephalitis, however female mice SJL-KitW-sh mice were 
protected. Interestingly the phenotype observed in the male SJL-W/Wv mice was 
linked to decreased frequency of mature ILC2s and ILC2s precursors, reduction in the 
type two cytokines and a shift to Th17 type of response mediating the diseases 
exacerbation. (Russi et al., 2015).  
The inhibition of the MAPKs ERK1/2 using MEK1/2 inhibitors led to a 
reduction in production of IL-13, IL-9 and IL-6. ERK1/2 have been shown to regulate 
IL-5 and IL-13 production in bone marrow derived ILC2s (Suzuki et al., 2015). 
However, my results did not indicate any effect of ERK1/2 on IL-5 production (Figure 
3.10).  This could be potentially explained by the different methodology of ILC2s 
extraction and cultures.  Deficiency of Spred1, which is known to negatively regulate 
ERK1/2 activation by supressing Raf1 phosphorylation, leads to exacerbation in OVA 
and papain induced airway inflammation. Spred1-/- mice have higher ILC2s increases 
in the papain-induced asthma model and significant increase in the production of type 
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two cytokines (Suzuki et al., 2015, Inoue et al., 2005). Interestingly, ERK1/2 regulates 
cytokine production in ILC2s in response to the neurone derived peptide neuromedin 
U (Cardoso et al., 2017). Taken together, our and others data support the importance 
of ERK1/2 in mediating ILC2s function and the potential of targeting these kinases 
for drug development. It will be also interesting to study the effect of the kinases 
downstream of ERK1/2 such as MSKs and RSKs in ILC2 cells.   
It has been demonstrated previously that upon stimulation with IL-33, p38 and 
GATA3 are phosphorylated in ILC2 cells. Using the p38 inhibitor SB203580 
Furusawa and his colleagues showed that inhibition of p38 leads to reduced 
phosphorylation of GATA3, which also resulted in blockade in the production of IL-
5, IL-13 and IL-6 (Furusawa et al., 2013). GATA3 can bind directly to the GATA3 
response element (CGRE), which is upstream of the il13 gene and upregulate il13 
expression in Th2 cells and ILC2 cells (Furusawa et al., 2013,  Yamashita et al. 2002). 
Here, I showed that the p38 inhibitor VX745 blocks not only IL-5, IL-6 and IL-13 
production, but it has also an effect on GM-CSF, and IL-9 responses (Figure 3.10 and 
3.11). The presence of p38 inhibitor also led to a reduction in the proliferation of ILC2, 
suggesting that p38 has a critical role in ILC2 function (Figure 3.10). While a number 
of p38 inhibitors failed to proceed in clinical trials, recently two p38 inhibitors BCT-
197 and AZD7624 have been developed for treatment of COPD and corticosteroid-
resistant asthma. One of the compounds, BCT-197, shows promising results in Phase 
II clinical trials, whereas the compound AZD7624 did not show any beneficial effect 
in patients with COPD (Patel et al., 2018). However AZD7624 is currently in a clinical 
trials for treatment of patients with corticosteroid resistant asthma (ClinicalTrials.gov, 
2016). 
Here, I showed that MK2/3 knock out mice have relatively normal ILC2 numbers. 
Despite this, when stimulated with IL-33 MK2/3 deficient ILC2 had lower production 
of IL-6 and IL-13 (Figure 3.16). Previous studies have found that knockout of MK2 
and 3 can lead to a decrease in p38a levels (Ronkina et al., 2007).  Importantly, similar 
results for IL-33 induced IL-13 and IL-6 production were obtained with a selective 
MK2/3 inhibitor (Figure 3.11 and 3.12), which does not affect p38 expression levels 
(Ronkina et al., 2007b, McCarthy et al., 2018).  Data from our lab showed that loss of 
MK2/3 in mast cells leads to inhibition of TNF-alpha and GM-CSF, whereas I did not 
observe any major difference in the production of GM-CSF in MK2/3 deficient ILC2 
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cells, suggesting that although the signalling pathways are very similar between the 
immune cells, there are some differences in how the production of individual cytokines 
is regulated. The mechanism of how MK2/3 regulate IL-13 and IL-6 production in 
ILC2s is still not clear, however the intracellular staining for IL-13 suggest that MK2/3 
is not blocking the secretion of the cytokine. In macrophages and mast cells MK2/3 is 
regulating cytokine production at the post-transcriptional level via TTP and possibly 
the related proteins Brf1 and Brf2 (Hitti et al., 2006, McCarthy et al., 2018). Therefore, 
it is possible that the same mechanism applies to ILC2s. Future studies will be required 
to confirm this hypothesis. In addition, in the next chapter I have demonstrated that 
Akt or mTORC1 inhibition leads to a similar reduction of IL-6 and IL-13. We have 
previously showed that in MK2/3 deficient macrophages and T cells have reduced 
phosphorylation of the ribosomal S6 protein and Akt, suggesting that the effect of 
MK2/3 in ILC2s could be also due to reduced activation in the mTOR pathway 
(Hayakawa et al., 2017, McGuire et al., 2013).  
MK2 has been shown to play a role in the OVA-induced asthma model. The 
authors proposed that the protective mechanism was due to decreased vascular 
permeability in the MK2 mice. Since adoptive transfer of activated MK2 sufficient T 
cells did not reconstitute the inflammation observed in the WT mice, they suggested 
that the rescue in lung inflammation does not rely on the immune system (Gorska et 
al., 2007). It should be considered however that in this study the mice were analysed 
after up to 96 hours after the OVA challenge. Recent reports have shown that ILC2 
rather than Th2 cells mediated early responses during papain and OVA induced 
inflammation, whereas Th2 are required for the latter responses. (Klein Wolterink et 
al., 2012, Halim et al., 2014).  Considering the role of MK2/3 in regulation of type 
two cytokine production in vitro, the impact of the immune cells should not be 
excluded.  
IL-13 is one of the main cytokines involved in the pathology of asthma 
(Corren, 2013). However the anti-IL13 antibody therapy lebrikuzimab recently failed 
in Phase 3 clinical trials and asthmatic patients did not have an improvement of the 
lung function upon anti-IL13 treatment (Korenblat et al., 2018).  Hence, targeting 
MK2/3 might provide an alternative approach for development of asthma treatment. 
In addition to IL-13, MK2/3 regulate production of other cytokines such as IL-6, TNF-
alpha and GM-CSF in mast cells. It will be also interesting to investigate the role of 
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MK2/3 in modulating Th2 cellular responses, which are a key population in regulating 
the pathology of asthma. We have previously shown that loss of p38 and MK2/3 leads 
to enhanced Treg frequencies, which may have another positive impact in limiting the 
pro-inflammatory type two response (Hayakawa et al., 2017). Therefore, it is critical 
to first establish the role of MK2/3 in the experimental model of asthma. To study the 
role of MK2 in regulating development of asthma, we have set up an Alternaria 
induced lung inflammation model, which will be carried initially in MK2-Vav-iCre 
mice, which have specific deletion of MK2 only in the immune cell compartment.
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IV. Singalling pathways regulating ILC2 
metabolism 
 
 Introduction 
 Immunometabolism 
In recent years the field of immunometabolism has emerged as a major new 
field in immunological research.  Immunometabolism can be subdivided into two main 
areas of research, the first area focuses on understanding the role of the immune system 
in regulating host metabolism, while the second area explores the cell-intrinsic 
metabolic changes within the immune cells and how these are shaping the immune 
responses (Pearce and Pearce, 2013). Inflammatory stimuli trigger a variety of 
processes in immune cells including proliferation, migration to the sites of 
inflammation, upregulation or downregulation of certain genes and production of 
inflammatory mediators, which all require energy and are accompanied with major 
metabolic changes within the cells.  For example, naïve T cells supply ATP through 
oxidative phosphorylation. Similarly, regulatory T cells and tissue resident memory T 
cells are also dependent on exogenous free fatty acids and their oxidative 
phosphorylation as a source of energy (Michalek et al., 2011, Pan et al., 2017). In 
contrast, when T cells encounter antigens they undergo clonal expansion and 
effectively “switch” their metabolism to use glycolysis as an energy source (Greiner 
et al., 1994). This fact is interesting as glycolysis is a much less efficient then oxidative 
phosphorylation in terms of generation of ATP. One reason for this phenomenon could 
be explained by the switch away from oxidative phosphorylation would mean amino 
acids and fatty acids would be less likely to be used for generating ATP, and hence 
more available to be used as cellular building blocks (Pearce, 2010). Furthermore, 
many of the glycolysis intermediates could feed into other pathways such as the 
pentose phosphate pathway leading to the synthesis of nucleotides (O'Neill et al., 
2016).  
Metabolic changes during activation are also characteristic for the innate 
immune cell populations. Cytokine stimulated NK cells upregulate both glycolysis and 
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oxidative phosphorylation, with a preferential increase in glycolysis (Gardiner and 
Finlay, 2017). Both metabolic pathways were found to be dependent on the activity of 
the transcription factor Srebp, which promotes fatty acid and cholesterol synthesis 
(Assmann et al., 2017). During activation with PMA, neutrophils use glycolysis as a 
source of energy. Moreover, it was found that the release of neutrophil extracellular 
traps (NETs) is dependent on glucose (Rodríguez-Espinosa et al., 2015). Similarly, 
dendritic cells activated by TLR stimulation also upregulate the glucose transporter 
Glut1 and switch their metabolism to glycolysis (Everts et al., 2012). Interestingly, 
availability of glucose was found to modulate DC responses and their ability to interact 
with T cells. Replacing glucose with galactose in the media of LPS stimulated DCs 
led to a prolonged expression of the co-stimulatory molecules CD80 and CD86 and 
increased IL12 mRNA levels (Lawless et al., 2017). CD8 T cells co-cultured with 
glucose deprived DCs had higher proliferative capacity and higher production of  
IFN-γ. The authors suggested that in an inflammatory environment T cells are 
competing with DC for nutrients and limiting the availability of glucose to DCs 
leading to enhanced proinflammatory DC responses, which in turn promote T cells 
(Lawless et al., 2017).  
Macrophages use two distinct metabolic pathways to supply energy depending 
on their phenotype. “Classical” macrophages are activated by bacterial derived 
antigens such as LPS or IFN-γ, have a highly inflammatory phenotype and rely on 
glycolysis to mount their response. In contrast, “M2a” macrophages, which are 
activated by IL-4 or IL-13, regulate responses during parasite infections and promote 
tissue repair, use oxidative phosphorylation of fatty acids (Vats et al., 2006).  IL-4 
promotes induction of PPARγ-coactivator-1β (PGC-1β), which is a transcriptional 
coactivator of genes involved in promoting mitochondrial biogenesis, fatty acid 
oxidation and oxidative phosphorylation (Lin et al., 2005). Another distinct feature of 
LPS and IL-4 activated macrophages is in the way they metabolise arginine. In M1 
macrophages arginine is converted to nitric oxide by  inducible nitric synthase 
(Lefrancais et al.), which is required for the killing capacity of the macrophages (Rath 
et al., 2014).  In IL-4 activated macrophages arginine is converted to ornithine and 
urea by the enzyme arginase (Rath et al., 2014). These evidences support the 
hypothesis that cell intrinsic metabolism plays an important role in determining the 
fate of the immune cells.  
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 Activation and regulation of mTOR signalling 
One of the kinases involved in the regulation of cell growth and metabolism 
of both adaptive and innate immune cells, is the mammalian target of rapamycin or 
mTOR. mTOR is a serine/threonine kinase from the PI3K-related kinase family, 
which can be activated by variety of stimuli such as grow factors, hormones, cytokines 
and antigen receptor ligation. mTOR can also sense changes in nutrients such as amino 
acids or the energy levels through the activation of AMPK.  (Jones and Pearce, 2017). 
mTOR exists as a catalytic subunit in two distinct complexes mTORC1 and mTORC2 
(Saxton and Sabatini, 2017). In mTORC1, mTOR makes a complex with Raptor 
(regulatory protein associated with mTOR) and mLST8. Raptor is involved in 
substrate recruitment, while mLST8 stabilises the catalytic domain. In the mTORC2 
complex, mTOR is associated with Rictor (rapamycin insensitive companion of 
mTOR), mLST8, and mSin1 (Saxton and Sabatini, 2017). The DEP-domain 
containing mTOR-interacting protein (DEPTOR) can bind to both of the complexes 
and inhibit their kinase activity (Peterson et al., 2009). 
The complexity of mTOR signalling is highlighted by the fact that the pathway 
is regulated at multiple levels (Figure 4.1). The canonical pathway of mTOR 
regulation requires PI3K (Phosphoinositide 3-kinase) and Akt (also known as protein 
kinase B) activation. PI3K activation leads to the generation of phosphatidylinositol-
3,4,5-triphosphate (PI(3,4,5,)P3), which is required for the activation of Akt by PDK1 
(PI(3,4,5)P3-dependent protein kinase). PDK1 phosphorylates Akt on T308 and 
facilitates its activation. (Alessi et al., 1997). The mTORC2 complex is required for 
the phosphorylation of Akt at S473, which then primes the phosphorylation of Akt at 
T308 (Sarbassov et al., 2005). Once activated, Akt phosphorylates and inhibits the 
activity of Tuberous Sclerosis Complex 2 (Heyen et al., Inoki et al., 2002). TSC2 is a 
GTPase-activating protein which supresses the activity of mTOR pathway by binding 
the GTPase Rheb and promoting the conversion of GTP to GDP (Inoki et al., 2003). 
The active GTP-bound form of Rheb is required for the activation of mTORC1 
(Laplante and Sabatini, 2009). mTOR activation can also occur independent of Akt. 
The Ras/Raf1/ERK pathway has been shown to inhibit the TSC2 suppressive effect in 
mTOR signalling pathway though an ERK2 dependent phosphorylation of TSC2 at 
S664 (Ma et al., 2005). MK2 can also phosphorylate TSC2 at S1210, this 
phosphorylation leads to the binding of 14-3-3 and TSC2, which leads to the inhibition 
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of the TSC1-TSC2 complex (Li et al., 2003).   In TLR stimulated macrophages MK2 
can also promote Akt phosphorylation and potentially mTOR activation, via 
increasing the levels of PIP3 in the membrane, although the substrate of MK2 in this 
process is not clear (McGuire et al., 2013). 
Amino acid availability is also known to activate mTORC1 through the Rag 
GTPases RagA, RagB, RagC and RagD. The Rag GTPases act as a heterodimers, in 
which either of RagA or RagB interacts with RagC or RagD (Powis and De Virgilio, 
2016). Increased concentrations of amino acids stimulates the binding of guanosine 
triphosphate (GTP) to RagA and RagB, whereas RagC and RagD are loaded with 
GDP, a process mediated by a group of proteins referred to as the Ragulator complex. 
The Ragulator complex is a pentameric complex made of  p18 (Lamtor1), p14 
(Lamptor2), MP1 (Lamptor3) and two additional proteins Lamtor 4 and 5 encoded by 
Lamtor1, Lamtor2, Lamtor3, C7orf59 and HBXIP respectively (Sancak et al., 2010, 
Bar-Peled et al., 2012). Moreover the Ragulator complex facilitates the localisation 
of the mTORC1 complex to the lysosomal membrane in a Rag-dependent manner, 
where it can interact with Rheb (Bar-Peled et al., 2012).  Once activated, mTORC1 
can phosphorylate the ribosomal protein S6 kinase p70 S6K and the eIF4E-binding 
protein (4E-BP1) leading to the activation of multiple factors involved in mRNA 
translation. mTORC1 also regulates PPARγ and the transcription factor sterol 
regulatory element-binding protein 1c (SREBP1c) to promote lipid metabolism 
(Zoncu et al., 2010). 
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Figure 4.1 Activation of mTOR signalling pathway.  
Ligation of the receptor tyrosine kinases leads to the activation of PI3K and the generation of 
PIP3 from PIP2. PIP3 is required for the activation of PDK1 kinase, which phosphorylates 
T308 and activates Akt. The mTORC2 complex also phosphorylates Ak on S437. Akt 
phosphorylates TSC2 and inhibits TSC2 suppressive function, leading to the activation of 
mTORC1 complex. Other kinases such as ERK1/2 and RSK1/2 also phosphorylate and inhibit 
TSC2. In contrast TSC2 phosphorylation by AMPK has opposite effect and leads to the 
inhibition of mTORC1 activity. Availability of amino acids leads to the GTP loading on the 
RagA/B dimer, which facilitate the co-localisation of Rheb and mTORC1 and the activation 
of the mTORC1 complex. The mTOR signalling regulates variety of processes such as cell 
cycle progression, growth, proliferation and lipid synthesis. 
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The mTOR pathway is negatively regulated by the AMP-activated protein 
kinase (AMPK). AMPK senses changes in the ATP/ADP and ATP/AMP ratios. 
AMPK is phosphorylated at T172 and activated by the LKB1-STRAD-MO25 
complex or the Calmodulin-activated protein kinase kinase CaMKKβ. This 
phosphorylation increases the affinity of AMPK to AMP (Hawley et al., 2003, 
Hawley et al., 2005). During energy stress leading to decrease in ATP and increase 
in AMP, AMPK is activated to switch on catabolism and the generation of ATP 
(Hardie et al., 2012). AMPK also switches off anabolism by inactivating mTORC1. 
AMPK phosphorylates TSC2 on T1227 and S1345 (Inoki et al., 2003). In contrast 
to the Akt phosphorylation which supresses TSC2, AMPK dependent 
phosphorylation has the opposite effect and stimulates TSC2 to supress mTORC1 
activation (Inoki et al., 2003). Moreover AMPK can inhibit mTORC1 complex 
directly, by phosphorylating Raptor leading to inactivation of Raptor through 14-3-
3 binding (Gwinn et al., 2008).  
 
 Metabolic pathways shaping ILC2s responses 
Little is known how ILC2s metabolism is regulated during homeostasis and 
during activation. A limited number of studies suggest a role of arginine and fatty acid 
metabolism in the regulation of ILC2s. As mentioned above differences in arginine 
metabolism determine the effector functions in macrophages. The enzyme arginase 1 
(Arg1) which metabolises arginine into urea and ornithine, is highly expressed in 
murine ILC2s precursors in the bone marrow and also in mature ILC2s from the 
peripheral tissues (Monticelli et al., 2016). Arginase specific deletion in IL-7 receptor 
expressing cells (Arg1flox/flox Il7r-Cre+) had a protective effect in murine mode of 
papain-induced lung inflammation. In this model, the Arg1flox/floxIl7rCre+ had 
significantly lower number of ILC2s and eosinophils, decreased production of IL-5 
and IL-13 and reduced airway remodelling relative to wild type mice (Monticelli et 
al., 2016). The authors suggested that this is due to lack of Arginase in ILC2s, and not 
in the other IL-7R expressing cells T and B cells, since Arg1 expression was not 
detected on T and B cells in naïve and papain stimulated WT animals. In vitro 
inhibition of Arg1 with Nω-hydroxy-nor-arginine (nor-NOHA) leads to reduction in 
the IL-33 dependent ILC2s proliferation, suggesting the critical role in the arginine 
metabolism for the ILC2s function. Interestingly, the authors demonstrated that nor-
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NOHA blocks the glycolytic pathway in IL-33 stimulated ILC2s, but not oxidative 
phosphorylation (Monticelli et al., 2016). In contrast, another study showed that Arg1 
is not required for ILC2s mediated responses in an infection model with the helminth 
Nippostrongylus brasiliensis (Bando et al., 2013). This could be explained by the fact 
that ILC2s function depends on the inflammatory context. Another explanation could 
be that, in Monticelli et al. study the authors suggested that Arg1 is required for the 
glycolytic pathway which might be important during papain-induced asthma, whereas 
it has been shown that in another model of helminth infection ILC2s relay on fatty 
acid oxidation (Wilhelm et al., 2016). Treatment with the fatty acid oxidation inhibitor 
etomoxir led to an impaired T. muris immune response. Mice treated with etoximir 
had increased worm burden, decrease in the ILC2s numbers and the production of IL-
5 and IL-13. In contrast, blocking glycolysis with 2-deoxy-d-glucose [2-DG] had no 
effect on the type 2 immune responses (Wilhelm et al., 2016). In support to these 
findings, transcriptional analysis of the different innate lymphoid cells revield that 
ILC2s express a number of genes involved in lipid metabolism, such as RXR, Pparγ, 
Dgat2, and Alox5 (Robinette et al., 2015). The RXR retinoid X receptor and 
peroxisome proliferator-activated receptor PPARγ complex recognise fatty acids 
and their metabolites and induce transcription of genes involved in the lipid and 
glucose metabolism. Dgat2 is a diacyglycerol acyltransferase which catalyses the 
final step in triglyceride synthesis. The arachidonate 5-lipoxygenase Alox5 is 
involved in the production of leukotrienes and reactive oxygen species from 
arachidonic acid (Robinette et al., 2015).  
 
 Regulation of host metabolism by ILC2 and IL-33 signalling 
Another aspect of immune metabolism is the understanding of how the 
immune system regulates the host metabolism. The immune system plays an important 
role in mediating the homeostasis of adipose tissue. Increased chronic production of 
pro-inflammatory cytokines, such as TNF-α, IL-6 and IFN-γ, has been associated with 
obesity.  In contrast, type two immune responses are associated with the lean adipose 
tissue and limit obesity by regulating the browning of the white adipose tissue and by 
supressing pro-inflammatory type 1 responses (Cautivo and Molofsky, 2016). An 
increasing number of studies suggest that both ILC2 and IL-33 are involved in the 
regulation of obesity, type two diabetes and atherosclerosis (Han et al., 2015, Miller 
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et al., 2010a, Hams et al., 2013b, Newland et al., 2017).  Administration of 
recombinant IL-33 reduces obesity in genetically obese ob/ob mice by enhancing type 
two immunity (Miller et al., 2010). IL-33 also increases the frequencies of ILC2s and 
eosinophils in mice on high fat diet. Furthermore, ILC2s produce methionine-
enkephalin and promote the upregulation of Ucp1 and the browning of the adipose 
tissue (Brestoff et al., 2014). Similarly IL-25 also promotes the regulatory effects of 
ILC2 and NKT cells during high fat diet induced obesity and adoptive transfer of ILC2 
and NKT cells in obese mice leads to transient weight loss in obese animals (Hams et 
al., 2013a).  
 
 Aims 
Considering the importance of IL-33 in ILC2s responses and the limited 
information about the metabolic changes that occur in activated ILC2s, the aim for 
this part of my project was to investigate IL-33 dependent metabolic changes in ILC2 
cells. I also looked at the role of mTOR signalling in ILC2s effector function. 
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 Results 
IL-33 stimulation in ILC2 cells led to a substantial increase in the size and 
granularity of the cells (Figure 4.2). The increase in size was detectable after 24 hours 
of IL-33 stimulation, however it was much greater following 72 hours stimulation 
(Figure 4.2). The longer stimulation also led to around 3-4 fold increase in cell number 
in comparison to the initially plated cells (Figure 4.2). Taken together, these results 
suggest that IL-33 induces changes in the growth and proliferation of the cells. 
  
Figure 4.2 IL-33 induces proliferation and an increase in size in ILC2 cells.  
Cultured ILC2 cells were plated +/- 100ng/ml of IL-33 for 24 or 72 hours. Cells were stained 
with DAPI (0.5 µg/mL) and analysed on BD FACSVerse to determine absolute numbers of 
live cells.  Plots represent FSC-A and SSC-A of DAPI negative live cells. Bar plots represent 
the average value of 3 technical replicates. Error bars represent the standard error of the mean. 
 
mTOR signalling plays a critical role in the regulation of cell growth and 
proliferation by activating anabolic pathways. ILC2s cultured in IL-2 and IL-7 had 
constitutive phosphorylation of the ribosomal S6 protein, therefore to address the 
question if mTOR is activated in ILC2 cells in response to IL-33, I rested the cells in 
complete RPMI media with no IL-2 or IL-7, before stimulation with IL-33 alone or 
IL-33 and the mTORC1 inhibitor rapamycin or the RSK1/2 inhibitor LJI308 and 
measured the phosphorylation of S6 on S235/236. IL-33 stimulation of ILC2s led to a 
phosphorylation of the ribosomal protein S6. This phosphorylation was completely 
blocked in the presence of rapamycin and only partially reduced in the presence of 
93 
 
RSKs inhibitor, suggesting that mTORC1 complex has a major role in the regulation 
of S6 phosphorylation in ILC2s (Figure 4.3). In addition flow cytometry analysis of 
the changes in the FSC-A and SSC-A showed that rapamycin reduced the increase in 
cell size in IL-33 stimulated ILC2 cells, but not their granularity (Figure 4.4). 
 
Figure 4.3 S6 activation in ILC2s.  
Cultured ILC2s were rested for 3 hours in ILC2 media lacking IL-2 and IL-7 and pre-incubated 
for a further 1 hour with rapamycin (20nM) or RSK inhibitor LJI308  (10 µM) or DMSO 
before stimulation with 100ng/ml of IL-33 for 0 or 20 minutes. Phosphorylation of S6 
ribosomal protein was measured by flow cytometry.  A. Live cells were gated based on FSC-
A and SSC-A and the overlaid histograms show p-S6. B. Bar plots show average of the median 
fluorescence intensity (MFI) of p-S6 from one biological replicate done in duplicate.  
 
 
Figure 4.4 mTORC1 controls ILC2 cell size.  
Cultured ILC2 cells were stimulated with DMSO, IL-33 (100ng/mL) or IL-33 and rapamycin 
(20nM) for 72 hours and analysed by flow cytometry BD LSRFortessa. The overlaid 
histogram show changes in FSC-A and SSC-A 
 
The of role mTORC1 in the regulation of IL-33 dependent cytokine production 
in ILC2s is largely unexplored, with only one study suggesting that mTORC1 
activation is required for the IL-5 and IL-13 production in ILC2s in vitro and 
rapamycin ameliorates IL-33 induced lung inflammation in vivo (Salmond et al., 
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2012). To confirm these findings and understand the effect of mTORC1 in the 
production of other cytokines, I stimulated ILC2 cells with IL-33 in the presence of 
the mTORC1 inhibitor, rapamycin. Inhibition of mTORC1 led to a significant 
reduction in IL-6 and IL-13 production, but did not affect any of the other cytokines 
tested including IL-5 (Figure 4.5).   
The canonical activation of mTORC1 is mediated by the PI3K/Akt pathway. 
To further dissect the pathway and understand the role of Akt in regulating ILC2s 
responses, ILC2s were stimulated with IL-33 in the presence of Akt inhibitor Akti-
1/2. Inhibition of Akt did not affect the viability of the cells, however, similar to 
rapamycin, it led to a significant reduction in IL-6 and IL-13 production (Figure 4.6).  
 
Figure 4.5 mTORC1 activation in ILC2s.  
Cultured ILC2 cells were pre-incubated with DMSO or rapamycin (20nM) and then stimulated 
with IL-33 (100ng/mL) for 24 hours. Control cells received DMSO but not IL-33.  Following 
the stimulation cells were stained with DAPI (0.5 µg/mL) and analysed on BD FACSVERSE 
to determine absolute numbers of live cells. Supernatants from the cell cultures were analysed 
for IL-5, IL-6, IL-13 and GM-CSF by multiplex cytokine assay. Bar plots represent the 
average value of stimulations done in triplicate. Error bars represent the standard error of the 
mean. Significance between IL-33 alone and inhibitor treated samples was calculated by two-
tailed unpaired Student’s t-test ; * denotes (p<0.05), ** denotes (p<0.01). 
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Figure 4.6 Regulation of cytokine production by Akt and PI3K.  
Cultured ILC2s cells were pre-incubated with DMSO or the Akt inhibitor Akti-1/2 (1M) and 
then stimulated with IL-33 (100ng/mL) for 24 hours. Control cells received DMSO but not 
IL-33. Following stimulation, cells were stained with DAPI (0.5 µg/mL) and analysed on BD 
FACSVERSE to determine absolute numbers of live cells. Supernatants from the cell cultures 
were analysed for IL-5, IL-6, IL-13 and GM-CSF by multiplex cytokine assay. Stimulation 
was done in triplicate and bar graphs show the average values +/- SEM.  Significance between 
IL-33 alone and inhibitor treated samples was calculated by two-tailed unpaired Student’s t-
test; * denotes (p<0.05), ** denotes (p<0.01). 
 
The proto-oncogene Myc plays a central role in the regulation of cellular 
metabolism leading to cellular proliferation and differentiation. The MYC family 
includes c-Myc, N-Myc and L-Myc (Chen et al., 2018).  Dysregulation of Myc 
members is involved in more than 50% of cancers, which is not surprising considering 
that Myc  are master transcription factors and regulate expression of around 15% of 
all genes (Dang et al., 2006). The transcriptional activity of c-Myc is required for the 
regulation of genes involved in the cell cycle, protein synthesis, ribosomal biogenesis, 
mitochondrial function and signal transduction (Dang et al., 2006). Using a tamoxifen-
inducible Cre system to delete c-Myc in T cells, it was shown that c-Myc was required 
both for growth and proliferation in activated CD8 T cells (Wang et al., 2011b, Preston 
et al., 2015).  c-Myc was also required for upregulation of genesinvolved in glycolysis 
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and glutaminolysis. In addition, loss of c-Myc led to a reduction in the amino acid 
transporter CD98  (Wang et al., 2011b).   
Given the critical role of c-Myc in modulating T cell growth, next I examined 
the expression of c-Myc in ILC2 cells using mice which express c-Myc GFP fusion 
protein, previously described by Huang et al. (Huang et al., 2008). Stimulation with 
IL-33 led to an increase of c-Myc expression in ILC2s (Figure 4.7). To ensure that the 
change in the fluorescence was not due to increased autofluorescence caused by the 
increase in the size and the granularity of the ILC2s, c-Myc WT ILC2s were also 
analysed at the same time. Only a minor shift was observed in the GFP channel of the 
IL-33 stimulated WT ILC2s.  Together these results suggest that IL-33 is indeed 
driving expression of c-Myc. 
 
Figure 4.7 IL-33 induces c-Myc in ILC2s. | 
ILC2s were prepared from wild type and GFP-Myc mice and cultured with or without IL-33 
(100 ng/mL) for 24 hours.  Cells were then analysed by flow cytometry.  The representative 
plot is gated on live cells based of forward and side scatter and shows expression of c-Myc in 
cultured ILC2 cells from WT and GFP-Myc mice. 
 
As mentioned above c-Myc was found to regulate the amino acid transporter 
CD98 in activated CD8 T cells (Wang et al., 2011b). CD98 is a heterodimer made of 
heavy and light chains (Nakamura et al., 1999). The heavy chain, which is encoded by 
Slc3a2, contains transmembrane and cytosolic domains, which are required for 
integrin signalling (Cantor and Ginsberg, 2012). There are several different light 
chains that can bind to the CD98 heavy chain through a disulfide bond such as Slc7a5 
(LAT1), Slc7a8 (LAT2), Slc7a7 (γ-LAT1) and Slc7a6 (γ-LAT2) (Cantor and 
Ginsberg, 2012). LAT1 and LAT2 are the two major transporters for large neutral 
amino acids such as leucine, isoleucine, tyrosine, methionine and tryptophan. The 
availability of amino acids such as leucine has been shown to activate mTORC1 
activity (Wolfson et al., 2016, Nicklin et al., 2009). In addition to the amino acid, the 
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supply for iron is also needed for enhanced cell metabolism and growth. Iron transport 
is mediated via the CD71 transferrin receptor, which expression has been shown to be 
increased on the surface of activated T cells (Motamedi et al., 2016). Moreover CD71 
expression was found to be dependent on c-Myc in TCR-stimulated CD8 T cells 
(Preston et al., 2015). Expression of both CD98 and CD71 were increased in ILC2s 
stimulated with IL-33, suggesting that the cells might have higher uptake of amino 
acids and iron. Whereas expression of CD98 was detected even in the unstimulated 
ILC2s, CD71 was only detected in ILC2s upon IL-33 stimulation. Interestingly, 
treatment with rapamycin led to a partial reduction in CD71 expression, but blocked 
the IL-33-induced increase in CD98.  
 
Figure 4.8 CD98 and CD71 expression in ILC2s. 
 Cultured ILC2 cells were preincunated with DMSO or rapamycin (20nM) and then stimulated 
with IL-33 (100ng/mL) for 72 hours. Control cells received DMSO but not IL-33. Cells were 
then analysed by flow cytometry on a BD LSRII (Fortessa). Live cells were gated based on 
FSC-A and SSC-A. Plots show expression of CD98 (left) and CD71 (right).  
 
Recently the Cantrell lab developed a single cell assay for monitoring System L 
amino acid transporters using the L-tryptophan metabolite kynurenine (Kyn) (Sinclair 
et al., 2018). Kynurenine emits fluorescence with an excitation wavelength of 380 nm 
and an emission spectrum of 480 nm, which can be detected by flow cytometry using 
the violet laser (Sinclair et al., 2018). Control or IL-33 stimulated ILC2s were first 
acquired for 2 minutes to measure basal fluorescence in the violet channel, then Kyn 
was added to the samples and they were further acquired for another 5 minutes to 
measure changes in fluorescence. IL-33 stimulated ILC2s had a higher uptake of 
kynurenine in comparison to the unstimulated cells (Figure 4.9). To ensure that Kyn 
was not binding unspecifically to the cell membrane, but is indeed transported in to 
the cell, BCH (2-aminobicyclo-(2,2,1)-heptane-2carboxylic acid), an inhibitor of 
System L amino acid transporter, was used (Kim et al., 2008). The presence of 
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inhibitor led to a substantial reduction in the fluorescent signal, confirming that the 
cells are taking up Kyn.  
 
 
Figure 4.9 Kyn uptake in ILC2 cells.  
Cultured ILC2 cells were stimulated with or without IL-33 (100ng/mL) for 24 hours.  After 
stimulation cells were analysed by flow cytometer using 405 nm excitation (violet laser) and 
band pass filter 450 ± 50 on BD FACSCanto Unstimulated and stimulated samples were 
acquired for 2 mins to determine baseline florescence before addition of Kyn (200uM). Where 
indicated the system L amino acid transporter inhibitor BCH (10mM) was added prior to 
acquisition.  Plots show fluorescence (450nm) of ILC2 cells over time. 
 
Slc7a5 expression is critical for CD8 differentiation, metabolic reprogramming and 
clonal expansion (Sinclair et al., 2013). More recently it has been demonstrated that 
Slc7a5 may also be regulating responses in human monocytes. Slc7a5 was induced in 
monocytes upon LPS stimulation.  In addition, pharmacological inhibition of Slc7a5 
with either BCH or the LAT1 inhibitor JPH203 supressed the production of IL-1β in 
LPS stimulated monocytes (Yoon et al., 2018).  Given the importance of Slc7a5 in 
immune function, next I investigated the role of Slc7a5 in ILC2s using Slc7a5fl/fl mice 
crossed to Vav-iCre mice, resulting in a conditional deletion of Slc7a5 in immune cell 
populations. Interestingly, the Slc7a5fl/flVav-iCre+/- mice had significant reduction in 
body weight, as well as in epididymal white adipose tissue weight (Figure 4.10).  ILC2 
cells were decreased in the eWAT, but not in the lungs (Figure 4.11). Macrophages 
were also reduced in the eWAT, in contrast to the eosinophils which were not changed 
in the knock out mice (Figure 4.12).  
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Figure 4.10 Loss of Slc7a5 in the immune cells leads to weight loss and body fat. 
Bar plots show total body weight and eWAT weight of 4 month old Slc7a5fl/flVav-iCre-/-and 
Slc7a5fl/flVav-iCre+/-. Each symbol represents individual biological replicate. Error bars 
represent standard error of the mean. Significance was calculated by two-tailed unpaired 
Student’s t-test; * denotes (p<0.05), ** denotes (p<0.01). 
 
Figure 4.11 Slc7a5fl/flVav-iCre+/- mice have reduced ILC2s in the eWAT.  
Lungs and epididymal white adipose tissue (eWAT) from Slc7a5fl/flVav-iCre-/-and 
Slc7a5fl/flVav-iCre+/- (4 months old) were digested to obtain single cell suspension. Cells were 
stained for expression of Lineage markers (FITC), CD45 (PerCP/Cy5.5), KLRG1(APC) and 
Sca1(APC/Cy7) and DAPI and analysed on BD LRSII Fortessa. (A) Representative plots are 
showing percentage of Lineage- and CD45+ve cells from all live single cells and percentage of 
KLRG1+veSca1+ve ILC2 cells within the Lineage-CD45+ve population in lungs and the eWAT. 
(B) Bar plots represent summary of absolute numbers of Lineage-veCD45+veKLRG1+veSca1+ve 
ILC2 cells in the lungs and eWAT (D) and body weight. Each symbol represents individual 
biological replicate. Error bars represent the standard error of the mean. Significance was 
calculated by two-tailed unpaired Student’s t-test; * denotes (p<0.05), ** denotes (p<0.01). 
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Figure 4.12 Slc7a5fl/flVav-iCre+/- mice have reduced Macrophages.  
Epididymal white adipose tissue (eWAT) from Slc7a5fl/flVav-iCre--and Slc7a5fl/flVav-iCre+/- 
(4 months old) were digested to obtain single cell suspension. Cells were analysed for 
expression of CD45 (BV510), CD11b (PE/Cy7), F4/80 (FITC) and Siglec-F (PE) on BD 
LRSII Fortessa. (A) Representative plots are showing percentage of CD45+veCD1b+ve and 
percentage of F4/80+veSiglec-F-ve Macrophages and F4/80lowSiglec-F+ve eosinophils. (B) Bar 
plots represent summary of absolute numbers of the macrophages and eosinophils in the 
eWAT (D) and body weight. Each symbol represents individual biological replicate. Error 
bars represent the standard error of the mean. Significance was calculated by two-tailed 
unpaired Student’s t-test; * denotes (p<0.05), ** denotes (p<0.01). 
 
Next, I wanted to understand if Slc7a5 is required for ILC2s cell growth during 
IL-33 stimulation. Cultured ILC2s from the mesenteric fat of Slc7a5fl/flVav-ICre-/-  and 
Slc7a5fl/flVav-iCre+/- mice were stimulated with IL-33 and analysed by flow 
cytometry. ILC2 cells isolated from Slc7a5fl/flVav-iCre+/- failed to enlarge in response 
to IL-33 suggested by FSC-A and SSC-A analysis (Figure 4.13). The size of 
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unstimulated Slc7a5 knockout ILC2s was also smaller in comparison those of WT 
ILC2s.  In addition, Slc7a5 knockout ILC2s failed to uptake Kyn. Taken together these 
data indicated that Slc7a5 plays a critical role in sustaining ILC2s in the adipose tissue 
and is also required for IL-33 dependent cell growth and amino acid uptake.  
 
Figure 4.13 Slc7a5 is required for ILC2s cell growth.  
ILC2 cells isolated from Slc7a5fl/flVav-iCre--and Slc7a5fl/flVav-iCre+/- were cultured +/- 
100ng/ml of IL-33(100 ng/ml) for 24. Cells were analysed on BD FACACanto and plots 
represent FSC-A and SSC-A of ILC2s. 
 
 
Figure 4.14 Slc7a5 transports Kyn in ILC2s.  
Purified ILC2 cells from Slc7a5fl/flVav-iCre--and Slc7a5fl/flVav-iCre+/- mice were stimulated 
with IL-33 (100ng/mL) and analysed by flow cytometer using 405 nm excitation (violet laser) 
and band pass filter 450 ± 50 on BD FACSCanto. Unstimulated and stimulated samples were 
acquired for 2 mins to determine baseline florescence. Kynurenine (200uM) was added to the 
cells and samples were acquired for another 5 minutes. Plots show fluorescence (450nm) of 
ILC2 cells over time. Results are representative for two biological replicates.  
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 Discussion 
Activation of immune cells is accompanied by major metabolic changes.  Here 
I showed that IL-33 induces cell growth and proliferation in ILC2s and activation of 
mTOR signalling pathway, as indicated by the phosphorylation of S6. Although 
RSK1/2 are shown under some circumstances to phosphorylate ribosomal protein S6 
on S235/236 independent of the mTOR-pathway (Roux et al., 2007), inhibition of 
RSK1/2/3 had only a partial effect on the S6 phosphorylation in ILC2s. In contrast, 
rapamycin completely blocked the phosphorylation of S6 suggesting that mTORC1, 
but not RSK1/2 are mediating S6 phosphorylation in IL-33 stimulated ILC2s (Figure 
4.3). Inhibition of mTOR by rapamycin led also to a reduction of IL-6 and IL-13 
(Figure 4.5). Interestingly, it has been found that rapamycin blocks IL-5 and IL-13 
production by ILC2s (Salmond et al., 2012), whereas I did not observe any effect of 
rapamycin on IL-5 production (Figure 4.5). This could be explained by the different 
methodology of isolating the cells since, they have used ILC2 isolated from lungs of 
mice treated with recombinant IL-33. Moreover in this study rapamycin was used at 5 
times higher concentration and it is possible that the reduction of IL-5 is due to an off 
target effect (Salmond et al., 2012).  
The exact mechanism of how IL-33 is inducing mTOR signalling activation is 
not clear. Both ERK and the downstream activated 90 kD ribosomal S6 kinases RSKs 
have been shown to phosphorylate TSC2 and activate the mTORC1 complex in 
HEK293 cells (Ma et al., 2005; Roux et al., 2004; Roux et al., 2007). In addition, 
ERK1/2 phosphorylates and activates Raptor to promote mTORC1 activity (Carriere 
et al., 2011).  However, the finding that RSK inhibition does not block S6 
phosphorylation would argue against this as the primary mechanism regulating mTOR 
activation.   Here, I demonstrated for first time that inhibition of Akt also blocks IL-6 
and IL-13 similar to rapamycin, which would be consistent with mTORC1 activation 
downstream of the PI3 kinase – Akt pathway (Figure 4.6).  However, based on these 
data is difficult to predict if Akt activation is directly dependent on IL-33 stimulation 
or is a secondary response. In mast cells stimulation with IL-33 induces 
phosphorylation of Akt that is sensitive to PI3 kinase inhibitors, although the 
molecular mechanism linking IL-33 to PI3 kinase signalling is unclear (Drube et al., 
2016)(McCarthy et al., 2018). Interestingly, it has been shown that in macrophages 
pharmacological inhibition or loss of MK2/3 leads to reduction of phosphorylation of 
103 
 
Akt on both S437 and T308 upon TLR stimulation by mediating the availability of 
PIP3 in the phospholipid membrane (McGuire et al., 2013). Another possible way in 
which IL-33 could activate PI3 kinase – Akt signalling would be via c-Kit. As 
discussed in the previous chapter c-Kit could synergise with the IL-33 receptor 
complex in mast cells (Drube et al., 2010). Upon ligation of c-Kit with SCF, the SH2 
domain of the receptor interacts with the p85 subunit of PI3K leading to allosteric 
activation of the PI3K catalytic subunit (Roskoski, 2005). Activation of PI3K and 
PDK1 would allow the phosphorylation of Akt on T308 (Alessi et al., 1997).   
mTOR inhibition led to a partial reduction of the IL-33 dependent size increase 
in ILC2s, suggesting that another pathway might be involved in driving the robust 
changes in ILC2s (Figure 4.4). I have shown that expression of c-Myc was also 
upregulated in ILC2 stimulated with IL-33 (Figure 4.7). Comprehensive 
transcriptomics analysis has highlighted the critical role of Myc in regulating T and B 
cells responses following antigen receptor activation (Murn et al., 2009, Wang et al., 
2011b, Sabò et al., 2014). Deletion of Myc in T cells severely impaired the 
proliferation and growth by controlling genes essential for the cell cycle progression 
such as cyclins and CDKs. Myc was also found to be critical for the downstream 
events in the mTOR signalling, suggested by the fact that Myc deficient T cells had 
lower levels of S6 phosphorylation (Wang et al., 2011b). The authors attributed that 
to a reduction of Slc3a2 (encoding CD98 heavy chain) and Slc7a5 amino acid (Wang 
et al., 2011b, Nicklin et al., 2009). Interestingly, Slc7a5 was required for c-Myc 
expression in CD8 T cells. Upon TCR activation both WT and Slc7a5 knock out T 
cells upregulated c-Myc levels mRNA levels, however Slc7a5 T cells did not 
upregulate c-Myc at the protein level, suggesting that there is a bidirectional regulation 
of Slc7a5 and c-Myc (Sinclair et al., 2013a). Similar findings were observed also in 
NK cells deficient of Slc7a5, which did not upregulate c-Myc at protein level upon IL-
2/IL-12 stimulation (Loftus et al., 2018).  
In agreement with the enhanced expression of Myc in ILC2s following IL-33 
stimulation, CD98 and CD71 expression was also upregulated (Figure 4.8). 
Unstimulated ILC2s also expressed measurable levels of CD98, this is in line with 
RNAseq data in the Immgen database showing that among the innate lymphoid cells 
ILC2 isolated from small intestine have the highest expression of Slc3a2 amongst the 
innate lymphoid cell populations analysed (Figure 4.13). In line with the increased 
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expression of CD98, I found that ILC2s stimulated with IL-33 showed an enhanced 
ability to take up the L-tryptophan metabolite kynurenine (Figure 4.9).  Among the 
light chains that can bind to the CD98 heavy chain and mediate transport of amino 
acids, Slc7a5 has been found to play a critical role in many cell types, including T 
cells, NK cells and human monocytes (Loftus et al., 2018, Sinclair et al., 2013a, Yoon 
et al., 2018). Here I demonstrated that Slc7a5 is also regulating ILC2s responses 
following activation. Slc7a5 deficient ILC2s had impaired cell growth upon activation 
with IL-33 and complete abrogation of Kyn uptake (Figure 4.13 and Figure 4.14). 
Moreover, ILC2s numbers were also significantly reduced in the white adipose tissue, 
but not in the lungs. These data suggested that there might be a differential mechanism 
of regulation of tissue ILC2s and a specific role of Slc7a5 in the adipose ILC2s. 
Another interesting observation is that according to Immgen database Slc7a8 (LAT2) 
has a much higher expression than Slc7a5 (LAT1) on ILC2s isolated from the small 
intestine (Figure 4.15). It is possible that resting ILC2 cells rely on Slc7a8, while in 
activated state when cells are rapidly growing they require Slc7a5. In addition, the 
prerequisite for either LAT1 or LAT2 function may depend on the tissues in which the 
ILC2s are found. This would explain why ILC2s numbers in the lungs were not 
affected in the Slc7a5fl/fl Vav cre mice while those in the  eWAT ILC2s were reduced.  
 
Figure 4.15 Slc3a2, Slc7a5 and Slc7a8 expression in innate lymphoid cells populations.  
Bar graphs were generated using the Immgen RNASeq data base and show the expression of 
Slc3a2, Slc7a5 and Slc7a8 in CD27+veCD11b+ve NK cells, ST2+ve ILC2s and  
NKp46+veCCR6-ve and NKP46+ve ILC3 isolated from the small intestine  
 
Finally, we have observed a decreased body weight in the Slc7a5fl/flVav-iCre+/- 
in comparison to Slc7a5fl/flVav-iCre-/-  mice, suggesting that the weight loss is a result 
of a defect in the immune cell compartment (Figure 4.10). Although ILC2s have been 
found to mediate the beiging of the white adipose tissue by secreting Met-Enkephalin 
in response to IL-33 (Brestoff et al., 2014), it is unlikely that ILC2s would be 
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responsible for the observed weight loss in the Slc7a5fl/flVav-iCre+/- mice. Considering 
that Slc7a5 deficient ILC2s have impaired cell growth in response to IL-33, it is likely 
that their ability to produce effector molecules such as IL-13, IL-4, IL-5 and Met-
Enkephalin will also be impaired. The numbers of white adipose macrophages were 
also reduced in the Slc7a5fl/flVav-iCre+/- knock out mice (Figure 4.12). At present it is 
not clear if this effect is intrinsic to the macrophages or as a result in a defect in ILC2s 
or another Slc7a5 dependent immune cell type affecting macrophage numbers. White 
adipose tissue macrophages are important mediators of adipose tissue homeostasis 
(Boutens and Stienstra, 2016). It has been shown that macrophages in lean and obese 
adipose tissue have different metabolic properties (Serbulea et al., 2018). For example 
the macrophages in obese adipose tissue are highly energetic and exhibit high 
oxidative phosphorylation rate as well as increased aerobic glycolysis (measured by 
the extracellular acidification rate ECAR), whereas macrophages obtained from lean 
mice had both low oxygen consumption rate (OCR) and low ECAR (Serbulea et al., 
2018). In human monocytes stimulated with LPS, inhibition of Slc7a5 with either 
BCH or JPH203 led to a significant reduction in ECAR. The authors showed that the 
leucine influx plays an important role in activation of mTOR and the glycolytic 
pathway (Yoon et al., 2018). Amino acid transport was also required for optimal TNF-
α and IL-β production. Therefore, it is possible that the body weight loss in the 
Slc7a5fl/flVav-icre+/- mice is due to the loss of Slc7a5 in macrophages, their impaired 
glycolytic metabolism and inability to produce pro-inflammatory cytokines 
(Tzanavari et al., 2010).   
 
 Conclusions and future prospective 
IL-33 induces activation of two major metabolic regulators in ILC2s, the 
mTOR pathway and transcription factor c-Myc. Inhibition of mTOR and Akt led to a 
significant reduction in the production of IL-6 and IL-13. Further research would be 
needed to understand the exact mechanism of how IL-33 is activating mTOR 
signalling in ILC2s and the molecular mechanism by which is regulated IL-6 and IL-
13 production. Inhibition of PI3K leads to reduction in the cytokine production in IL-
33 stimulated mast cells (McCarthy et al., 2018). Therefore, it will be also interesting 
to investigate the role of PI3K in the ILC2s cytokine production. The massive increase 
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in the ILC2s size upon IL-33 stimulation suggest a major changes in the metabolic 
pathways, therefore it will be critical to establish if in this context ILC2s rely on 
glycolysis similarly to activated T cells or oxidative phosphorylation, which is a 
typical metabolic pathway for IL-4 stimulated macrophages (Pearce and Pearce, 
2013). A recent study suggests that blocking glycolysis promotes ILC2s development 
in vitro, whereas blocking oxidative phosphorylation has a negative impact (Li et al., 
2018b). The authors demonstrated that mice with conditional deletion of the E3 ligase 
VHL have a substantial decrease in the ILC2s numbers in the periphery due to 
enhanced HIF1α expression (Li et al., 2018b). VHL is an E3 ligase that ubiquitinates 
and targets HIF1α for proteasomal degradation (Haase, 2009). HIF1α transcription 
factor is regulating the expression of a number of genes involved in the glycolysis 
pathway including key enzymes such as hexokinase 1 and 2, 6-phosphofructokinase 
(Marin-Hernandez et al., 2009). Therefore it will be interesting to study the role of 
HIF1α in ILC2s cells development and function.  
We found that the Slc7a5 amino acid transporter regulates cell growth and Kyn 
uptake in ILC2s. The role of Slc7a5 in mediating the effector function of ILC2s is still 
unknown, however it is possible that similar to T and NK cells, Slc7a5 is required for 
the expression of Myc in IL-33 stimulated ILC2s (Sinclair et al., 2013a, Loftus et al., 
2018). Future work will be required to understand the role of Slc7a5 in both the 
cytokine production and proliferative capacity of ILC2s and activation of the mTOR 
pathway. More work will be also required to understand, how the loss of Slc7a5 in the 
immune cell compartment is regulating the body weight in mice. As discussed above 
the macrophages might play an important role in this process, therefore it will be 
interesting to study the metabolic properties and the cytokine production in Slc7a5 
knock out macrophages.  
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V. Investigating the role of ABIN1 in the 
development of autoimmunity 
 
 Introduction 
 Regulation of MyD88 signalling by the ubiquitin system 
The TLRs play a critical role in mediating innate immune responses and 
pathogen clearance. TLR ligation leads to activation of the MAPK signalling as well 
as NF-κB resulting in the production of multiple inflammatory mediators such as 
cytokines and chemokines. However, if not controlled, these inflammatory mediators 
could disturb immune haemostasis and cause autoimmunity or inflammatory diseases 
(Kondo et al., 2012). Posttranslational modifications including ubiquitination are key 
regulators of innate immune signalling (Aksentijevich and Zhou, 2017). 
Ubiquitination is a process in which a monomeric or polymeric ubiquitin molecule is 
attached to a protein. Ubiquitination is a three step process.  The first step is mediated 
by Ub-activating enzymes E1 and consists of transferring of free ubiquitin (Ub) to the 
active site cysteine residue on E1, a process which requires energy from ATP.  The 
second step is catalysed by the E2 ubiquitin conjugating enzyme and leads to the 
transfer of Ub from E1 to an active site cysteine residue on E2.  In the final step an E3 
ligase catalyses the transfer of the Ub to a lysine residue of the target protein. This 
process results in a covalent bond being formed between the C-terminus of Ub and the 
amino group in the lysine side chain.  Ub contains 7 lysine residues all of which can 
potentially be ubiquitinated allowing the formation of poly Ub chains.  In addition, Ub 
can be also linked to an N-terminal methionine (Met) residue of another Ub molecule 
leading to formation of linear ubiquitin chains.   The structure of a poly Ub chain 
depends on the amino group in the Ub molecule that is used, and different chain types 
have different properties and functions.  For example, addition of ubiquitin chains 
linked via Lys11 and Lys48 targets protein for degradation by the proteasome system, 
while Lys63 or Met1 linked chains facilitate protein interactions and are involved in 
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regulating a number of cellular processes including innate immune signalling and 
DNA damage pathways (Aksentijevich and Zhou, 2017).  
Activation of the TLR and IL-1 family members leads to the recruitment of 
MyD88, IRAK4, IRAK1 kinases and IRAK2 pseudokinase leading to formation of 
the Myddosome. Interaction of TRAF6 with the C-terminal regions of IRAK1 and 
IRAK2 is required for the activation of TRAF6 and the downstream signalling (Ye et 
al., 2002). IRAK1 and IRAK4 also phosphorylate and enhance the E3 ligase activity 
of Pellino isoforms (Ordureau et al., 2008). It has been demonstrated that in HEK293 
cells stably expressing IL-1R both TRAF6 and Pellinos are required for the generation 
of the K63 Ub chain downstream of the IL-1 receptor, suggested by the fact that K63-
Ub chains formation was completely abolished  in TRAF6/Pellino1/Pellino2 triple 
CRISPR/Cas9  knock out cells, but not in TRAF6 or Pellino1/2 knock out cells 
(Strickson et al., 2017).  In addition, the E3 ligase LUBAC (linear ubiquitin assembly 
complex) catalyses the attachment of M1 linked linear ubiquitin chains to the K63 
chains. The NF-κB essential modulator (NEMO), which is the regulatory subunit of 
the IKK complex and the TAK1-binding proteins (TAB2 and TAB3) that is part of 
TAK1 complex, bind to M1 and K63 ubiquitin chains, respectively. This leads to co-
recruitment of the TAK1 and IKK complexes and the TAK1 dependent activation of 
the IKK complex and activation of NF-κB and downstream signalling events 
(Emmerich et al., 2013b, Cohen and Strickson, 2017).  Ubiquitination is a reversible 
process and is controlled by deubiquitinases (DUBs). In the context of innate immune 
signalling DUBs such as cylindromatosis (CYLD), OTULIN and A20 have a key role 
in the negative regulation of NF-κB signalling (Lork et al., 2017) (Figure 5.1).  CYLD 
catalyses the removal of several polyubiquitin linkages including K63 chains. CYLD 
removes ubiquitin chains on several components of the MyD88 signalling pathway 
including TRAF6, TAK1 and NEMO (Kovalenko et al., 2003, Sun, 2009) (Figure 
5.1A).  OTULIN specifically cleaves Met1-Ub and overexpression of OTULIN 
attenuated NF-κB activation and delayed JNK phosphorylation (Keusekotten et al., 
2013, Fiil et al., 2013) (Figure 5.1B). In humans, loss of function mutations in Otulin 
lead to an early onset auto-inflammatory condition, characterised with neutrophilic 
dermatitis, inflammation, diarrhoea and failure to thrive (Zhou et al., 2016). Mutation 
of the active site cysteine to alanine (C129A) in OTULIN leads to embryonic lethality 
in mice. The embryonic lethality is delayed when the mice are crossed to RIPK1-/- 
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mice. Using a tamoxifen inducible Cre system it has been demonstrated that 
inactivation of OTULIN in adult animals leads to rapid weight loss, increased 
inflammation, cell death and organ damage (Heger et al., 2018). This phenotype was 
ameliorated when blocking necroptosis and apoptosis by crossing the mice to caspase-
8 and RIPK3 mutant mice, suggesting that the phenotype was dependent on 
inflammation caused by increased cell death (Heger et al., 2018).   
 
Figure 5.1 Regulation of TLR signaling by ubiquitin chains. 
TLR ligation leads to recruitment of MyD88 and the kinases IRAK4, IRAK1 and IRAK2 and 
the subsequent recruitment of the E3 ligase TRAF6. TRAF6 together with Pellino 1/2  and the 
E2 conjugating complex Ubc13-Ueva1are required for the generation of K63 ubiquitin chains. 
LUBAC is another E3 ligase which catalyses the attachment of M1 ubiquitin chains to the 
K63 chains leading to formation of linear polyubiquitin chains. The last are required for co-
recruitment of TAK1 and IKK complexes. A. CYLD is a deubiquitinase which removes K63 
ubiquitin chains from TAB2/3 and NEMO, preventing the co-recruitment of the TAK1 and 
IKK complexes. B. OTULIN specifically cleaves M1 ubiquitin chains and similarly to CYLD 
regulates the activation of IKK complex. C. A20 is an ubiquitin editing enzyme which have 
dual activity, it can cleave K63 linked ubiquitin chains, but it can also add K48 ubiquitin to 
the E2 ligase Ubc13, leading to Ubc13 degradation. In this way the interaction between 
TRAF6 and Ubc13 is disrupted leading to inhibition of NF-κB signalling. In addition A20 can 
be bind the K63/M1 polyubiquitin chains through a non-covalent binding. This facilitates an 
interaction between the ZnF7 domain of A20 and NEMO and blocks the activation of the IKK 
complex. 
 
The ubiquitin editing protein A20 (TNF-α induced protein 3 (TNFAIP3)) was 
discovered in 1990 as primary response gene in TNF-α stimulated endothelial cells 
(Dixit et al., 1990, Opipari et al., 1990). Genomic studies have linked polymorphisms 
in the A20 gene to multiple human autoimmune diseases including, rheumatoid 
arthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and type I diabetes 
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(Fan et al., 2011, Tejasvi et al., 2012, Wang et al., 2010, Bank et al., 2014). A20 
knockout (TNFAIP3-/-) mice show signs of a spontaneous inflammatory response 
characterised by increased numbers of lymphocytes, granulocytes and myeloid cells 
as well as severe tissue damage in multiple organs, cachexia and premature death. The 
TNFAIP3-/- mice displayed also aberrant differentiation of the skin, with an increase 
of the thickness of the epidermal and dermal layers (Lee et al., 2000). A20 is thought 
to regulate the MyD88 signalling via several mechanisms. The catalytic activity of the N-
terminal OTU (ovarian tumor) domain of A20 is required for the hydrolysis of K63 
ubiquitin chains, while the C-terminal zing finger ZnF4 domain catalyses the addition of 
K48 ubiquitin to proteins targeting them for proteasomal degradation (Verstrepen et al., 
2010; Wertz et al., 2015)(Shembade et al., 2010) (Figure 5.1C).  Interestingly, mice with 
mutation in the OTU DUB domain of A20 (TNFAIPC103A) or with a mutation in the 
E3 ligase domain ZnF4 (TNFAIPZNF4/ZNF4) are born normal, do not develop 
autoimmunity and have normal lymphocyte numbers, suggesting that the DUB and 
the E3 ligase activity of A20 alone are not sufficient for limiting NF-κB signalling (De 
et al., 2014, Lu et al., 2013). In addition, it has been demonstrated that A20 can supress 
IKK complex activation by a non-catalytic mechanism.   This inhibition was mediated 
by the ZnF7 domain of A20 which is required for binding of polyubiquitin chains. The 
last were found to mediate A20-NEMO interaction, which was required for preventing 
the phosphorylation of IKK by TAK1 (Skaug et al., 2011) (Figure 5C).  
 
 Regulation of innate immune signalling by ABIN1 
The ABIN1 protein was discovered in 1999 as an A20 binding protein using 
yeast two-hybrid screening (Heyninck et al., 1999).  Overexpression of ABIN1 was 
found to have a similar effect as A20, suggesting that the inhibitory effect of A20 in 
the NF-κB signalling is mediated by its interaction with ABIN1 (Heyninck et al., 
1999). ABIN1 is part of a family of 5 proteins, including NEMO, ABIN2, ABIN3 and 
optineurin (OPTN). As discussed above NEMO plays a critical role in the co-
recruitment of IKK and TAK1 complexes and the activation of IKK by the TAK1 
complex (Emmerich et al., 2013). ABIN2 is part of the TPL2 kinase complex, which 
is made of ABIN2, p105 and TPL2 and regulates ERK1/2 activation in response to 
LPS or TNF stimulation (Papoutsopoulou et al., 2006). ABIN2 is important for the 
stabilisation of TPL2 kinase and in Tnip2-/- macrophages the expression of TPL2 is 
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lost (Papoutsopoulou et al., 2006). Enforced expression of ABIN3 (encoded by 
TNIP3) was found to play a negative role in the regulation of NF-κB in response to 
TLR, IL-1 or TNF stimulation in THP-1 cells. However, macrophages isolated from 
TNIP3-/- deficient mice had no differences in TLR signalling activation in comparison 
to WT mice. This was due to the fact that in mice, ABIN3 does not have a complete 
homology with the human ABIN3 and lacks the ubiquitin-binding domain (Weaver et 
al., 2007). OPTN binds to the TANK-binding kinase TBK1 and is phosphorylated by 
TBK1 at S177 (Morton et al., 2008, Gleason et al., 2011). Mutation of D477 to N 
(OPTND477N/D477N) which renders OPTN (OPTND477N/D477N) unable to bind ubiquitin 
chains, results in reduced IFNβ production in LPS or Poly(I:C) stimulated BMDMs 
(Gleason et al., 2011). In contrast, NF-κB activation was increased in the 
OPTND477N/D477N BMDMs in response to RANKL stimulation (Obaid et al., 2015). 
More recent studies have shown that OPTN binds to IRAK1 and regulates NF-κB 
activation recruiting the deubiquitinating enzyme CYLD and preventing TRAF6 
polyubiquitination. (Tanishima et al., 2017).  
The ABIN1 protein is encoded by the TNIP1 gene (Tumor necrosis factor-
induced protein 3-interacting protein 1) located on chromosome 5q32–33.1 in humans 
and chromosome 11 in mice (Verstrepen et al., 2009). The importance of ABIN1 
function has been highlighted by a number of genetic studies showing that in humans 
polymorphism in TNIP1 gene is associated with psoriasis, psoriatic arthritis, SLE and 
systemic sclerosis (Nair et al., 2009, G'Sell et al., 2015, Gateva et al., 2009, He et al., 
2010, Indhumathi et al., 2015, Zuo et al., 2015, Bossini-Castillo et al., 2013, Caster et 
al., 2013).Reduced expression of TNIP1 mRNA has been found also in SLE and 
psoriatic patients (Adrianto et al., 2012, Chen et al., 2015b). 
ABIN1is expressed in several tissues including peripheral blood skeletal 
muscle, liver, but the level of expression of ABIN1 is quite high in immune organs 
such as thymus and spleen (Verstrepen et al., 2009) (Gleason et al., 2011). ABIN1 has 
four ABIN homology domains (AHD). The AHD-1 domain is required for the 
interaction with A20. The AHD-2 domain has an ubiquitin binding function and shares 
sequence homology with ubiquitin binding domains of ABIN2, ABIN3, NEMO and 
OPTN. Therefore, the AHD-2 domain has been also known as UBAN domain 
(ubiquitin binding domain of ABIN and NEMO) (G'Sell et al., 2015). The mechanism 
by which ABIN1 regulates NF-κB signalling is still not fully understood.  Mutation in 
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ABIN1, which impaired the ability of ABIN1 to bind either NEMO or A20  were not 
sufficient to supress NF-κB activation, however when both of the regions required for 
binding of A20 and NEMO in the ABIN1 protein were mutated, NF-κB activation was 
blocked (Mauro et al., 2006). Therefore, the authors proposed that ABIN1 interacts 
with NEMO and recruits A20 to the NEMO/IKK (Figure 5.2A). In contrast, in another 
study it has been demonstrated that deletion of the UBAN domain in ABIN1 alone is 
sufficient to inhibit NF-κB activation in HEK293T cells, suggesting that ABIN1 might 
mediate NF-κB signalling independent of its interaction with A20 (Heyninck et al., 
2003). Considering that both ABIN1 and NEMO bind preferentially M1-linked 
ubiquitin chains it is possible that ABIN1 inhibits NF-κB by competing with NEMO 
for binding ubiquitin chains and therefore disrupting the activation of the IKK 
complex (Clark et al., 2013) (Figure 5.2B).  
 
Figure 5.2 A model of ABIN1 dependent regulation of TLR signalling. 
A. ABIN1 could interact with NEMO, A20 and polyubiquitin chains and potentially recruit 
A20 to the NEMO/IKK complex leading to inhibition of downstream signalling.  B. Another 
possible mechanism by which ABIN1 restricts the activation of the pathway is by direct 
competition with NEMO for binding K63/M1 polyubiquitin chains.  
 
In addition to restricting NF-κB activation, ABIN1 also has a critical role in 
regulating TNF-α-induced cell death (Oshima et al., 2009). Upon TNF stimulation the 
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TNF receptor (TNFR) associates with the TRADD adaptor protein (TNFR-associated 
death domain protein) and the Fas associated protein with death domain (FADD). This 
process is required for the recruitment of pro-caspase-8, which is then proteolytically 
cleaved to its active form. Cleaved caspase-8 mediates the activation of other caspases 
including caspase-3. Activated caspase-3 then triggers DNA fragmentation and 
degradation of cytoskeletal proteins (Sedger and McDermott, 2014). TNF-α 
stimulation induced increased cell death in TNIP1-/- deficient MEFs, Jurkat T cells, 
HepG2 hepatoma cells and HT1080 fibrosarcoma cells (Oshima et al., 2009).  Oshima 
and his colleagues demonstrated that ABIN1 inhibits the association of FADD and 
caspase-8 and that ABIN1 deficient cells have enhanced association between caspase-
8 and FADD. Restoring WT ABIN1 into TNIP1-/- 3T3 cells led to a protection from 
TNF-induced cell death. In contrast, restoring the TNIP1-/- 3T3 cells with ubiquitin 
binding domain mutant of ABIN1 did not rescue the susceptibility of TNIP1-/- 3T3 
cells to TNF-induced cell death, suggesting ABIN1 restricts cell death through its 
ubiquitin binding function.  (Oshima et al., 2009). TNIP1-/- mice were born below 
Mendelian ratio due to enhanced TNF-α induced apoptosis in the liver. The mice that 
survived after birth developed lupus like autoimmunity, neutrophilia, immune cell 
infiltration in the tissues and glomerulonephritis, cachexia and died prematurely 
within 4 months of age (Zhou et al., 2011). Whereas crossing the TNIP1-/- mice to 
TNFR1 knock out mice rescued the TNF-induced apoptosis in the liver, the 
inflammatory phenotype was not affected in the double knock mice (Zhou et al., 
2011).  
Mutation of Asp 485 to Asn in murine ABIN1 or Asp 472 to Asn in human, 
which is in the UBAN domain of ABIN1, impairs the ability of ABIN1 to bind 
ubiquitin chains.  Mice homozygous for the knock-in mutation of Asp 485 to Asn 
(ABIN1[D485N]) are born at normal Mendelian ratios, but  develop a lupus-like 
inflammatory condition with splenomegaly, increased formation of germinal centres, 
production of anti-nuclear antibodies and deposition of immunocomplexes in the 
kidney leading to glomerulonephritis (Nanda et al., 2011). B cells and bone marrow 
derived dendritic cells isolated from ABIN1[D485N] mice have enhanced NF-κB and 
MAPK activation and cytokine production in response to TLR stimulation in 
comparison to cells isolated from WT mice (Nanda et al., 2011).   To examine the 
pathways that drive autoimmunity in these mice, the ABIN1[D485N] mice have been 
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crossed onto a number of other different knockouts.  While cross to RIP2 or IFNAR1 
knockout mice did not supress the inflammatory phenotype in the ABIN1[D485N] 
mice, crossing to MyD88 deficient mice or mice with catalytically inactive IRAK4 
and IRAK1 kinases led to a rescue of the lupus like autoimmunity (Nanda et al., 2011, 
Nanda et al., 2016).  
 
 Immunopathogenesis in systemic lupus erythematosus 
Systemic lupus erythematosus is an autoimmune diseases, characterised by the 
presence of autoreactive antibodies against nucleic acids or nuclear proteins and 
formation of immune complexes which can be detected in various organs. The 
manifestation of SLE are diverse and can range from mild cutaneous inflammation to 
severe kidney pathology and cardiovascular problems with life-threatening prognosis 
(Tsokos et al., 2016). SLE is a relatively rare disease and affects more women than 
men (Carter et al., 2016). In the UK the disease incidence during 1999-2012 were 
4.91/100 000 people and overall prevalence of 97.04/100 000 in 2012 with a highest 
incidence and prevalence within the Black Caribbean ethnicity (Rees et al., 2016). 
Similar number of incidence of 5.5 and 5.6 per 100 000 were reported also in two 
independent studies in the US (Somers et al., 2014, Lim et al., 2014). The current 
biological therapies for SLE treatment are very limited and although a substantial 
progress has been made in the understanding of SLE pathogenesis, there is only one 
targeted drug that has been approved in the last 50 years for treatment of lupus: 
belimumab or benlysta. Belimumab is a human monoclonal recombinant antibody 
which recognises and binds to the B cell-activating factor BAFF, leading to the 
decreased B cell survival and reduction of the antibody production (Dubey et al., 
2011). In addition, the anti-CD20 chimeric monoclonal antibody rituximab is also 
used as an “off-label” drug (Felten et al., 2018). Standard therapies include non-
corticosteroid anti-inflammatory drugs and immunosuppressants such as 
corticosteroids, methotrexate, azathioprine, cyclophosphamide, and mycophenolate 
mofetil  (Dubey et al., 2011). However, broad spectrum immunosuppression, increases 
the risk of infections in the patients, therefore more specific therapies are required for 
treatment of the disease. 
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One of the key mechanisms for breaking immune tolerance in SLE is proposed 
to be the impaired clearance of apoptotic cells. This notion has been supported by 
studies showing that monocyte derived macrophages from SLE patients have impaired 
phagocytosis of apoptotic cells (Tas et al., 2006, Munoz et al., 2009). Increased 
apoptotic cell number has been also found in the skin of patients with SLE (Kuhn et 
al., 2006).  The link between apoptosis and SLE has been also demonstrated in mice.  
MRL/lpr mice, which are one of the most commonly used models for SLE, have a 
mutation in the death receptor Fas (Watanabe-Fukunaga et al., 1992). In another lupus 
prone mouse strain, (NZB x NZW) F1 mice, the levels of DNase I mRNA, which is 
involved in the fragmentation of DNA during apoptosis were reduced and as a result 
chromatin particles were deposited in the kidneys of (NZB x NZW)F1  (Zykova et al., 
2008). Other cell death pathways such as necrosis are also considered as contributing 
factors for lupus development (Fan et al., 2014). In contrast to apoptosis, where dying 
cells are phagocytosed and cleared, during necrosis the membrane integrity of the cells 
is lost and cellular components are released including factors such as nucleic acids and 
ribonucleoproteins, mitochondrial components and ATP that can act as damage 
associated molecular patterns (DAMPs) and stimulate the innate immune system 
(Vanden Berghe et al., 2010).  
Another potential source of nuclear antigens are the neutrophil extracellular 
traps (NETs), which  contain DNA, histones, elastase, myeloperoxidase and other 
granular proteins.  In response to microbial stimuli the neutrophils release 
decondensed DNA and granular proteins. Although NET formation is important for 
microbial clearance, the insufficient clearance or overproduction of NETs can promote 
tissue damage and development of lupus (Villanueva et al., 2011, Mistry and Kaplan, 
2017, Apel et al., 2018). A specific type of neutrophils called low density gradient 
(Nair et al.) neutrophils has been identified in blood samples from lupus patients 
(Villanueva et al., 2011, Kaplan, Lood et al., 2016). LDG neutrophils have enhanced 
capacity to produce NETs and higher cytokine production in response to GM-CSF 
stimulation than autologous “normal” neutrophils (Denny et al., 2010, Villanueva et 
al., 2011).  
 
116 
 
 TLRs in systemic lupus erythematosus 
The nucleic acid sensing TLRs TLR3/7/8 and 9 have been implicated in the 
pathology of lupus, with a most prominent role of TLR7. These TLRs are important 
in the recognition of pathogen derived nucleic acids.  They can however also recognise 
some host nucleic acids; as this would stimulate inflammation, mechanisms have 
evolved to prevent this happening.  Key amongst these is the endosomal and ER 
restricted location of TLR3/7/8 and 9; this protects from recognition of the host nucleic 
acid present in the cytoplasm or released into the extracellular space during cell death. 
However, internalisation of nuclear immune complexes through the FcγR could lead 
to the activation of nucleic acid sensing TLRs (Santiago-Raber et al., 2009). The 
critical role of TLR7 in the development of SLE has been highlighted by a number of 
studies in mice. BXSB mice develop lupus like autoimmunity, which is greatly 
accelerated in the BXSB.Yaa males, in which translocation of portion of the X 
chromosome to the Y chromosome leads to duplication of 17 genes including TLR7 
(Pisitkun et al., 2006). Transgenic mice expressing more copies of TLR7 also 
developed lupus like autoimmunity  (Deane et al., 2007). Loss of TLR7 in MRL/lpr 
attenuates disease progression, autoantibody production and immune cell activation 
(Christensen et al., 2006).  TLR7 is also required for the spontaneous formation of 
germinal centre B cells, which are involved in the auto-antibody production in lupus 
(Soni et al., 2014). Increased expression of TLR9 has been reported in patients with 
SLE (Rao et al., 2015). Cross of MRL/lpr mice to TLR9-/- mice led to a reduction in 
anti-dsDNA antibodies, however it did not reduce the infiltration of activated 
lymphocytes or the kidney pathology (Christensen et al., 2005). In addition, TLR9 
deficiency has been shown to exacerbate disease severity in MRL/lpr mice rather than 
having protective effect (Christensen et al., 2006). Later it was demonstrated that 
TLR7-/- cross rescues the exacerbated phenotype in the TLR9-/-/MRL/lpr. Therefore, 
the authors suggested that TLR9 limits the activity of TLR7 and loss of TLR9 results  
in enhanced TLR7 signalling and disease exacerbation (Nickerson et al., 2010).  
 Plasmocytoid dendritic cells (pDCs) are a specialised subset of dendritic cells 
which express TLR7 and TLR9 and can sense nucleic acids (Buechler et al., 2013). 
Moreover, they are considered as the most potent producers of IFNγ and thereby 
mediating immunity in viral infections (Siegal et al., 1999). Whereas pDCs are 
decreased in the blood of patients with lupus, their numbers seem to be increased in 
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the skin and kidneys, suggesting that pDC might migrate from the blood into the 
tissues (Cella et al., 1999, Fiore et al., 2008, Vermi et al., 2009). In lupus patients pDC 
have been shown to internalise nucleic acid containing immune complexes trough the 
FcγRIIa, leading to the recognition of these IC by the TLR9 and TLR7 receptors and 
production of IFN-α (Means et al., 2005). A number of studies have shown that 
peripheral blood mononuclear cells isolated from lupus patients are characterised by 
upregulation of IFN induced genes (Bennett et al., 2003, Crow and Wohlgemuth, 
2003, Baechler et al., 2003). As a result, one of the main current strategies for the 
development of therapies for lupus is focused on targeting the IFN pathway (Felten et 
al., 2018).  
 
 Aims  
Considering the role of ABIN1 in the development of SLE both in human and 
mice, the aim of the project was to characterise the changes in innate immune cells in 
ABIN1[D485N] mice and to further investigate the mechanism underlying the 
pathology in these mice. While in the beginning we wanted to look at ILCs, the initial 
experiments indicated that there was a massive increase in monocytes in the 
ABIN1[D485N] mice.  Changes in the monocytes were also investigated in 
ABIN1[D485N] mice crossed to MyD88 KO or IRAK4 and IRAK1 knock in mice, in 
which the lupus phenotype is prevented. I also characterise the potential of 
pharmacological inhibition of IRAK4 to prevent and/or treat lupus like autoimmunity 
observed in ABIN1[D485N] mice. Last, the importance of TLR7 in mediating 
inflammatory responses in ABIN1[D485N] was studied by crossing ABIN1[D485N] 
mice to TLR7 KO mice. The role of TLR7 in mediating monocyte responses in vitro 
and in vivo was also addressed.   
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 Results 
 Characterisation of innate immune populations in ABIN1[D485N] 
mice 
ABIN1[D485N] mice are characterised by splenomegaly with an increase in 
the total number of splenic B cells, Gr1+veCD11b+ve cells and also aberrant T cells with 
an activated phenotype (Nanda et al., 2011). However, the changes in the innate 
immune compartment in lymphoid and non-lymphoid tissues of ABIN1[D485N] mice 
have not been extensively investigated. Analysis of the innate lymphoid populations, 
revealed that there is a slight increase in the lineage negative ILC2 populations in the 
lungs of ABIN1[D485N] mice (not shown), however a much bigger change was 
observed in the lineage positive cells. Further characterisation of the lungs showed 
that the ABIN1[D485N]  increase in the lineage positive gate was due to a massive 
increase in a  population of cells expressing high levels of CD11b and intermediate 
levels of CD11c (Figure 5.3).  
 
Figure 5.3 Expansion of CD11bhighCD11cinter cells in the lungs of ABIN1[D485N] mice. 
Lungs cells from WT and ABIN1 mice were stained with anti-mouse CD11b (PE/Cy7) and 
anti-mouse CD11c (APC) antibodies and DAPI and acquired on BD FACSCanto. Leukocytes 
were gated based on FSC-A and SSC-A. Doublets were gated out using FSC-W and FSC-A 
and live cells were gated as DAPI negative. The representative plots show percentage of 
CD11bhighCD11cinter from live single cells.  
CD11b and CD11c   are expressed in many immune cells including monocytes, 
macrophages, and dendritic cells (Yu et al., 2016). In addition, CD11b expression is 
also found in NK cells and granulocytes such as neutrophils and eosinophils (Misharin 
et al., 2013, Yu et al., 2016, Fu et al., 2011). In mice there are two distinct population 
of monocytes: Ly6C+ve inflammatory (also referred as classical) monocytes and  
Ly6C-ve patrolling (non-classical) monocytes, which express CD11b, the M-CSF 
receptor CD115, the fractalkine chemokine receptor CX3CR1 and CD64 (Geissmann 
et al., 2003, Jakubzick et al., 2017). Monocytes develop in the bone marrow and 
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migrate through the blood into the tissues where they can differentiate into tissue 
macrophages or dendritic cells (Jakubzick et al., 2017, Yona et al., 2013). Moreover 
it has been demonstrated Ly6C+ve inflammatory monocytes act as an intermediate 
precursor from which the Ly6C-ve patrolling monocytes develop (Yona et al., 2013). 
Since patrolling monocytes haven been characterised by expression of both CD11b 
and CD11c, next we wanted to address the question if the increased population of cells 
in the ABIN1[D485N] mice express other markers characteristic for the patrolling 
monocytes. Therefore, a 10-color staining panel was optimised and cells isolated from 
blood, lungs, spleen and kidneys were analysed by flow cytometry. Details of the 
antibodies used in the stain are listed in Table 5.1.  
Table 5.1 Flow cytometry panel for characterisation of innate immune cell populations in 
ABIN1[D485N] mice. 
Target Fluorophore Clone Dilution Stock conc Source 
CD45 BV510 30-F11 1:200 0.2 mg/ml BioLegend 
NK1.1 APC/Cy7 PK136 1:200 0.5 mg/ml BioLegend 
CD11c PE/Dazzle594 N418 1:200 0.2 mg/ml BioLegend 
CD11b PE/Cy7 M1/70 1:600 0.2 mg/ml BioLegend 
Ly-6G/Ly-6C (Gr-1) PerCp/Cy5.5 RB6-8C5 1:400 0.2 mg/ml BioLegend 
Ly-6C FITC HK1.4 1:400 0.5 mg/ml BioLegend 
CX3CR1 PE SA011F11 1:200 0.2 mg/ml BioLegend 
CD115 APC AFS98 1:200 0.2 mg/ml BioLegend 
I-A/I-E (MHC II) AlexaFluor700 M5/114.15.2 1:200 0.5 mg/ml BioLegend 
 
The gating strategy for identifying blood monocytes is represented in Figure 
5.4.  Doublets and dead cells were excluded from the analysis. The blood monocytes 
were characterised as CD115 and CD11b double positive cells and were subdivided 
into Ly6C+veCX3CR1+ve and Ly6C-veCX3CR1+ve populations. Both of these 
populations were further analysed for expression of CD11c and MHCII. Blood 
inflammatory monocytes were defined as CD11b+veCD115+veLy6C+veCX3CR1+ve and 
patrolling monocytes as CD11b+veCD115+veLy6C-veCX3CR1+veMHCII-ve.  While the 
patrolling monocytes expressed low to intermediate levels of CD11c, the Ly6C+ve 
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monocytes were negative for both CD11c and MHCII. The CD115-veCD11b+ve 
population was predominantly made of Gr1high neutrophils (PMN) and NK1.1+ve cells.  
 
Figure 5.4 Gating strategy for identifying monocytes in murine blood. 
Blood leukocytes isolated from WT mice were stained with DAPI, and with fluorophore 
conjugated antibodies against CD45 (BV510), CD115 (APC), CD11b (Pe/Cy7), Ly6C (FITC), 
CX3CR1 (PE), MHCII (AlexaFluor700), CD11c (PE-Dazzle 594), Gr1 (PerCp/Cy5.5) and 
NK1.1 (APC/Cy7) and analysed on BD LSR Fortessa II. Leukocytes were gated based on 
FSC-A and SSC-A, doublets were gated out using FSC-W and FSC-A and live cells were 
identified as DAPI negative cells. Live cells were than analysed for expression of CD115 and 
CD11b. CD115+veCD11b+ve positive cells were split into two populations based on expression 
of Ly6C+ve and CX3CR1+ve: Ly6C+ve CX3CR1+ve and Ly6C-ve CX3CR1+ve cells. The last were 
further analysed for expression of MHCII and CD11c. Patrolling monocytes were defined as 
Ly6C-veCX3CR1+veMHCII-ve and the inflammatory monocytes as Ly6C-veCX3CR1+veMHCII-
veCD11c-ve. Gr-1+ve cells within the CD115-veCD11b+ve were defines as neutrophils (PMN) and 
NK1.1+ve as NK cells.  
The expression of CD115 defines monocytes both in human and mouse blood, 
however it has been demonstrated that CD115 stability depends on multiple factors 
and could be downregulated if blood samples are not refrigerated (Breslin et al., 2013). 
Isolation of cells from non-lymphoid tissues such as lungs and kidneys requires 
digestion at 37°C or both digestion and density gradient centrifugation, which can 
impair the stability of CD115. Therefore, an alternative gating strategy was applied to 
characterise monocytes in the spleen and lung tissues (Figure 5.5 A and B).  Doublets 
and dead cells were excluded and proportion of CD45+ve immune cells, which were 
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negative for NK1.1 were gated for further characterisation. NK1.1 positive cells were 
excluded from the analysis as some NK cells subsets express CD11b and CX3CR1 
(Hamann et al., 2011, Fu et al., 2011). The Gr1high cells were defined as neutrophils 
(PMN) and remaining CD11b positive cells were analysed for expression of CX3CR1 
and Ly6C. Although eosinophils also express CD11b and Ly6C, they do not express 
CX3CR1 and therefore CD45+veNK1.1-veCD11b+veLy6C+veCX3CR1+ve cells were 
characterised as inflammatory Ly6C+ve monocytes (Jung et al., 2000). The patrolling 
Ly6C-ve monocytes were defined as CD45+veNK1.1-veCD11b+veLy6C-
veCX3CR1+veMHCII-ve. In contrast to the blood, where in the Ly6C-veCX3CR1+ve gate 
majority of the cells were MHCII-ve patrolling monocytes, splenic and lungs Ly6C-
veCX3CR1+ve cells contained population of a MHCII+veCD11c+ve cells (potentially 
representing CD11b+ve monocyte derived dendritic cells) and MHCII+veCD11c- cells 
(Figure 5.5 A and B). The monocyte derived dendritic cells are characterised as 
CD11b+veCD11c+veMHCII+veCD24+ve. In addition, in some tissues such as the skin and 
gut it has been demonstrated that they express SIRP-α and CX3CR1 (Ginhoux et al., 
2009, Ko and Chang, 2015). 
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Figure 5.5 Gating strategy for identifying monocytes in murine lungs and spleen. 
Single cell suspensions from the lungs and spleen were isolated as described in the Materials 
and Methods and red blood cells removed by RBC lysis. Cells were stained and acquired as 
in Figure 5.2. The representative plots show gating strategy for identifying monocytes in the 
spleen (A) and lungs (B). Leukocytes were gated based on FSC-A and SSC-A, doublets were 
gated out using FSC-W and FSC-A and live cells were identified as DAPI negative cells. Live 
cells were than analysed for expression of CD45 and NK1.1. CD45+veNK1.1-ve were gated and 
further analysed for Gr-1 and CD11b expression. PMN neutrophils were identified as 
Gr1highCD11bhigh. The remaining CD11b+ve cells were subsequently analysed to identify 
Ly6C+veCX3CR1+ve and Ly6C-veCX3CR1+ve cells. MHC II-ve, MHC II+veCD11c-ve and MHC 
II+veCD11c+ve populations were identified within the Ly6C-veCX3CR1+ve cells. 
 
ABIN1[D485N] mice develop splenomegaly and autoantibodies when they 
are 3-4 months old (Nanda et al., 2011). To characterise the monocyte populations and 
how the change in their numbers correlates with disease progression and spleen 
enlargement, WT and ABIN1[D485N] mice were analysed at 4, 8, 16 and 22 weeks 
of age using the above described staining panel. While there was no difference in 
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spleen size in the 4 and 8 week old WT and ABIN1[D485N] mice, 16 and 22 week 
old ABIN1[D485N] mice had more than 3 fold bigger spleens in comparison to WT 
mice (Figure 5.6).  
 
 
Figure 5.6 Increased spleen size in ABIN1[D485N] mice.  
The plot represents spleen weights of 4, 8, 16 and 22 week old WT and ABIN1[D485N] mice. 
Symbols indicate individual mice. Significance between the two genotypes was calculated by 
two-way ANOVA and Tukey HSD as posthoc test; *** denotes p<0.001. Error bars represent 
± standard error of the mean.  
 
Analysis of the blood of WT and ABIN1[D485N] mice showed a massive 
increase in CD115+veCD11b+ve monocytes in ABIN1[D485N] mice by 22 weeks of 
age (Figure 5.7). A more detailed analysis showed that difference between the 
inflammatory Ly6C+ve monocytes in WT and ABIN1[D485N] was observed only in 
the 22 week old animals (Figure 5.7B). In contrast, a higher percentage of 
CD115+veCD11b+veLy6C-veCX3CR1+veMHCII-ve patrolling monocytes was found 
even in the 4 week old ABIN1 knock in mice. Moreover, in the 16 and 22 week old 
ABIN1[D485N] mice the patrolling monocytes were representing more than 30% of 
all blood leukocytes, whereas in WT animals patrolling monocytes were only around 
3%.  
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Figure 5.7 Increase in patrolling monocytes in the blood of ABIN1[D485N] mice.  
Blood leukocytes were isolated from 4, 8, 16 and 22 week old WT and ABIN1[D485] mice 
and stained with DAPI and with fluorophore conjugated antibodies against CD45 (BV510), 
CD115 (APC), CD11b (Pe/Cy7), Ly6C (FITC), CX3CR1 (PE), MHC II (AlexaFluor700), 
CD11c (PE-Dazzle 594), Gr1 (PerCp/Cy5.5) and NK1.1 (APC/Cy7) and analysed on BD LSR 
Fortessa II. A. The representative FACS plots show monocytes in blood of 22 week old WT 
and ABIN1 mice. The first plots show the percentages of CD115+veCD11b+ve and CD115-
veCD11b+ve populations from all live (DAPI negative) single cells. CD115+veCD11b+ve cells 
were further gated and analysed for expression of Ly6C and CX3CR1. The final gates show 
the percentages of MHC II+ve and MHC II-ve cells within the Ly6C-veCX3CR1+ve population. 
B. Bar graphs show the percentages (relative to the total number of of Ly6C+ve inflammatory 
monocytes (Ly6C+veCX3CR1+ve), Ly6C-ve patrolling monocytes (Ly6C-veCX3CR1+veMHC II-
ve) and Ly6C-veCX3CR1+veMHC II+ve. Error bars show the average values ± SEM. Significance 
between genotypes was determined by two-way ANOVA and Tukey HSD as posthoc test;  
* denotes p<0.05, ** denotes p<0.01, and *** denotes p<0.001.  
 
Major changes in the innate immune populations were also observed in the 
spleens of ABIN1 mice (Figure 5.8A and B). Both the inflammatory Ly6C+ve and the 
patrolling monocytes Ly6C-ve monocytes were increased in the 16 and 22 week old 
knock in animals. Similar to the blood, differences in the numbers of patrolling 
monocytes were apparent even in the 4 week old mice. The absolute numbers of  
both CD45+NK1.1-veCD11b+veLy6C-veCX3CR1+veMHCII+veCD11c-ve and the 
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CD45+NK1.1-veCD11b+veLy6C-veCX3CR1+ve MHCII+veCD11c+ve monocyte derived 
dendritic cells were also increased (Figure 5.8B). As previously reported (Nanda et 
al., 2011), the neutrophil population was also expanded in the spleens of 
ABIN1[D485N] mice (Figure 5.8B). Interestingly, ABIN1[D485N] neutrophils had 
lower expression of Gr-1 and SSC-A, suggesting that they have lower granularity and 
might represent low density gradient neutrophils, similar to those described in lupus 
patients (Figure 5.8C)  (Villanueva et al., 2011).  
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Figure 5.8 Characterisation of splenocytes in ABIN1[D485N] mice.  
Splenocytes were isolated from 4, 8, 16 and 22 week old WT and ABIN1[D485] mice. 
Samples were stained and analysed as in Figure 5.5. A. Representative FACS plots showing 
the gating strategies for identifying immune cell populations in 22 week old WT and ABIN1 
mice. B. Bar graphs show the absolute numbers of Ly6C+ve inflammatory (CD45+NK1.1-
veCD11b+veLy6C+veCX3CR1+ve), Ly6C-ve patrolling monocytes  
(CD45+NK1.1-veCD11b+veLy6C-veCX3CR1+veMHCII-veveCD11c-ve),  
CD45+NK1.1-veCD11b+veLy6C-veCX3CR1+veMHCII+veCD11c-ve and  
CD45+NK1.1-veCD11b+veLy6C-veCX3CR1+veMHCII+ve CD11c+ve populations C.  Absolute 
numbers of neutrophils (CD45+NK1.1-veCD11b+veGr1+ve cells) in the spleens of WT and 
ABIN1[D485] mice.  Error bars show the average values ± SEM. Symbols represent data from 
individual mice. Significance between genotypes was determined by two-way ANOVA and 
Tukey HSD as posthoc test; *denotes p<0.05, ** p<0.01, and *** denotes p<0.001.  E. 
Representative histogram showing SSC-A in WT and ABIN1 [D485N] neutrophil gate 
(CD45+veNK1.1-CD11b+veGr-1high).  
 
In the lungs, no difference in the inflammatory monocytes between WT and 
ABIN1[D485N] mice was observed by 22 weeks of age, however the patrolling 
monocytes were significantly increased in the 16 and 22 week old ABIN1[D485N] 
mice (Figure 5.9B). The 16 week old knock in mice had also higher numbers of  
CD45+NK1.1-veCD11b+veLy6C-veCX3CR1+veMHCII+veCD11c-ve cells and  
CD45+NK1.1-veCD11b+veLy6C-veCX3CR1+veMHCII+veCD11c+ve monocyte derived 
dendritic cells. In contrast to spleen, the neutrophils in the lungs of ABIN1[D485N] 
had normal Gr1 expression, normal SSC-A (data not shown) and no significant 
difference in neutrophil numbers were found when compared to WT (Figure 5.9B).  
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Figure 5.9 Characterisation of lung cells in ABIN1[D485N] mice.  
Cells were isolated from lungs of 4, 8, 16 and 22 week old WT and ABIN1[D485] mice were 
stained and analysed as in Figure 5.5B. A. Representative FACS plots showing the gating 
strategies for identifying immune cell populations in the lungs of 22 weeks old WT and ABIN1 
mice. B.  Bar graphs show the absolute numbers of Ly6C+ve inflammatory and Ly6C-ve 
patrolling monocytes, CD45+NK1.1-veCD11b+veLy6C-veCX3CR1+veMHCII+veCD11c-ve cells 
and the monocyte derived dendritic cells. Error bars show the average values ± SEM. 
Significance between genotypes was determined by two-way ANOVA and Tukey HSD as 
posthoc test;* denotes p<0.05, ** denotes p<0.01, and *** denotes p<0.001.  
 
Substantial changes in the immune cells were also found in the kidneys of 22-
week old ABIN1[D485N] mice (Figure 5.10). Interestingly, staining for CD11b+ve 
cells showed that in the kidneys of WT mice there is a population of CD11b+ve 
intermediate expressing cells. This population was almost absent in the knock in mice, 
where most of the CD11b positive cells appeared to express high levels of CD11b 
(Figure 5.10A). Further characterisation of the CD11b+ve cells revealed that the 
CD11binter cells in the WT mice were mostly Ly6C-veCX3CR1+veMHCII+veCD11c+ve 
monocyte derived dendritic cells (moDC). The percentages of the moDC in the 
ABIN[D485N] mice were reduced (Figure 5.10A) in contrast to the patrolling 
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monocytes, which were more than 10 times higher than those in the WT mice (Figure 
5.10B).  
 
Figure 5.10 Characterisation of kidney cells in ABIN1[D485N] mice.  
Cells isolated from the kidneys of 22 week old WT and ABIN1[D485] mice were stained 
described above. A. The representative FACS plots are showing the gating strategies used for 
identifying immune cell populations in the kidneys. B.  Bar graphs show the absolute numbers 
of Ly6C+ve inflammatory and Ly6C-ve patrolling monocytes,  
CD45+veNK1.1-veCD11b+veLy6C-veCX3CR1+veMHCII+veCD11c-ve cells and  
monocyte-derived dendritic cells. Error bars show the average values ± SEM. Significance 
between genotypes was calculated by unpaired Student’s t-test; * denotes p<0.05  
. 
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 The autoimmunity in ABIN1[D485N] mice is a result of defect in 
the hematopoietic cells.  
ABIN1[D485N] knock in mice display aberrant phenotype in multiple 
immune cell populations, with a more than 10-fold increase in patrolling monocytes. 
However, it has not been demonstrated if the autoimmune pathology in the 
ABIN1[D485N] mice is a result from a primary defect in immune cells or non-immune 
cells. To address this question, we carried out a bone marrow chimera experiment. 
CD45.1 WT host mice were lethally irradiated and split into control group engrafted 
with CD45.2 WT bone marrow cells (BM) and experimental group that received 
CD45.2 ABIN1[D485N]   and CD45.1 WT bone marrow cells mixed  in a 1:1 ratio. 
Mice were sacrificed 4 months after the adoptive transfer and tissues were analysed 
(Figure 5.11). Initially experiments were carried out by reconstituting WT host 
animals only with ABIN1 BM cells, however reconstitution with ABIN1 cells in 
combination with the irradiation was not well tolerated and the mice developed skin 
inflammation similar to psoriasis before appearance of the lupus phenotype (data not 
shown).  
 
Figure 5.11 Bone marrow chimera experimental design.  
Female and male CD45.1 WT (120 days old) mice were lethally irradiated with 9.5 Gy and 
reconstituted 24 hours after the irradiation with 2.5x106 bone marrow cells from either CD45.2 
WT mice (control chimera) or cells isolated from CD45.1 WT mice and CD45.2 
ABIN1[D485N] mixed in 1:1 ratio (mixed chimera). Donor and recipients were gender 
matched. The mice were culled 4 month after the irradiation.  
 
130 
 
The mice that received the mixed ABIN1[D485N] and WT bone marrow had 
multiple autoimmunity hallmarks observed in the ABIN1[D485N] knock in mice 
including splenomegaly, increased anti-nuclear antibodies (ANA) and germinal centre 
B cells (Figure 5.12).  The monocyte populations were also significantly increased in 
comparison to the control group (Figure 5.13). Taken together, these data indicated 
that the autoimmunity in the ABIN1[D485N] mice is a result of mutation in ABIN1 
in hematopoietic cells and not in non-immune cells. To address the question if the 
increase in the monocytes is a result of a cell intrinsic defect, the Ly6C+ve inflammatory 
and Ly6C-ve patrolling monocytes were analysed for expression of CD45.1 (WT cells) 
and CD45.2 (ABIN1[D485N] cells). In 5 out of 7 mice that received mixed CD45.2 
ABIN1[D485N] and CD45.1 WT bone marrow cells, the proportion of CD45.2 cells 
was higher in both types of monocytes. However, in two of the mice the monocytes 
were predominantly CD45.1+ve from WT origin, suggesting the environment could 
also influence the increase of  monocytes and is not completely restricted to the lack 
of ABIN1 ubiquitin binding function in the monocytes. 
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Figure 5.12 Autoimmunity in ABIN1[D485N] mice is due to a defect in immune cells.  
Mice were treated as described in Figure 5.11 A. Representative image showing spleen size. 
The bar graph shows average values of the spleen weights. B. Total antinuclear antibodies 
(ANA) in the serum were measured by ELISA and plots show average values ±SEM. C.  
Splenocytes were stained with DAPI, anti-B220(APC), anti-CD95(PE) and anti-GL-7(FITC) 
antibodies and analysed on BD FACSCanto. Doublets and dead cells were gated out. The 
FACS plots represent the gating strategy used for identifying germinal centre B cells. D. The 
representative plots show percentage of CD95+veGL-7+ve germinal centre B cells from the 
B220+ve population. The bar graph show average values of GCB cell percentages. Error bars 
reperesent standard error of the mean. Significance between the two groups was calculated 
using unpaired Student’s t-test. * denotes p<0.05 and *** denotes p<0.001.  
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Figure 5.13 Adoptive transfer of ABIN1[D485N] bone marrow cells into WT mice leads 
to increase in the monocytes.  
Mice were treated as described in Figure 5.11. A. Representative flow cytometry plots show 
the percentage of CD115+veCD11b+ve cells from DAPI negative single cells and the 
percentages of Ly6C+veCX3CR1+ve and Ly6C-veCX3CR1+ve from the CD115+veCD11b+ve gate. 
The bar graphs show the average of the percentages of Ly6C+veCX3CR1+ve and Ly6C-
veCX3CR1+ve from all live cells. Symbols represent individual biological replicates 
Significance between the two groups was calculated using unpaired student’s t-test. * denotes 
p<0.05 and *** denotes p<0.001. B.  The representative plots show the proportion of CD45.1 
and CD45.2 positive cells in the DAPI-ve live cell, Ly6C+veCX3CR1+ve and Ly6C-veCX3CR1+ve 
gates. The bar graphs show the percentages of CD45.1 and CD45.2 positive for each individual 
mouse engrafted with mixed CD45.1 WT and CD45.2 ABIN[D485N] bone marrow cells.  
 
133 
 
 Loss of MyD88 or IRAK1 and IRAK4 kinase activity rescues the 
increase of the monocytes in ABIN1[D485N] mice 
The ABIN1 ubiquitin binding function is required to limit responses 
downstream of TLRs in B cells and in myeloid cells. B cells and BMDCs isolated 
from ABIN1[D485N] mice have increased MAPK and NF-κB activation and higher 
cytokine production in response to either LPS (a ligand for TLR4) or R848 (a ligand 
for TLR7/8), suggesting that these pathways could contribute to the lupus-like 
phenotype (Nanda et al., 2011). Moreover, loss of components of the TLR signalling 
pathway such as the adaptor protein MyD88 or the IRAK1 and IRAK4 kinase activity  
leads to complete rescue of the splenomegaly, autoantibody production and kidney 
pathology in the ABIN1[D485N] mice (Nanda et al., 2011, Nanda et al., 2016). To 
understand if enhanced MyD88 signalling in the ABIN[D485N] mice is driving the 
massive increase in the monocytes, next I characterised the monocyte populations in 
ABIN1[D485N] x MyD88 KO, ABIN1[D485N] x IRAK1[D359A] and 
ABIN1[D485N] x IRAK4[D329A] KI mice.  The increase in Ly6C-ve patrolling 
monocytes in blood, lungs and spleen was rescued in all three double mutant mice 
(Figure 5.14). Similarly, the increase in Ly6C+ve inflammatory monocytes in the blood 
was prevented. The Ly6C+ve inflammatory monocytes in the  
ABIN1[D485N] x IRAK4[D329A] mice were also significantly reduced in the lungs 
and spleens. Reduction in the Ly6C+ve monocytes in the spleen and lungs was observed 
also in the other two double mutants, however more replicates will be needed to 
determine the significance. In addition to the changes in the monocytes populations, 
the neutrophil numbers in the spleens of the ABIN1[D485N]xMyD88 KO, 
ABIN1[D485N]xIRAK1[D359A] and ABIN1[D485N]xIRAK4[D329A] KI mice 
were also significantly decreased in comparison to the ABIN1[D485N] mice. These 
data suggested that MyD88 signalling is important for the expansion of the monocytes 
populations in the ABIN1[D485N] mice and targeting this pathway could be 
beneficial in terms of developing therapies for SLE treatment.  
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Figure 5.14 Increase in the monocytes is prevented in ABIN1[D485N] crossed to 
MyD88 knock out mice or kinase-inactive mutants of IRAK1 and IRAK4.   
Blood leukocytes and single cell suspensions from the lungs and spleens of 4 month old WT, 
ABIN1[D485N], MyD88 KO, ABIN1[D485N]xMyD88 KO, IRAK1[D359A], 
IRAK4[D329A]    ABIN1[D485N]xIRAK1[D359A] and ABIN1[D485N]xIRAK4[D329A] 
mice were stained as described in Figure 5.4 and 5.5 and analysed on BD LSR Fortessa II. A. 
The representative plots are showing percentages CD115+veCD11b+ve and CD115-veCD11b+ve 
populations from live (DAPI negative) single cells. CD115+veCD11b+ve cells were further 
gated and analysed for expression of Ly6C and CX3CR1. Inflammatory monocytes were 
defined as CD115+veCD11b+veLy6C+veCX3CR1+ve. The CD115+veCD11b+veLy6C-veCX3CR1+ve 
were further analysed for expression of MHC II. Patrolling monocytes were defined as 
CD115+veCD11b+veLy6C-veCX3CR1+veMHCII- . B. Bar graphs show the average value 
(±SEM) of percentages of Ly6C+ve inflammatory monocytes, Ly6C-ve patrolling monocytes 
and the neutrophils (CD115-veCD11b+veGr-1high) from the live cell gate in the blood and  total 
numbers of  Ly6C+ve inflammatory monocytes, Ly6C-ve patrolling monocytesand neutrophils 
in the lungs and spleen. Symbols represent individual biological replicates. Statistical 
significance between genotypes was calculated using one-way ANOVA and Tukey HSD. * 
p<0.05, **p<0.01 and *** denotes p<0.001.  
 
To further elucidate the therapeutic potential of inhibition of IRAK4, next we 
fed 6 week old ABIN1[D485N] mice with chow diet containing the IRAK4 inhibitor 
PF-06426779. The inhibition of IRAK4 led to a rescue of the splenomegaly in the 
ABIN1[D485N] mice (Figure 5.15A). The percentage of germinal centre B cells in 
the spleen also appeared to be reduced, although not significant with the numbers of 
animals analysed (Figure 5.15B). Blood samples were collected at the beginning of 
the study, at 5 weeks and in the end of the study (10 weeks) to monitor changes in the 
monocyte populations. Flow cytometry analysis showed that an increase in the 
patrolling monocytes was detected in the ABIN[D485N] animals even at the start of 
the study when the mice were 6 weeks old (Figure 5.16A). Whereas the patrolling 
monocytes continue to increase in the ABIN1[D485N] on normal chow diet, the 
ABIN1[D485N] mice fed with IRAK4 inhibitor containing diet had a significantly 
lower percentage of monocytes at the end of the study. Moreover, IRAK4 inhibition 
prevented the increase in the patrolling monocytes also in the lungs and spleen (Figure 
5.16B). Taken together, we have demonstrated that IRAK4 inhibition reduces the 
lupus like autoimmunity in ABIN1[D485N] mice. 
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Figure 5.15 Pharmacological inhibition of IRAK4 prevents autoimmunity development 
in ABIN1[D485N] mice.  
6 week old ABIN[D485N] mice were given either normal chow or chow containing 1000mpk 
PF-06426779 (IRAK4 inhibitor). Mice were culled 10 weeks after the start of the study. A. 
The bar graph show average values of the spleen weights ±SEM and the right image shows 
spleen enlargement, bar equals 1 cm. B. The representative plots show the percentage of 
splenic CD95+veGL-7+ve germinal centre B cells from the B220+ve population. Statistical 
significance between groups was calculated using one-way ANOVA and Tukey HSD. *** 
denotes p<0.001.  
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Figure 5.16 Pharmacological inhibition of IRAK4 rescues increase in the monocytes in 
ABIN1[D485N] mice.  
Mice were treated as in previous figure. Blood samples were collected at 6, 11 and 16 week 
via tail vein or cardiac puncture and analysed for changes in the monocyte populations.  Flow 
cytometry analysis was done as described above (Figure 5.4 and 5.5). A. Representative flow 
cytometry plots show changes in the CD115+veCD11b+ve, 
CD115+veCD11b+veLy6C+veCX3CR1+ve and CD115+veCD11b+veLy6C-veCX3CR1+ve populations 
in 16 week old animals. The bar graph represents average values of the Ly6C-ve patrolling 
monocytes percentages from the live cells gate in 6, 11 and 16 weeks old animals.   
Significance was calculated by two-way ANOVA followed by Tukey HSD. B. Bar graphs 
show changes in the Ly6C-ve patrolling monocytes in the lungs and spleen. Significance was 
calculated by one-way ANOVA followed by Tukey HSD. Error bars represent ±SEM. * 
p<0.05, **p<0.01 and *** denotes p<0.001. Tail bleeds and welfare monitoring was done by 
Dr. Sambit Nanda.  
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 Investigating the role of TLR7 in the SLE development in 
ABIN1[D485N] mice. 
All TLR receptors except TLR3 require MyD88 adaptor protein for mediating 
downstream signalling (Kawai and Akira, 2011).  Among the TLR receptors, the 
nucleic acid sensing TLR7 and 9 have been linked to human SLE (Celhar and 
Fairhurst, 2014). Enhanced expression of TLR7 has been found in a Mexican 
population with SLE (Garcia-Ortiz et al., 2010). TLR7 overexpression in mice also 
leads to lupus like autoimmunity development (Deane et al., 2007). Analysis of the 
inflammatory and the patrolling monocytes in blood, lungs and spleens of 
ABIN1[D485N] x TLR7 KO mice showed significant reduction when compared to 
ABIN1[D485N] mice, suggesting that TLR7 signalling has a critical role in driving 
the autoimmune responses in the knock in mice (Figure 5.17). In addition, crossing of 
the ABIN1[D485N] mice to TLR7 KO mice led to a significant reduction in the 
splenomegaly, as well as reduction of in the numbers of germinal centre B cells.  The 
expansion of germinal centre B cells requires help from a specialised Th subset 
referred to as T follicular helper (Tfh) cells. Numbers of Tfh cells were increased in the 
spleens of ABIN1[D485] and this was rescued in TLR7 KO crosses (Figure 5.18). 
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Figure 5.17 Characterisation of monocyte populations in ABIN1[D485N]xTLR7 KO 
mice.  
Blood, lungs and spleens of 4 month old WT, ABIN1[D485N] and ABIN[D485N]xTLR7 KO 
mice were analysed for changes in the monocytes. A. The flow cytometry plots show changes 
in the CD115+veCD11b+ve, CD115+veCD11b+veLy6C+veCX3CR1+ve and 
CD115+veCD11b+veLy6C-veCX3CR1+ve populations in the blood. The bar graph represents 
average values of the percentage of Ly6C+ve inflammatory and Ly6C-ve patrolling monocytes 
from all live cells. B. Same as A, except bar graphs show total numbers of Ly6C+ve 
inflammatory monocytes and Ly6C-ve patrolling in lungs and spleen. Symbols represent 
individual biological replicates. Statistical significance between genotypes was calculated 
using one-way ANOVA followed by Tukey HSD. * p<0.05, **p<0.01 and *** p<0.001. 
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Figure 5.18 Characterisation of ABIN1[D485N]xTLR7 KO mice.  
A. Average values of spleen weights of 4 month old WT, ABIN1[D485N] and 
ABIN1[D485N]xTLR7 KO mice B. The representative flow cytometry plots show the 
percentage of splenic CD95+veGL-7+ve germinal centre B cells from the B220+ve population. 
The bar graph show the average value of the absolute numbers of the germinal centre B cells 
in the spleens. C. Splenocytes were stained with DAPI, anti-CD4 (PerCP/Cy5.5), anti-TCR-
β(FITC), anti-PD-1 (BV421) and anti-CXCR5(APC) to describe T follicular helper cells 
(TFH). Flow cytometry plots show the gating strategy used for identifying TFH . D. Plots show 
percentage of PD-1+veCXCR5+ve cells from the TCR-β+veCD4+ve gate and bar graph show total 
number of TFH cells in the spleen. Statistical significance between genotypes was calculated 
using one-way ANOVA and Tukey HSD. * p<0.05, **p<0.01 and *** denotes p<0.001.  
 
To address the question if monocytes respond to TLR7 stimulation, I next 
stimulated flow cytometry sorted Ly6C+ve inflammatory monocytes  
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(DAPI-veCD45+veNK1.1-veCD11b+veLy6ChighCX3CR1+veCD115+ve) from spleens of 
WT and ABIN[D485N] mice with the TLR7 agonist R837 (imiquimod) and measured 
cytokine production by multiplex cytokine assay. The ABIN1[D485N] inflammatory 
monocytes had significantly higher production of TNF-α and MIP-β following 6 hours 
stimulation with TLR7 than WT monocytes (Figure 5.19).  The production of IL-6 and 
KC also showed a trend towards upregulation in the ABIN[D485] cells, however due 
to the small sample number, the increase was not statistically significant and more 
replicates will be required to confirm these findings.  
 
 
Figure 5.19 TLR7 stimulation induces cytokine production in Ly6C+ve monocytes.  
 
RBC, NK, T and B cells were magnetically depleted from spleen cells obtained from WT and 
ABIN1 mice and inflammatory monocytes  
(DAPI-veCD45+veNK1.1-veCD11b+veLy6ChighCX3CR1+veCD115+ve) were sorted on BD 
Influx™. 2.5x104 cells  were plated in a 96 well plate and stimulated with the TLR7 agonist 
R837( 1µg/mL) for 6 h. Culture media was collected and analysed for cytokine production by 
multiplex cytokine assay. Bar plots represent the average value of 3 biological replicates for 
each genotype. Error bars represent the standard error of the mean. Significance between the 
samples was calculated by two-way ANOVA followed by Tukey HSD  posthoc test; * denotes 
p<0.05 and ** denotes p<0.01 for comparisons of ABIN1[D485N]and wild type cells. nd 
indicates that levels of the cytokines were below detection limit.  
 
To further confirm these findings, I next stimulated cells from lungs and spleen 
of WT and ABIN1[D485N] mice with R837 and measured TNF-α and IL-6 by flow 
cytometry. In the spleen, induction of TNF-α was observed in both WT and 
ABIN[D485N] inflammatory and patrolling monocytes (Figure 5.20). There was also 
an upregulation of IL-6 positive inflammatory monocytes. The percentage of splenic 
TNF-α+ve cells for both inflammatory and patrolling monocytes was higher in the 
ABIN1[D485N] cells compared to wild type cells (Figure 5.20A). In addition the 
percentage of IL-6+veTNF-α+ve cells was higher in the ABIN1[D485N] inflammatory 
monocytes.  In lungs the proportion of TNF-α+ve and IL-6+veTNF-α+ve cells in the 
stimulated Ly6C+ve inflammatory monocytes was also higher in the ABIN1 knock in 
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mice (Figure 520B). The percentages of TNF-α+ve cells patrolling monocytes in the 
lungs of WT and ABIN[D485N] were similar (Figure 5.20B). Interestingly, in the 
knock in mice the TNF-α+ve cells were detected amongst the patrolling monocytes even 
in the absence of R837 stimulation, suggesting that these cells could produce 
inflammatory cytokines at steady state and therefore contribute to the inflammatory 
phenotype in the in ABIN1[D485N] mice.  
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Figure 5.19 TLR7 stimulation induces TNF-α production in the inflammatory and 
patrolling monocytes.  
1x106 spleen and lung cells from WT and ABIN1[D485N] (4 months old) mice were cultured 
in 1 mL of complete RPMI media with or without the TLR7 agonist R837 (1µg/mL) in the 
presence of  Brefeldin A (5 µg/mL) and Monensin (2 µM) for 4 hours. Cells were fixed, 
permeabilised and stained with fluorophore conjugated antibodies against NK1.1 (APC/Cy7), 
CD11b (Pe/Cy7), Ly6C (FITC), CX3CR1 (BV510), Gr-1 (PerCp/Cy5.5), MHCII 
(AlexaFluor700), IL-6(PE) and TNF-α(APC). Inflammatory Ly6C+ve monocytes were defined 
as NK1.1-veCD11b+veLy6C+veCX3CR1+ve and patrolling Ly6C-ve monocytes as NK1.1-
veCD11b+veLy6C-veCX3CR1+veMHCII-ve. A-B. Flow cytometry plots show expression of TNF-
α and IL-6 within the corresponding monocyte populations in spleen(A) and lungs (B). Bar 
graphs show the average values of the percentage of TNF-α+ve , TNF-α+ve IL-6+ve inflammatory 
monocytes and the TNF-α+ve patrolling monocytes. Symbols represent individual biological 
replicates.  
Epicutaneous application of the TLR7 agonist imiquimod (Aldara cream) is 
known to cause skin inflammation and is used as a mouse model of psoriasis (van der 
Fits et al., 2009). In addition, long term stimulation with imiquimod leads to systemic 
inflammation, splenomegaly, glomerulonephritis and production of anti-double 
stranded DNA antibodies (Yokogawa et al., 2014). To investigate the role of TLR7 
signalling in vivo, Aldara cream was applied on the ears of WT mice for 2, 3, 4 or 5 
days. Naïve age matched WT mice were used as a control group. Enlargement of the 
spleen was detected in the animals stimulated for 3, 4 and 5 days (Figure 5.21A). 
Although the overall proportion of the CD115+veCD11b+ve monocytes in the 2 day 
treated animals was comparable to this in the control mice, the percentage of Ly6C+ve 
inflammatory monocytes in naïve mice was 30% from all monocytes, whereas in the 
2 day treated animals Ly6C+ve inflammatory monocytes represented more than 70% 
of the monocytes (Figure 5.21B).  Moreover, a significant increase of the Ly6C+ve 
inflammatory monocytes was detected in the blood of 4 and 5 days simulated animals. 
In contrast, the patrolling monocytes were reduced initially, followed by a gradual 
increase. A similar trend was also observed in the spleen. These data are in line with 
previous studies, showing that the Ly6C+ve inflammatory monocytes act as a 
precursors for the development of the patrolling monocytes and would explain the 
delay in the increase of the Ly6C-ve monocytes.   
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Figure 5.21 In vivo administration of the TLR7 agonist Imiquimod (Aldara) induces 
changes in the monocytes populations.  
10-12 week old WT mice were treated with 60 mg experimental cream containing 5% of the 
TLR7 agonist imiquimod (Aldara) once per day on both sides of the ears for 2,3,4 or 5 days. 
Untreated age matched mice were used as a control group. A. Bar graphs show increase in the 
spleen size following treatment with imiquimod. B. Blood and spleens were analysed by flow 
cytometry as described in Figure 5.4. The flow cytometry plots show changes in the 
CD115+veCD11b+ve, CD115+veCD11b+veLy6C+veCX3CR1+ve and CD115+veCD11b+veLy6C-
veCX3CR1+ve populations in the blood. C. The bar graph represents average values (± SEM) of 
the percentage of Ly6C+ve inflammatory and Ly6C-ve patrolling monocytes from all live cells. 
D. Absolute numbers of Ly6C+ve inflammatory and Ly6C-ve patrolling monocytes in the 
spleen. Symbols represent individual biological replicates. Statistical significance between 
genotypes was calculated using one-way ANOVA followed by Tukey HSD. * p<0.05, 
**p<0.01 and *** p<0.001. In vivo administration of the cream was done by Dr Manuel Van 
Gijsel Bonnello. 
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 Characterisation of ABIN1[D485N]xIL-6 KO mice 
IL-6 is a pleiotropic cytokine, which has been linked to SLE development. 
Increased level of IL-6 is also detected in the serum samples of lupus patients (Ripley 
et al., 2005). IL-6 together with IL-21 is required for the expression of the B cells 
lymphoma 6 (Bcl6) transcription factor which promotes differentiation of T follicular 
helper cells (Nurieva et al., 2009). The Tfh cells provide signals for survival and 
proliferation of the B cells in the germinal centres and promote the affinity maturation 
of B cells (Crotty, 2014). BXSB.Yaa mice have increased proportion of Tfh cells, 
which is rescued when the mice are crossed to IL-6 knock out mice. Moreover, IL-6 
deficiency led to a prolonged survival of BXSB.Yaa mice and reduction of CD11b+ve 
and GR-1+ve cells.  The authors demonstrated that number of immune cell populations 
in the BXSB.Yaa mice including the CD115+ve monocytes secrete IL-6 in response to 
TLR7/8 stimulation with R848 (Jain et al., 2016). To understand if IL-6 plays a role 
in lupus development in the ABIN1[D485N] mice, ABIN1[D485N]xIL-6 KO double 
mutant mice were analysed for changes in the spleen size and the immune cell 
population. Loss of IL-6 in the ABIN1[D485N] mice led to a partial reduction of 
splenomegaly (Figure 5.22). The germinal centre B cells were massively reduced in 
the ABIN1[D485N]xIL-6 KO mice in comparison the ABIN1[D485N] mice. There 
was also a reduction in the Tfh in double mutant mice (Figure 5.22). However, analysis 
of the monocyte populations showed that the percentage increase in the Ly6C+ve and 
Ly6C-ve monocytes was not rescued in ABIN1[D485N]xIL-6 KO knock out mice, 
suggesting that IL-6 is not driving the massive expansion of the monocyte cell 
populations (Figure 5.23).  Although monocytes were not reduced in the double 
mutant mice, it is possible that by producing IL-6 they contribute to the formation of 
germinal centres and the spontaneous auto-antibody production. Therefore, it will be 
interesting to understand if monocyte-derived IL-6 is required for the Tfh and germinal 
centre B cells expansion in the ABIN1[D485N] mice. Future studies will be also 
required to address the question, if in the ABIN1[D485N]xIL-6 KO rescues the kidney 
pathology and the  production of autoreactive antibodies. 
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Figure 5.22 Characterisation of ABIN1[D485N]xIL-6 KO mice. 
 6 months old WT, IL-6 KO, ABIN1[D485N] and ABIN1[D485N]xIL-6 KO were analysed 
to characterise changes in the spleen size, the germinal centre B cells and T follicular helper 
cells. A. Average values of spleen weights (±SEM). B. The representative flow cytometry 
plots show the percentage of splenic CD95+veGL-7+ve germinal centre B cells from the B220+ve 
population.  The bar graph show the average value of the percentages of the germinal centre 
B cells from the B220+ve cells. C. The representative flow cytometry plots show percentages 
of PD-1+veCXCR5+ve cells from the TCR-β+veCD4+ve gate and bar graph show the average 
values ±SEM.  
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Figure 5.23 Characterisation of monocytes populations in ABIN1[D485N]xIL-6 KO 
mice.  
Tissues from 6 months old WT, IL-6 KO, ABIN1[D485N] and ABIN1[D485N]xIL-6 KO 
were analysed as described in Figure 5.4 and 5.5. A. Representative plots showing changes in 
the CD115+veCD11b+ve, CD115+veCD11b+veLy6C+veCX3CR1+ve and CD115+veCD11b+veLy6C-
veCX3CR1+ve populations. The bar graph represents average values of the percentage of blood 
Ly6C+ve inflammatory and Ly6C-ve patrolling monocytes from all live cells. B. Bar graphs 
show percentages of Ly6C+ve inflammatory monocytes and Ly6C-ve patrolling monocytes from 
the live cell gate in the lungs and spleen. Symbols represent individual biological replicates. 
Error bars indicate standard error of the mean. 
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 Discussion 
 Expansion of patrolling monocytes in ABIN1[D485N] mice 
Here I have shown that the lupus inflammatory phenotype in ABIN1[D485N] 
mice is driven by the hematopoietic cells. The ABIN1[D485N] mice are characterised 
with changes in multiple immune cell populations including neutrophils, germinal 
centre B cells, follicular T helper cells. However, the most profound increase was 
observed in the numbers of the Ly6C-ve patrolling monocytes (Figures 5.7, 5.8 and 
5.9). The increase in the monocytes was detected even in 4 week old animals before 
the appearance of autoantibody production and splenomegaly (Figure 5.7). Moreover, 
in 22 week old animals the patrolling monocytes represented 30-40% of the leukocytes 
in the blood, lungs and kidneys of ABIN1[D485N] mice (Figures 5.7, 5.8 and 5.9). An 
increase in the Ly6C+ve inflammatory monocytes was also detected in the 22 week old 
animals, however this increase was not as great as seen in the patrolling monocytes 
(Figures 5.7, 5.8 and 5.9). The Ly6C+ve monocytes have a short life span of 
approximately 20 hours, whereas Ly6C-ve monocytes life span is 2.2 days at steady 
state and in the absence of Ly6C+ monocytes can extend to 11 days. (Yona et al., 2013, 
Patel et al., 2017).  Adoptive transfer of CX3CR1GFP/+Ly6C+ve splenic inflammatory 
monocytes in WT mice have shown that by day 3 the CX3CR1GFP/+Ly6C+ve 
differentiate into CX3CR1GFP/+Ly6C-ve. Similar observations were made by i.p. 
injection of BrdU in WT mice. BrdU staining was detected in all Ly6C+ve monocytes 
1 day after the i.p but then gradually decreased in this population. In contrast, BrdU+ve 
Ly6C-ve monocytes were not detected on day 1, however by day 5 more than a third 
of the patrolling monocytes were positive for BrdU (Yona et al., 2013). Therefore, it 
is possible that in the ABIN1[D485N] mice the Ly6C+ve inflammatory monocytes are 
constantly converted into Ly6C-ve patrolling monocytes, which have a longer lifespan 
and are accumulating in the tissues.  
Monocyte were originally described to develop from a common monocyte-
macrophage DC progenitor (MDP) (Fogg et al., 2006). However, a more recent study 
has identified a common monocyte progenitor (cMoP) cells in mouse bone marrow 
cells, which give rise to monocytes and macrophages, but not to DCs and are 
characterised as Lin−veCD117+veCD115+veCD135−veLy6C+veCD11b-ve (Hettinger et 
al., 2013). This population was found also in the spleen, but with much lower 
frequency (Hettinger et al., 2013). Although we have demonstrated that the monocytes 
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in the ABIN1[D485N] mice are increased in the peripheral tissues, it will be also 
interesting to understand if these mice are characterised with changes in the monocyte 
progenitors and this will be a subject of future work in the lab. In addition, there are 
some evidences suggesting that Ly6C-ve monocytes can develop independently of 
Ly6C+ve monocytes. IRF8-/- mice have severely reduced numbers of Ly6C+ve 
inflammatory monocytes, however the loss of IRF8 did not have such a major effect 
on the patrolling monocytes, which were only partially reduced (Kurotaki et al., 2013). 
Therefore, it is possible that the Ly6C-ve monocytes can develop directly from the 
cMoP.  
 
 Ly6C-ve patrolling monocytes in other mouse models of SLE 
In mice at steady state Ly6C-ve monocytes crawl along the vascular 
endothelium and remove cellular debris from dying cells (Ginhoux and Jung, 2014). 
However, it has been demonstrated that during infection patrolling monocytes could 
extravasate into tissues. Following i.p injection of Listeria monocytogenes, the 
patrolling monocytes were rapidly recruited to the peritoneum even before neutrophils 
and Ly6C+ve inflammatory monocytes, and were the only cells producing TNF-α at 
the early time point after the infection. In addition, Ly6C-ve monocytes upregulated 
genes involved in the recruitment and activation of other immune cells such as IL1β, 
CXCL1 (KC), Eotaxin, CCL22(Auffray et al., 2007).  
Increased numbers of patrolling monocytes have been also described in the 
lupus prone BXSB.Yaa mice, which have duplication of the tlr7 gene (Amano et al., 
2005). In 8 months old BXSB.Yaa monocytes represented around 50% of all blood 
leukocytes, similar to what I have demonstrated in the ABIN1[D485N] mice (Amano 
et al., 2005). The patrolling monocytes in the BXSB.Yaa mice were also found to 
express high levels of the immune complex (IC) activating receptor FcγR and low 
levels of the inhibitory receptor FcγRIIB. Deletion of the FcγR in the BXSB.Yaa mice 
led to a significant reduction of the Gr-veCD11b+ monocytes (Santiago-Raber et al., 
2009b). In addition to phagocytosis, FcγR receptor signalling can trigger cell 
activation, cell survival and cytokine production in monocytes. (Bournazos et al., 
2016). A more recent study has demonstrated that the Ly6C-ve monocytes are critical 
for IgG-mediated phagocytosis and, although many cells express FcγR, the Ly6C-ve 
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monocytes have the highest capacity to mediate antibody-dependent cellular 
cytotoxicity (Biburger et al., 2011). Deficiency of FcγRIIB in C57BL/6, but not 
BALB/c background also leads to spontaneous autoantibody production and immune 
complexes-mediated lupus like autoimmunity (Bolland and Ravetch, 2000). 
Interestingly, a polymorphism in the gene encoding FcγRIIB has been associated with 
SLE in Caucasians (Su et al., 2004, Blank et al., 2005).   
An increased proportion of CD11b+veCD11c+veCX3CR1+ve cells has also been 
found in the kidneys of other lupus prone strains including the MRL/lpr and 
NZBxNZW. These cells displayed pro-inflammatory gene signature and had the 
ability to promote survival and proliferation of CD4 T cells (Liao et al., 2017). 
Although the authors suggested that the CD11b+veCD11c+veCX3CR1+ve  cells are renal 
infiltrating dendritic cells, these cells were characterised with a much lower MHCII 
expression than conventional dendritic cells and had higher expression of CD115 than 
inflammatory monocytes, suggesting they are rather patrolling monocytes and not 
dendritic cells (Liao et al., 2017). Interestingly, administration of anti-CX3CR1 
antibody led to a decreased body weight loss in the MRL/lpr mice, as well as reduced 
proteinuria, suggesting that the CX3CR1+ve cells have a pathogenic role in this model.  
In the ABIN1[D485N] the proportion of monocyte derived dendritic cells 
(CD11b+veLy6C-veCX3CR1+veCD11c+veMHCII+ve) was reduced in the kidneys in 
contrast to the patrolling monocytes(CD11b+veLy6C-veCX3CR1+veCD11c+veMHCII-
ve), which were massively increased (Figure 5.10).  
  
 Human monocytes and their role in SLE 
In humans, a similar population of CD14dimCD16+ve monocytes has been 
found to produce inflammatory cytokines such as TNF-α, IL-1β and CCL3 in response 
to stimulation with TLR7/8 agonists (Cros et al., 2010). Moreover, the authors 
demonstrated that the CD14dimCD16+ve monocytes are observed in the IgG deposits in 
the glomerular vessels of patients with class IV  lupus nephritis, in which more than 
50% of the total number of glomeruli are affected  (Cros et al., 2010) (Weening et al., 
2004).  Stimulation of CD14dimCD16+ve monocytes isolated from healthy controls with 
sera from lupus patients induced production of inflammatory cytokines, which was 
reduced in the presence of RNase or DNase, and/or Ig depletion, suggesting that 
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CD14dimCD16+ve monocytes respond both to nucleic acids and Fc-receptor signals 
(Cros et al., 2010). Another study has shown that patients with proliferative lupus 
nephritis have a significant induction of the CX3CR1 ligand fractalkine in the 
glomeruli, which correlated with an increase in the number of CD16+ve monocytes 
expressing CX3CR1 as well as the disease pathology (Yoshimoto et al., 2007). 
Similarly, another study also reported accumulation of CD16+ve (SlanMo) monocytes 
in kidney glomeruli of type III and IV lupus nephritis patients. These cells were found 
to produce high levels of TNF-α, IL-6 and CXCL2 following stimulation with heat-
aggregated IgG. Interestingly, TNF-α production led to an upregulation of fractalkine 
on endothelial cells (Olaru et al., 2018).  
 
 TLR7 signalling in Ly6C-ve patrolling monocytes 
Here, I have demonstrated that both Ly6C+ve and Ly6C-ve monocytes produce 
high levels of TNF-α upon TLR7 engagement (Figure 5.19).  Moreover, the splenic 
Ly6C+ve and Ly6C-ve monocytes isolated from ABIN1[D485N] had significantly 
higher induction of TNF-α in comparison to WT monocytes when stimulated with 
imiquimod. Interestingly, in the knock in animals, TNF-α+ve monocytes were detected 
even in non-stimulated patrolling monocytes, suggesting that they have an activated 
phenotype (Figure 5.19). In vivo stimulation with imiquimod induced rapid increase 
in the Ly6C+ve inflammatory monocytes (Figure 5.20). The kinetics of Ly6C-ve 
monocytes increase was slightly delayed and in the blood upregulation of the 
patrolling monocytes was detected upon 5 days stimulation (Figure 5.20).  This is in 
line with previous studies suggesting that Ly6C+ve are intermediate precursors from 
which Ly6C-ve monocytes develop (Yona et al., 2013, Hettinger et al., 2013).  
There is strong evidence in the literature showing that TLR7 stimulation elicits 
responses in patrolling monocytes. Administration of the TLR7/8 agonist R848 in 
mouse kidney led to a significant increase in the retention and numbers of patrolling 
monocytes in the kidney capillaries. In contrast, PBS or LPS treatment did not lead to 
changes in the recruitment of monocytes (Carlin et al., 2013). Mechanistically, the 
retention of monocytes was explained by the fact that treatment with R848 induced 
increased expression of the CX3CR1 ligand fractalkine (CX3CL1) in the kidney cortex 
leading to receptor-ligand interaction, which retained the monocytes. In addition, 
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CX3CR1-/- deficiency abolished the monocyte increase in the kidneys (Carlin et al., 
2013). The authors also demonstrated that R848 induced recruitment of neutrophils, 
which was dependent on the Ly6C-ve patrolling monocytes and led to necrosis of 
endothelial cells (Carlin et al., 2013). In vivo administration of TLR7 or TLR9 agonists 
also has been shown to promote maturation of inflammatory monocytes toward 
patrolling monocytes, which was accompanied by down regulation of the FcγRIIB 
inhibitory receptor on patrolling monocytes (Santiago-Raber et al., 2011). In the TLR-
7 (imiquimod) or IL-23 induced psoriasis mouse model, Ly6C+ve inflammatory 
monocytes and monocyte derived dendritic cells were found to play a critical role in 
mediating local skin inflammation (Singh et al., 2016). Depleting monocytes and 
neutrophils with an anti-Ly6C antibody, but not neutrophils alone with anti-Ly6G 
antibody, led to a significant reduction in ear swelling and thickening and reduction 
of pro-inflammatory cytokines (Singh et al., 2016).  Analysis of imiquimod treated 
MyD88fl/fl LysM cre+/- mice demonstrated that deletion of MyD88 in the myeloid 
lineage (macrophages, monocytes, neutrophils) leads to reduction of the levels of 
proinflammatory cytokines in the skin such as IL-23, IL-1β, IL-17A, IL-22, IL-6 and 
CXCL1, as well as reduction in the numbers of activated γδ-T cells both in the skin 
and draining lymph nodes. This reduction was not observed in MyD88fl/flMRP8-Cre+/- 
which results in predominant deletion in the neutrophils, suggesting that MyD88 
signalling in monocytes and macrophages, but not neutrophils play a role in disease 
exacerbation (Costa et al., 2017). Another study showed that downregulation of 
ABIN1 using shRNA leads to exacerbation of imiqimod induced psoriasis, suggesting 
the ABIN1 plays a critical role in limiting TLR7 signalling in this model. However 
the authors did not look at changes in the immune cell populations and it is not clear 
if monocytes contributed to the exacerbated imiquimod response in this study (Chen 
et al., 2015b).  
Consistent with the literature supporting the role of TLR7 in monocyte 
recruitment and activation, here I have shown that TLR7 deficiency rescues the 
increase in patrolling and inflammatory monocytes in ABIN1[D485N] mice (Figure 
5.17). The splenomegaly and the increase in the germinal centre B cells and follicular 
T helper cells were also rescued in ABIN1[D485N]xTLR7[KO] mice (Figure 5.18). 
This would suggest that excessive TLR7 signalling is driving the autoimmunity in the 
ABIN1[D485N] mice. Although the exact mechanism of how ABIN1 ubiquitin 
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binding function prevents development of autoimmunity is not completely clear, it is 
possible that ABIN1 regulates this process on two levels. First, it has been 
demonstrated that loss of ABIN1 leads to enhanced K63 ubiquitination of RIPK1 and 
sensitises cells to necroptosis (Dziedzic et al., 2018). Therefore, is possible that there 
is an increased level of cell death in the ABIN1[D485N] mice. This in turns would 
lead to increased cellular debris and availability of nucleic acids which triggers 
TLR3/7/8/9 signalling and generation of immune complexes. Additionally, as we have 
demonstrated enhanced TLR7 signalling induces proliferation in the monocytes as 
well as production of proinflammatory cytokines such as TNF-α, which could further 
amplify the cell death process.   The monocytes may also produce IL-6, which can 
promote germinal centre formation and auto-antibody production. The latter was 
illustrated by the fact that although cross of ABIN1[D485N] to IL-6 knock out mice 
did not rescue the increase in the patrolling monocytes, it led to a reduction of the 
spleen weight and complete loss of the germinal centre B cells and the follicular T 
helper cells (Figure 5.22 and 5.23). Additional experiments will be required to 
understand if the IL-6 KO cross to ABIN1[D485N] mice rescues the kidney pathology 
and increase auto-antibodies in the serum.  
Excessive production of IFN-α and altered IFN gene signature has been shown 
to correlate with disease activity in patients with SLE (Kirou et al., 2004, Baechler et 
al., 2003). Plasmocytoid dendritic cells (pDCs) are a major IFN-α producing cell type 
and are found to accumulate in the skin lesions of lupus patients (Siegal et al., 1999) 
(Farkas et al., 2001). Depletion of pDC in the BXSB.Yaa by crossing to BDCA2-DTR 
Tg mice and treating mice with diphtheria toxin (DT) led to a reduction in the number 
of activated T cells and age associated B cells (ABCs), reduction in the anti- nuclear 
antibodies and IgG/C3 deposition in the kidneys, suggesting that these cells contribute 
to the pathology in the BXSB.Yaa. In contrast to these findings, suppression of type I 
IFN signalling by crossing ABIN1[D485N] mice to IFNAR KO did not rescue the 
development of  autoimmunity in the ABIN1[D485N] mice (Nanda et al., 2016).  In 
addition, the massive changes in the myeloid populations were also not rescued in the 
ABIN1[D485N] x IFNAR KO mice (Appendix A).  
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 Targeting MyD88 signalling for treatment of SLE 
Last, we investigated the role of the TLR signalling and the potential of 
targeting this pathway for treatment of SLE in ABIN1[D485N] mice. Ligation of 
TLR7 receptor leads to the recruitment of the MyD88 adaptor protein and IRAK1, 
IRAK2 and IRAK4. Cross of ABIN1[D485N] mice to MyD88 KO or IRAK4 and 
IRAK1 knock in mice completely rescued the SLE phenotype, suggesting that 
inhibition of IRAK1 and IRAK4 could provide a strategy for SLE treatment (Nanda 
et al., 2016, Nanda et al., 2011). I have shown that the increase in patrolling monocytes 
is also rescued in the double crosses, providing another link that these cells could be 
involved in the pathology of SLE (Figure 5.14).  
Treatment of the ABIN1[D485N] mice with an IRAK4 inhibitor led to a 
significant reduction in splenomegaly and increase in the patrolling monocytes (Figure 
5.15 and 5.16). These findings were in line with another study, showing that inhibition 
of IRAK4 with the compound BMS-986126 had a protective effect in the lupus prone 
mouse strains MRL/lpr and NZB/NZW  (Dudhgaonkar et al., 2017).  In both strains 
the IRAK4 inhibitor led to a significant reduction in proteinuria, anti-dsDNA 
antibodies, inflammatory cytokine production and kidney damage. Administration of 
BMS-986126 in combination with the glucocorticosteroid prednisolone had a 
synergistic effect and led to a further reduction of the auto-antibody production and 
proteinuria in the MRL/lpr mice (Dudhgaonkar et al., 2017). Furthermore, in the 
imiqiomod induced psoriasis model, the BMS-986126 compound also led to a 
significant reduction in skin thickening, erythema and splenomegaly (Dudhgaonkar et 
al., 2017). Taken together, our and others data have demonstrated that inhibition of 
IRAK4 could have beneficial effect in patients in lupus. Moreover, considering that 
the IRAK4 inhibitor blocked the expansion of the patrolling monocytes in the 
ABIN1[D485N] mice, it will be interesting to understand if inhibition of IRAK4 has 
a protective effect in other diseases, which are associated by deregulation of the 
patrolling monocytes function. In a K/BxN serum transfer induced arthritis (STIA) 
model patrolling monocytes were found to play a critical role in the disease initiation 
and progression. Depletion of monocytes with clodronate liposomes prevented disease 
development in the STIA model of arthritis. However, disease development was 
restored when Ly6C-ve monocytes were adoptively transferred in to mice treated with 
the K/BxN serum and clodronate liposomes (Misharin et al., 2014).  
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Finally, I have also shown that neutrophils in the spleens of ABIN1[D485N] 
mice are also increased and have lower granularity, suggesting that they might have 
similar properties as the LDG neutrophils, described in lupus patients (Villanueva et 
al., 2011). Interestingly, those differences were not observed in the other tissues of the 
ABIN1[D485N] mice. The spleen has a specific function and acts as a filter, where 
altered RBC can be recognised and removed from the circulation (Pivkin et al., 2016). 
Damaged RBCs are phagocytosed by a specific type of macrophages called red pulp 
macrophages, which are described as F4/80highCD68+veCD11blow and have high 
autofluorescence (Kohyama et al., 2009). Preliminary data indicate that the 
ABIN1[D485N] mice have increased proportion of F4/80+veCD11blow macrophages 
(Appendix B) in the spleen. Future studies will be required to understand if impaired 
function of the red pulp macrophages is driving the expansion of the neutrophils. It 
would be also interesting to investigate if splenic neutrophils in the ABIN1[D485N] 
mice have a higher production of NETs and proinflammatory cytokines than WT 
neutrophils. 
 
 Future work 
The appearance of the increase in monocytes precedes the development of  
clinical symptoms such as auto-antibody production and kidney pathology, however 
it remains an open question whether the patrolling monocytes are driving the diseases 
in the ABIN1[D485N] mice. Therefore, a conditional knock-in mice of the 
ABIN1[D485N] will be generated, which will be crossed to the appropriate Cre 
transgenic mice such as LysM-Cre, CD11c-Cre or CX3CR1-Cre. This would allow us 
understand the relative contribution of different immune cells to the pathology 
observed in the total knock in mice. Alternative strategies to deplete monocytes such 
as treatment with clodronate liposome will be also applied (Rooijen and Sanders, 
1994).  
To further characterise the monocytes populations, Ly6C+ve and Ly6C-ve 
monocytes isolated from WT and ABIN1[D485N] mice will be analysed by RNA 
sequencing. It will be interesting to understand if ABIN1[D485N] regulates 
transcription factors or proteins involved in the development of monocytes. 
Interestingly, hypomorphic mutation of Gfi1 in mice (referred as Genista mice) results 
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in accumulation of atypical neutrophils and expansion of CD11b+veLy6G-ve cells 
(Ordonez-Rueda et al., 2012). The Genista mice were made through an N-ethyl-N-
nitrosourea (ENU) mutagenesis screen, which aim was to identify mutations affecting 
the immune cell development. The Genista mice carry mutation Cys318 to Tyr in the 
zinc finger domain of Gfi1 (Ordonez-Rueda et al., 2012). The Genista mice also 
develop spontaneously lupus like autoimmunity, which is rescued by cross to TLR7 
KO mice (Desnues et al., 2016). Gfi1 is a transcriptional repressor regulating 
expression of multiple genes. Levels of Gfi1 expression have been shown to determine 
the fate of granulocyte-monocyte precursors, and high Gfi1 expression determined 
granulocyte maturation (Vassen et al., 2012). Therefore, it is possible that, ABIN1 is 
involved in the regulation of Gfi1 by the ubiquitin system. Future experiments will 
determine if ABIN1[D485N] monocytes have changes in Gfi1 mRNA and protein 
levels.  
 
 Conclusions  
Here, I have shown that the development of lupus in ABIN1[D485N] mice is 
a result of a defect in the immune cell compartment and loss of ABIN1 ubiquitin 
binding function leads to a massive increase in the patrolling monocytes. Cross of 
ABIN1[D485N] mice to TLR7 KO mice prevented the development of splenomegaly, 
germinal centre formation and monocyte expansion. Moreover, the monocytes were 
hypersensitive to stimulation with TLR7 and produced inflammatory cytokines. I have 
also demonstrated that ABIN1[D485N] mice crossed to IRAK4 or IRAK1 kinase 
inactive knock in mice have normal patrolling monocyte numbers. The fact that the 
patrolling monocytes are more than 10 times increased in the mutant mice,  have pro 
inflammatory properties and their expansion is prevented in the double mutant mice, 
where the phenotype is rescued, suggests that they are most likely  involved in the 
development of lupus pathology in the ABIN1[D485N] mice.  Pharmacological 
inhibition of IRAK4 did rescue the expansion of the monocytes and the splenomegaly 
in the ABIN1[D485N] mice showing that IRAK4 inhibition has the potential to 
provide new therapeutic approach for lupus patients and other immune diseases which 
are mediated by aberrant monocyte responses.  
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Appendices 
Appendix A:  
 
Figure 6.1 
Spleen and lungs cells isolated from 4 months old WT, ABIN1[D485N], IFNAR1 KO, and 
ABIN1[D485N]xIFNAR1 were analysed for expression of CD45 (APC/Efluor780), NK1.1 
(FITC), Gr-1 (PerCp/.Cy5.5),CD11b (Pe/Cy7) and CD11c(APC) and DAPI. Cells were first 
gated on FSC-A and SSC-A, DAPI negative live cells were gated for further characterisation. 
Cells were then analysed for expression of CD45 and NK1.1. CD45+veNK1.1+ve population 
was further gated for expression of Gr-1 and CD11b. The representative FACS plots show 
CD45+veNK1.1+veGr-1high and CD45+veNK1.1+veGr-1-ve populations in the spleen and lungs of 
the corresponding genotypes.  
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Appendix B:  
 
Figure 6.2 
Spleen cell susprensions from 6 months old WT and ABIN1[D485N were stained with 
antibodies against F4/80 (APC), CD11b (Pe/Cy7), CD72 (PE), CX3CR1 (BV510) and 
Ly6C(BV421) and DAPI. Cells were first gated on FSC-A and SSC-A, DAPI negative live 
cells were gated for further characterisation. The representative FACS plots show expression 
of percentages of F4/80+veCD11b+ve cells from all live cells.  
 
